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Abstract

Nova-1, an autoantigen in paraneoplastic opsoclonus myoclonus ataxia (POMA), a

disorder associated with gynecologic cancer and CNS motor dysfunction, is a neuronspecific nuclear RNA binding protein. The work presented here confirms that Nova-1

acts as a regulator of alternative splicing in vivo. In addition to the known targe

Nova-dependent splicing regulation, exon 3A of glycine receptor a2 subunit (GlyRa2),

two new targets are identified, which are the alternative exon, E9 in the inhibitory

neurotransmitter receptor subunit, GABAARy2, and the alternatively spliced exon H in

Nova-l's own message. Nova acts to enhance alternative exon inclusion in GlyRcc2 an
GABAARy2 mRNAs and to repress alternative exon usage in its own message, thus

acting as a dual function splicing regulator. Sequence elements necessary and suffi

for Nova-dependent splicing regulation of these two new targets were elucidated, an

model is presented whereby Nova differentially regulates exon inclusion in a manner
dependent on the location of the Nova binding site within the pre-mRNA. Also, Nova

proteins localize to distinct subnuclear foci, but fail to co-localize with a numbe
known proteins that occupy sub-nuclear structural domains. Unlike nuclear speckles,

which contain a number of other splicing factors, Nova foci are disrupted by treatm

the cells with actinomycin-D, consistent with the hypothesis that the formation and

maintenance of Nova foci is an active process that is transcription dependent. Fina

differential gene expression screens were undertaken, leading to the identification
number of additional potential targets of Nova regulation.

Chapter
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Introduction

Functions of RNA-binding proteins (RBPs)

The process of eukaryotic gene expression involves an ordered and linked series of

events within various subcellular compartments. RBPs act at multiple levels to regu
and diversify gene expression, and such functions are likely to be of particular

importance to neurons. The regulation of neuronal differentiation and function is l

depend on a large number of neuron specific genes; it has been estimated that 30-50%

all genes are specifically transcribed within the brain (He and Rosenfeld, 1991). Br

specific gene expression is not only regulated by transcriptional controls (Ghosh e

1994; Lemke, 1993) but also, through the action of both ubiquitous and neuron-specif
RBPs, post-transcriptional controls. The RBPs critical to these processes recognize
small subset of RNA targets in a sea of cellular RNAs. One question central to the

understanding of gene expression is how do these proteins recognize their targets i

to subsequently mediate their regulation? This problem is well illustrated by consi
RNA editing.

RNA editing.
Post-transcriptionally, two forms of processing result in changes in the coding
capacity of the transcribed RNA at the sequence level: RNA splicing, the removal of

intronic regions of pre-mRNA, and RNA editing. RNA editing can involve insertion or
deletion of nucleotides from a pre-mRNA, a process which has been described in
protozoa such as trypanosomes (Benne et al., 1986). Alternatively, nucleotides in a

m R N A may be modified. In mammals, the two most c o m m o n modifications that occur

are adenosine-to-inosine (A-I) and cytidine to uracil (C-U) editing. C-U modificati
occurs in the pre-mRNA of apolipoprotein B (apoB) pre-mRNA by the action of the
cytidine deaminase APOBEC1 (apoB mRNA-editing enzyme catalytic polypeptide
l)(Benne et al., 1986). This enzyme forms a complex with ACF (APOBEC

complementation factor) which contains three single stranded RNA recognition motifs
(RRMs) at the amino-terminus and a double stranded RNA binding domain at the
carboxyl-terminus of the protein, and supplies the RNA binding function (Lellek et
2000; Mehta et al., 2000). The result of C-U modification in the apoB transcript is

change from the coding of a glutamate to a stop codon, resulting in a second, short
apoB protein isoform. This process is further influenced by at least one other RNA
binding protein, GRY-RBP (Gly-Arg-Tyr-rich RNA-binding protein) which inhibits
RNA editing (Blanc et al., 2001). In addition, KSRP, a KH-domain containing protein
involved in alternative splicing regulation copurifies with ACF, and can bind apoB

however the functional consequences of these interactions are not yet known (Lellek
al., 2000).
A-I RNA editing is most prevalent in the central nervous system (Keegan et al.,

2001). In this instance the enzymes responsible for the catalysis of the reaction, A
(adenosine deaminases acting on RNA), harbor two or three double-stranded RNA-

binding domains in their amino-termini, obviating the need for an RNA-binding cofac

RNA binding occurs to a double stranded region formed by base-pairing of the editin
site to an editing site complementary sequence (ECS), often present in a downstream
intron (Higuchi et al., 1993). The consequence of adenosine deamination is that the

modified base is then interpreted by the translation machinery as a guanosine. In some
instances this results in a single amino-acid change in the resultant protein, for

an arginine to glutamine (R-Q) change in the glutamate receptor subunit GluR-B, whi

occurs in the channel-pore lining segment of the protein and drastically alters the
permeability of the channel (Sommer et al., 1991). Alternatively, RNA editing can
influence pre-RNA splicing, for example ADAR2 edits its own pre-mRNA creating a 3'

splice-site which, when used, results in the addition of 47 nucleotides to the resu
mRNA and changes the open reading frame (Rueter et al., 1999).
It is clear from these examples that even single nucleotide changes can have

profound biological effects. The specific recognition of sites to be modified is ac
through the action of one or more RBPs either working in concert with the enzymatic
components of the complex, or in the case of ADARs, by also supplying the catalytic

function within a separate domain of the protein. Specific recognition also depends
specificity within the RNA, both at the level of primary sequence and secondary
structure.

Pre-mRNA splicing

Pre-mRNA splicing also involves the concerted interactions of a large number of pro
factors, some of which are required to mediate the recognition of the RNA elements
define the splice sites. Newly synthesized pre-mRNA in the eukaryotic nucleus is
recognized by the splicing apparatus which includes small nuclear RNAs (snRNAs)

complexed with a multitude of proteins which form what have been termed small nucle
ribonucleoproteins (snRNPs). These snRNPs (Ul, U2, U4, U5, and U6) associate with

the p r e - m R N A in an orderly way and constitute the basal machinery that mediates
splicing (reviewed in (Staley and Guthrie, 1998)).
While introns can vary substantially in size and sequence, they maintain several

conserved motifs. In mammals, the 5' splice site (splice donor site) consensus seque

AG/GURAGU ("/" denotes the exon-intron junction) and 3' splice site (splice accepto
site) consensus is YAG/N. The branchpoint (YNYURAC) and polypyrimidine tract lie
close to the 3' end of the intron. These motifs are recognized by components of the
splicing machinery during assembly of a large multicomponent ribonudeoprotein

complex called the spliceosome. Initially, Ul snRNP binds to the 5' splice site, fol
by the binding of SF1 (splicing factor 1, also called branch point binding protein
the branch point and U2 auxiliary factor (U2AF) to the polypyrimidine tract and 3'

site. This complex is termed the early, or E, complex. U2 snRNP is recruited which b
to the branch point resulting in A complex formation. B complex is formed when

U4/U6MJ5 tri-snRNP is added to the complex. The spliceosome then undergoes extensiv
remodeling to become the catalytically active C complex. Two transesterification

reactions follow; first, the branch point adenosine attacks the 5' splice site, clea

and resulting in lariat intermediate formation. Second, after further rearrangement
complex, the 3' hydroxyl of the cleaved 5' exon attacks the 3' splice site, joining
exons, and releasing the lariat.
The mechanism by which exons are differentiated from introns is both important

and obscure, and the significance of the problem is magnified where exon splicing i

regulated and may involve exons that are skipped (cassette exons), mutually exclusiv

contain more than one splice sites (5' or 3')- The consensus sequences recognized b

core splicing machinery are both short and degenerate and therefore cannot account for
the exquisite recognition and accuracy achieved during pre-mRNA splicing. However,
individual splice sites are not recognized independently, but involve interactions

the 5' and 3' splice sites and the factors that bind them. These interactions can o

across the intron (intron definition) or across the exon (exon definition) (reviewe

(Berget, 1995)), and usually involve a number of additional proteins, including RBPs.

Nuclear RNA export

After transcription and processing in the nucleus, mRNAs must be actively transporte

the cytoplasm prior to their translation. RNA signals play a part in determining exp
for example the presence of a 5' cap (and the concomitant cap-binding complex)
stimulates export (Izaurralde et al., 1992; Visa et al., 1996), whilst the presence

unspliced introns inhibits export. However, the most important mediator of mRNA expo
is the complement of RBPs bound to them. The majority of proteins and RNAs are

transported via the nuclear pore complex (NPC) from the nucleus to the cytoplasm an

require interaction with specific transport receptors. The best-studied of these rec

are the karyopherin receptors. These receptors mediate both nuclear export and impor

proteins and RNAs. During export, the receptor plus cargo bind to RanGTP, followed b
translocation to the cytoplasm. These complexes are then released in the cytoplasm
hydrolysis of RanGTP to RanGDP. Import occurs in essentially the reverse manner.
Nuclear export of tRNA, rRNA and snRNAs all require karyopherin-type receptors.
Shuttling hnRNP proteins such as hnRNP Al have been suggested to play a role in
mRNA export by acting as adapters between the RNP and transport machinery via
karyopherin receptors.
6

A n alternative pathway involves export of m R N A s through a different class of

transport receptors, the Tap/NXF family. RNA export via this pathway can be stimulat

by RNA splicing, in particular the recruitment of the mRNA export factor, Aly, durin
spliceosome assembly (Luo and Reed, 1999; Zhou et al., 2000). Aly, the mammalian
homologue of yeast Yralp contains a central RNA binding domain flanked by RGG rich
regions. Aly is one component of a complex of proteins deposited 20-24 nucleotides

upstream of exon-exon junctions during splicing (Le Hir et al., 2001). Aly interacts
directly with Tap, a shuttling mRNA export factor that in turn associates with the
(Stutz et al., 2000) to mediate export. SR proteins, an essential component of the
spliceosome, have also been implicated in mRNA export (Huang and Steitz, 2001).
Conversely, non-shuttling hnRNP proteins have been suggested to play a role in the
retention of partially spliced RNAs or the RNA byproducts of splicing, the excised
introns within the nucleus (Reed and Magni, 2001). Thus RBPs play a crucial role in
regulation of RNA export from the nucleus.

RNA localization

RNA localization as a mechanism to regulate local protein concentrations through lo

protein synthesis has been documented in a wide variety of systems. For example, Ash

mRNA is localized to the tip of the daughter cell in budding yeast, preventing matin

type switching (Sil and Herskowitz, 1996). During development, morphogen gradients of

some proteins are established by localization of the RNA, for example bicoid mRNA i
localized to the anterior pole of Drosophila oocytes. What is common to all systems

the requirement of cis-acting RNA sequences, often located in the 3' untranslated r

(UTR) of the message, and trans-acting protein factors that bind them. In fibroblast
7

actin m R N A is localized to the leading edge, a process requiring a "zip code" 3' U T R

sequence to be bound by a protein named zipcode-binding protein 1 (ZBP-l)(Ross et a
1997). ZBP-1 is an RNA binding protein containing four KH (hnRNP K homology) and
one RRM (RNA recognition motif) RNA binding domains. RNA binding proteins are not

only involved in directing the localization of the mRNA to a particular site, but al

anchoring it upon arrival. In the case of bicoid mRNA, Staufen, an RBP containing fi
double-stranded RNA binding domains anchors the RNA at the anterior pole of
Drosophila oocytes (Ferrandon et al., 1994).
RNA localization also plays important roles in regulation of gene expression in

neurons. Several mRNAs are localized to discrete subcellular regions in neurons. For
example, microtubule associated protein MAP2 mRNA is found in dendrites (Garner et
al., 1988), while tau mRNA is restricted to the proximal segment of axons in mature

neurons (Litman et al., 1993). RNA localization in neurons has also been linked to l

control of translation of mRNAs such as the a subunit of calcium/calmodulin-depende
protein kinase II (CAMKIIcc) in dendrites (Kang and Schuman, 1996; Martin et al.,

1997). Furthermore, RNA localization and local synthesis of protein in dendrites hav

been coupled to synaptic activity in the case of Arc (activity-regulated cytoskelet

associated) which is localized to the synapse in response to NMDA receptor activati
(Steward and Worley, 2001).

Alternative

splicing

Alternative splicing allows for different mRNAs, and thereby different proteins,
to be produced from a single pre-mRNA by regulating the choice of exons to be spliced
together. Regulation of alternative splicing is mediated through interactions of the
splicing machinery with additional protein factors that enhance or repress the
spliceosome. Understanding of this process comes largely from Drosophila, where
protein factors that regulate splicing bind to specific RNA target elements present either
within regulated exons or in adjacent intronic sequences.
One of the first known and best characterized examples of alternative splicing
regulation via an intronic element is the regulation of the transformer (tra) pre-mRNA by
sex lethal (Sxl) in Drosophila sex determination (reviewed in (Lopez, 1998)). The protein
Sxl is expressed exclusively in females and blocks the more upstream of two competing
3' splice sites in the first intron of tra pre-mRNA. By switching splicing to the
downstream 3'splice site, Sxl allows translation of functional Tra protein by exclusion of
an in-frame stop codon. Sxl binds to a U-rich stretch of the polypyrimidine tract of the
regulated (upstream) 3' splice site (Inoue et al., 1990), thus precluding binding of U2AF
and favoring splicing to the downstream, weaker 3' splice site. In vitro experiments have
confirmed that Sxl binds with approximately 100-fold higher affinity than U2AF65 to the
upstream polypyrimidine tract, and that Sxl binding excludes binding of U2AF65
(Valcarcel et al., 1993). Further evidence for this mechanism of regulation comes from
experiments both in vitro and in vivo where the RS (serine-arginine repeat) domain of
U2AF65, which mediates protein-protein interactions, was fused to Sxl. This fusion

transforms Sxl into an activator of the upstream 3' splice site (Granadino et al., 1997;
Valcarcel etal., 1993).
Exonic splicing regulatory elements have also been documented in many
instances. A well studied example of an exonic splicing enhancer (ESE) is femalespecific inclusion of doublesex exon 4 in Drosophila. Exon 4 becomes the last exon in the
transcript in females, and this splice choice results in the production of sex-specific

transcription factors with different carboxyl-termini. Splicing to the 3' splice site adjacen
to exon 4 requires a region of six 13-nucleotide repeats and a purine rich element (PRE)
located approximately 300 nucleotides into the exon. Protein complexes form at each of
these sequence elements, involving the binding of SR proteins: Tra-2 (transformer-2) and
either RBP-1 (RNA-binding protein-1) at the repeats or dASF/SF2 (Drosophila
alternative splicing factor/splicing factor 2) at the PRE. Specificity is introduced by Tra
(transformer), which is expressed only in females and is crucial for stable complex
formation at these sites (Lynch and Maniatis, 1996). Interestingly, the position of the ESE
sequences relative to the 3' splice site is critical in maintaining the regulation of this
splicing decision. If the enhancer is placed closer to the intron/exon junction, Tra is no
longer required for stable complex formation and the subsequent splicing activation.
Alternative splicing of the Drosophila P-element transposase is mediated through
an exonic splicing silencer (ESS). The expression of this transposase is inhibited in
somatic cells by repression of intron 3 splicing. A complex of at least 4 proteins is
involved which when bound to the regulatory sequence in the exon causes Ul snRNP
assembly at a nonfunctional pseudo-5' splice site and thus sequesters it away from
binding to the authentic 5' splice site. The Drosophila homologue of hnRNP Al (hrp48)

10

and P S I (P-element somatic-cell-specific inhibitor), a K H - d o m a i n containing

RNA

binding protein, both contribute to this complex (Adams et al., 1996).
Similar mechanisms to those determined in Drosophila appear to be important in
the regulation of alternative splicing in mammals. For example, PTB (polypyrimidine tract binding protein) acts in a manner reminiscent of Sxl to inhibit 3' splice site
selection. PTB proteins have been implicated in inhibition of 3' splice site selection in
several pre-mRNAs including c-src, GABAARy2 and muscle a- and (3- tropomyosins
(Ashiya and Grabowski, 1997; Chan and Black, 1997; Mulligan et al., 1992), presumably
through interference with binding of positive factors in this region. These examples will
be discussed in more detail below.

Splicing can influence cytoplasmic fate

In addition to creating a diversity of protein products from a single gene, an under
appreciated function of alternative splicing is to generate transcripts which are
differentially regulated post-transcriptionally. In particular, splicing of non-coding
regions of a transcript can result in incorporation of different signals which result in
altered stability, polyadenylation, or nuclear export, and hence translation of the same
protein. By extension of this paradigm, alternative splicing of non-coding regions could
also influence mRNA localization within a cell since cis-acting sequences required for
subcellular localization of a number of messages have been located in the 3'UTR of the
mature transcripts (reviewed in (King et al., 1999; Oleynikov and Singer, 1998)). While
specific examples linking alternative exon usage to control of cytoplasmic mRNA

translation and/or localization have not been clearly described, it is interesting to note t
MAP2, tau and CAMKIIa all undergo alternative splicing.
11

There is also increasing evidence that nuclear splicing is coupled to cytoplasmic
events through more than just specification of the mature mRNA sequence. Using

experiments involving microinjection of Xenopus oocytes Matsumoto et al. (Matsumoto

et al., 1998) demonstrated that splicing dramatically influences translation of the
sequence in the cytoplasm. Luo and Reed (Luo and Reed, 1999) showed that splicing
alters association of a message into mRNP particles, and is required for efficient
export of some messages. Le Hir et al. (Le Hir et al., 2000) used site-specifically

modified RNAs to demonstrate that splicing influences the association of proteins w
RNA molecule.
Thus it appears that many RNA transcripts must go through a particular nuclear

pathway involving splicing in order to attain the correct mRNP composition and thus
processed correctly in the cytoplasm. For example, proteins that regulate splicing
direct regulation of mature mRNA in the cytoplasm in a manner analogous to the way
that the well characterized Drosophila alternative splicing factor, Sxl, represses

translation of msl-2 (male-specific lethal 2) in females (Bashaw and Baker, 1997; K
et al., 1997). Sxl blocks splicing of an intron in the 5' UTR of msl-2 pre-mRNA via

binding to high-affinity Sxl-binding sites within the intron. In the cytoplasm, Sxl

thought to remain bound to these intronic sites, and this association causes repres
Msl-2 translation (Gebauer et al., 1998). Thus the assembly of specific splicing
complexes is likely to lead to regulation of cytoplasmic mRNA in ways that are just
beginning to be explored.

12

A l t e r n a t i v e s p l i c i n g in t h e n e r v o u s

system

Alternative splicing is an important mechanism for generating cellular
complexity, resulting in a versatile repertoire of functionally different proteins

individual cells. The significance of alternative splicing is clearly evident in hig
specialized cells such as neurons. For example, all of the major neurotransmitter

receptors contain subunits that are alternatively spliced, which can alter receptor

localization, ligand binding, signal transduction and electrophysiological properti

(Conn and Pin, 1997; Ehlers et al., 1995; Lin et al., 1997; Macdonald, 1995; Picett
1997; Stamm et al., 1994). Moreover, aberrant splicing of mRNAs encoding proteins
critical for proper functioning of neurons has been associated with a number of
neurological diseases some of which will be discussed in detail below.
Since the discovery that the transcript encoding the thyroid hormone calcitonin is

alternatively spliced in neurons to generate the neuropeptide transmitter CGRP (Ama

al., 1982), speculation exists that there are specific systems that regulate splicin
neurons. This has been an elusive area of discovery most of what we know regarding

the regulation of neuron specific protein isoforms generated by alternative splicin
involves contributions from splicing factors that are ubiquitously expressed. Such

no doubt play essential roles in neuronal splicing, but are not likely to explain t

regulation of all splicing events unique to neurons. Study of neurologic disease ha

resulted in the identification of Nova-1 (Buckanovich et al., 1993), a protein invol

splicing regulation which is unique to neurons (Jensen et al., 2000a). This is the f

demonstration of a neuron-specific alternative splicing factor in a mammalian syste
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and has exciting implications for the discovery of such a neuron-specific system for
regulation of alternative splicing.
Studies of neuron-specific splicing in transcripts such as c-src, GABAA receptor
y2 subunit, N-methyl-D-aspartate receptor NR1 subunit and clathrin light chain B
mRNAs (Ashiya and Grabowski, 1997; Chan and Black, 1995; Chan and Black, 1997;
Wang and Grabowski, 1996; Zhang et al., 1996; Zhang et al., 1999) have identified a

number of cis-acting repressor elements that mediate the exclusion of the neuron-sp

exons in other tissues. These repressor sequences are mostly polypyrimidine-rich and

when present as competitors in vitro, stimulate neuronal splicing patterns (Chan an

Black, 1997; Zhang et al., 1999). These observations led to the suggestion that neuro
specific splicing is selectively repressed in non-neuronal tissues by trans-acting

binding proteins and that in neuronal cells, this repression is relieved by the pres

positive regulators that compete for the same or overlapping binding sites on the p
mRNA (Grabowski, 1998; Zhang et al., 1999).
Biochemical approaches have been used to identify trans-acting factors that bind

such regulatory sequences adjacent to alternatively spliced neuronal exons, includin
hnRNP H, hnRNP F and KSRP (Chou et al., 1999; Min et al., 1997). In addition, the
ubiquitous RNA binding protein, polypyrimidine tract-binding protein (PTB), was

identified through a variety of in vitro approaches as a trans-acting factor involv
repression of n-src and GABAA receptor splicing (Ashiya and Grabowski, 1997; Chan

and Black, 1997). The in vitro approaches used to identify trans-acting factors whic

bind to specific messages and affect neuron-specific splicing have provided importa

information on the contribution of generally expressed factors to this process. Howe
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these approaches have yet to identify tissue specific factors which explain the unique
patterns of alternative splicing seen in the nervous system.
The physiology of neurons may allow them to modify trans-acting factors and
thereby regulate alternative splicing in unique ways. Post-translational modifications of
RNA-binding factors in response to stimuli such as neuronal activity may provide one
means of regulating their function. For example, phosphorylation of the SR splicing
proteins regulates their splicing enhancer or repressor function, and proteins that regulate
this modification have been identified (Cao et al., 1997; Kanopka et al., 1998; PetersenMahrt et al., 1999; Xiao and Manley, 1997). Although there is no evidence to date for
brain-specific post-translational modifications able to regulate splicing, neuronal activity
itself can alter the splicing of a number of primary transcripts (Daoud et al., 1999;
Vezzani et al., 1995; Xie and Black, 2001).
For example, excitation has been specifically linked to the splicing regulation of
the NR1 subunit of NMDA ionotropic glutamate receptor. Alterations in the inclusion of
exon 21 in the hippocampus of rats exposed to .kindling electrical stimulation (Vezzani et
al., 1995), and in the cortex of rats treated with the muscarinic receptor agonist
pilocarpine (Daoud et al., 1999) have been reported. Exon 21 inclusion in turn alters
subcellular distribution (Ehlers et al., 1995), cell surface expression (Okabe et al., 1999),
and phosphorylation of NR1 by protein kinase C (PKC) (Tingley et al., 1993). One
plausible mechanism for such a phenomenon could be activity dependent changes in
protein phosphorylation. More recently Xie and Black (Xie and Black, 2001) showed that
depolarization of GH3 rat pituitary cells in culture represses splicing of the STREX exon
in Slo pre-mRNA transcripts. The presence of this exon confers higher Ca:+ sensitivity on
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the B K (Slo) potassium channel (Ramanathan et al., 1999; Shipston et al., 1999; Xie and
McCobb, 1998). Repression of splicing to this exon is mediated through a CAMK IVresponsive RNA element (CaRRE) present at the 3' splice site of the STREX exon, and

this element was shown to be sufficient for repression of splicing of a heterologou
by CAMK IV (Xie and Black, 2001).

Splicing and complexity of gene products

The diversity of cell types and functions, the richness of cell-cell contacts and n
formed, and the ability to adapt to environmental cues imply that a complex set of
mechanisms regulate gene expression in the brain. Alternative splicing provides a

plausible means for generating diversity during development and plasticity of the n

system. In some instances, for example the neurexins (see(Missler and Sudhof, 1998)f
review) and the Drosophila axon guidance receptor, Dscam (Schmucker et al., 2000),

hundreds to thousands of different splice forms are produced from a single gene, al
it is not yet clear what proportion of these messages get translated into protein.

central question is how are such complex splicing decisions made? One possibility i

such splicing choices are stochastic, analogous to the generation of immunoglobulin

diversity in the immune system. Interestingly, the organization of the genes encodi

cadherin-related neuronal receptors bears striking resemblance to that of immunoglo

and T-cell receptors in the immune system. The genes are arranged in clusters and e

contains a large number of "variable region" exons followed by three "constant regi

exons (Kohmura et al., 1998; Sugino et al., 2000; Wu and Maniatis, 1999). Although no

evidence of gene rearrangement akin to that of the immune system has been documente
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in the brain, alternative splicing of these genes m a y underlie the generation of a multitude
of protein products.
Alternatively, the choice of exon inclusion, even in complex transcripts, may be
precisely regulated. Such control has the potential to generate both protein diversity and
control of mRNA expression in a fashion that could respond to specific signals, providing
a more sophisticated control of gene expression. The current model for the generation of
diversity in this manner without the need for as many regulatory proteins as there are
regulated events, is through combinatorial control (reviewed in(Smith and Valcarcel,
2000)). Alterations in the relative proportions of positive and negative factors within
different cell types as well as the presence or absence of specific binding sites within the
RNA targets would result in alterations in the composition of complexes which form to
regulate individual splice sites. This ultimately would allow for splicing events to be
regulated independently of each other, and for a particular splice junction to be regulated
differently within different cells or at different times. In many ways this idea is
mechanistically similar to models of the regulation of transcriptional control of gene
expression (see(Hertel et al., 1997) for review). An attractive model for regulation in this
manner would be for a small number of key factors to coordinately regulate a
functionally similar set of RNA targets in a specific manner. Within the nervous system,
this type of regulation is probably important in neural development and plasticity where
concerted changes in numerous different messages are required in response to an
environmental signal.
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Neurologic

disease associated

with a b e r r a n t splicing

of

mRNAs

Inherited frontotemporal dementia and Parkinsonism linked to
chromosome 17 (FTDP-17)
Inherited frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP17) is characterized by behavioral, cognitive and motor disturbances with frontotemporal
atrophy associated with gliosis and intraneuronal tau-containing deposits. Multiple
mutations in tau, a neuronal protein which binds to microtubules and promotes their
assembly and stability, have been found in FTDP-17 patients and, in some cases, these

mutations lead to aberrations in regulated splicing (Hutton et al., 1998; Spillantini et al.
1998). At least seven missense and one deletion mutation in tau coding regions, most of
which alter the ability of tau to promote microtubule assembly, have been associated with
FTDP-17 (D'Souza et al., 1999; Hasegawa et al., 1998; Hong et al., 1998; Poorkaj et al.,
1998). In some cases, these coding region mutations also stimulate heparin-induced
assembly of tau into filaments (reviewed in (Goedert and Spillantini, 2000)).
At least five other mutations in the tau gene have also been found which exert
subtle effects on exon utilization suggesting that aberrant regulation of alternative
splicing may lead to FTDP-17 in these cases. Tau transcripts undergo alternative splicing
in 3 of the 11 coding exons to generate 6 major protein isoforms, and these splicing
events are highly regulated both spatially and developmentally (Goedert et al., 1989;
Kosik et al., 1989). Exon 10 encodes a microtubule-binding repeat domain, and
alternative splicing of this exon results in the production of protein with either 3 or 4
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microtubule binding domains. Missense, silent and intronic tau mutations have been
identified in FTDP-17 patients which are associated with two- to six-fold increases in
exon 10 utilization in vivo (D'Souza et al., 1999; Hutton et al., 1998).
Exon trapping and minigene experiments in cultured cell lines have confirmed the
effects of these mutations on the splicing of exon 10 (Grover et al., 1999; Hutton et al.,
1998; Jiang et al., 2000). A widely held view is that many of these mutations disrupt the
formation of a stem-loop present at the 3' boundary of exon 10. This secondary structure
is thought to be necessary for the correct regulation of alternative splicing at this site
through prevention of efficient interaction of Ul snRNA with the 5' splice site (Jiang et
al., 2000). In addition, cis-acting sequence elements that are involved in the regulation of
tau exon 10 alternative splicing include both a splicing enhancer and silencer within the
exon 10(D'Souzaetal., 1999).
These findings, as well as an animal model in which mice overexpressing the
shortest human tau isoform develop CNS pathology similar to FTDP-17 (Ishihara et al.,
1999), strongly imply that mutations that disrupt splicing regulation lead to FTDP-17,
most likely through generation of tau aggregates. Thus relatively subtle changes in the
ratio of spliced products (two- to six-fold) can lead to neurodegenerative disease,
highlighting the importance of systems that tightly regulate alternative splicing in the
nervous system.

Spinal muscular atrophy (SMA)
SMA is a fatal neurodegenerative disease of childhood, characterized by progressive
paralysis with muscular atrophy due to degeneration of lower motor neurons. Linkage
mapping resulted in the identification of SMN (for survival of motor neurons), as the
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disease gene in S M A (Brzustowicz et al., 1990; Lefebvre et al., 1995; Melki et al., 1990).

SMN protein is expressed in all tissues in the body with particularly high levels d

in motor neurons. The protein is present in distinctive speckles termed gems within
nucleus of cells, as well as the cytoplasm (Liu and Dreyfuss, 1996).
SMN protein has been shown to form complexes with a number of spliceosomal
small nuclear ribonucleoproteins (snRNPs), and analysis of a dominant negative form

the protein indicates that SMN is critical for snRNP assembly in the cytoplasm of s

cells (Pellizzoni et al., 1998). SMN also appears to be involved in maintenance and/

regeneration of splicing-competent snRNP complexes in vitro (Pellizzoni et al., 1999
Mutant forms of SMN found in SMA patients show reduced self-oligomerization, the

degree of which correlates with disease severity (Lorson et al., 1998), as well as r

binding to a subset of snRNP proteins (Pellizzoni et al., 1999). However, there is n

evidence that SMN plays a regulatory role itself in alternative splicing, but rathe
maintaining the snRNP machinery in all cells.
Interestingly, two distinct SMN genes exist in humans that apparently encode

identical proteins (Lefebvre et al., 1995). The telomeric copy of the gene, SMN1 (als

known as SMNT), is deleted (93% of cases), interrupted (5.6%) or mutated in nearly al
SMA patients Lefebvre, 1995 #442]. Homozygous deletions of the centromeric copy of
the gene, SMN2 (SMNC) do not result in pathology, and an intact SMN2 gene cannot
compensate for the deletion of SMN1. This curious result has been explained by

differential splicing of exon 7 (Lorson et al., 1999). Exon 7 is constitutively incl
during the normal processing of SMN1, however the predominant product of SMN2
excludes exon 7. Careful analysis of the five nucleotides that differ between SMN1
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S M N 2 has identified a silent C-to-T alteration within exon 7 which has been shown to

mediate exon skipping, yielding predominantly SMNA7 transcripts (Lorson et al., 1999

This alteration occurs within an exonic splicing enhancer (ESE) in SMN1 and abrogat

binding of ASF/SF2 resulting in the inefficient inclusion of exon 7 in SMN2 (Carteg
and Krainer, 2002).
The majority of the mutations documented in SMN1 of SMA patients are either

point mutations or small deletions in the consensus splice sites of introns 6 and 7
result in exon 7 skipping to yield SMNA7. Together, these studies and those of SMN2

indicate that SMA results from loss of function of SMN through defects in a constit
splicing event. Several reasons why SMNA7 cannot fully compensate for full length

SMN protein have been postulated, including reduced self-oligomerization (Lorson et
1998), reduced binding to snRNP Sm proteins (Pellizzoni et al., 1999) and reduced
stability (Lorson and Androphy, 2000) of SMNA7. It is as yet unclear how defects in
SMN result in a pathology that is so specific to a-motor neurons. It is likely that

aberrations in SMN result in a general defect in snRNP recycling to which motor neu

are particularly sensitive. In this way, the role of SMN in motor neuron disease ma

similar to the proposed role of defects in other genes involved in motor neuron dis
such as the superoxide dismutase gene, SOD1 (see below), which is involved in
regulating general metabolic responses to oxidative stress.

Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive neurological dis

characterized by degeneration of upper and lower motor neurons. While the mechanism

of ALS pathogenesis are not well understood, oxidative stress is thought to contrib

motor neuron degeneration in a large proportion of A L S cases, either through mutations

in SOD1 (found in 15-25% of familial ALS) (Brown, 1996; Siddique and Deng, 1996), or

via glutamate-mediated excitotoxicity. A decrease in EAAT2 protein has been observe
in approximately two thirds of patients with sporadic ALS (Rothstein et al., 1994;
Rothstein et al., 1992; Shaw et al., 1995). EAAT2, which is expressed by astrocytes
(Rothstein et al., 1994), is a glutamate transporter which pumps glutamate from the

extracellular space into cells where it is metabolized. Motor neurons are particula
susceptible to excitotoxicity as a result of exposure to high levels of glutamate,
such decreased EAAT2 levels may account for their selective vulnerability in ALS.
One study associated the presence of aberrant splice forms of EAAT2 with ALS

suggesting that altered splicing and/or RNA metabolism could contribute to the decr
in EAAT2 protein seen in some ALS patients (Lin et al., 1998). However, subsequent

studies by two independent groups failed to substantiate the claims that such defec

not found in normal or disease controls and are restricted to neuropathologically a

areas in ALS patients (Honig et al., 2000; Meyer et al., 1999). Both of these subsequ

groups reported slight differences in the proportions of some of these aberrant spl

forms in ALS versus control brains, some of which have been shown to act in a domin

negative fashion in transfection assays (Lin et al., 1998). Thus it is conceivable t

slight changes in the proportion of protein isoforms may have profound effects on p

function and disease state, as is the case for tau in FTDP-17. However, the link bet
splicing regulation and disease is far more tenuous for ALS than for other examples

discussed here and more work needs to be done to establish whether splicing regulat
plays an important role in ALS.

Spinocerebellar ataxias ( S C A 1 a n d S C A 8 ) a n d Myotonic Dystrophy
(DM)

The spinocerebellar ataxias are autosomal dominant neurodegenerative disorders whic

result in often fatal incoordination of limb movement, speech and gait. The majority

these disorders (SCA types 1,2,3,6 and 7) are caused by expansions of CAG trinucleo

repeats. These are translated into long polyglutamine tracts which are thought to im
the corresponding protein with a toxic gain of function. SCA1 is caused by

polyglutamine expansion in ataxin-1, a nuclear RBP of unknown function. Although the
mechanism of pathogenesis of mutant ataxin-1 is unclear, a number of RNA binding

proteins have been identified as disease modifiers in Drosophila suppression screen
and Zoghbi, 2001), including couch potato and mub, a 3 KH domain-containing protein
related to mammalian Nova.
Recently, a novel form of ataxia, SCA8, was reported to be associated with an
untranslated CTG expansion (Koob et al., 1999). While the mechanism by which CTG

expansion causes neurologic disease is not known, much information can be drawn from

the model of myotonic dystrophy (DM), the first (and only other) disease reported t
caused by a non-coding CTG expansion.
DM is caused by CTG repeat expansion in the 3' UTR of DM protein kinase
(DMPK). DMPK RNA containing the CUG repeats is retained in the nucleus (Davis et

al., 1997; Taneja et al., 1995) and these repeats in heterologous RNA transcripts a

necessary and sufficient to cause a DM-like phenotype in mice (Mankodi et al., 2000)
CUG repeats have been found to bind an RNA binding protein termed CUG-BP
(Timchenko et al., 1996). One model of DM pathogenesis suggests that in cells
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harboring C U G repeats, C U G - B P and perhaps other cellular factors are sequestered
resulting in abnormal processing of unrelated target transcripts. Indeed, alternative
splicing of human cardiac troponin T (cTNT) pre-mRNA is perturbed in cells expressing
transcripts containing C U G repeats, including tissue from D M patients (Philips et al.,
1998). B y analogy, S C A 8 may also be caused by sequestration of cellular factors
resulting in dysregulation of splicing of unrelated transcripts. The difference in
pathogenesis of the two diseases may relate to the different populations expressing
transcripts with C U G repeats. S C A 8 transcript is expressed in brain tissue, but is absent
or present in much lower levels in other tissues (Koob et al., 1999), consistent with the
neurological symptoms of the disease.

Neurologic

disease

neuron-specific R N A

associated

with

immune

targeting

of

binding proteins

Paraneoplastic neurologic disorders (PNDs)
Paraneoplastic neurologic disorders (PNDs) are rare immune-mediated disorders
associated with ectopic expression of neuron-specific proteins in tumors (reviewed in
(Darnell, 1996; Musunuru and Darnell, 2001)). Immune targeting of these antigens in the
central nervous system is thought to result in the neurological symptoms displayed by
P N D patients. Patients harbor high titers of antibodies specific for these antigens in their
sera, which has enabled the expression cloning of a number of proteins whose expression
is entirely restricted to neurons. These antigens fall into four general categories based on
their function;
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(1) nerve terminal and vesicle-associated proteins including glutamic acid
decarboxylase (GAD), a target antigen in stiff-man syndrome (SMS) (Solimena et

al., 1988) which was one of the first proteins identified in this context. A var

of SMS that develops in patients with breast cancer has also been associated wit
paraneoplastic antibodies against amphiphysin, a protein that appears to play a

role in synaptic vesicle endocytosis (David et al., 1996; De Camilli et al., 199
further member of this category is (3-NAP, a novel adaptin-like vesicle coat
protein identified using antiserum from a patient with cerebellar degeneration
(Newman et al., 1995).
(2) putative neuronal signaling proteins such as recoverin, a protein
involved in receptor signaling in the photoreceptor and associated with

paraneoplastic retinal degeneration and small cell lung cancer (SCLCa) (Polans e
al., 1991; Thirkill et al., 1992), and the leucine-zipper protein cdr2 which is
expressed in Purkinje cells in the cerebellum and was cloned using Yo antisera
(Dropcho et al., 1987; Fathallah-Shaykh et al., 1991; Sakai et al., 1990).
(3) neuromuscular junction proteins implicated in paraneoplastic disease
include the a-subunit of the nicotinic AChR expressed in thymomas associated
with myasthenia gravis (MG) (Gattenlohner et al., 1994; Kornstein et al., 1995).
(4) neuron-specific RNA-binding proteins (n-RBPs). This family will be
discussed in detail below.
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Paraneoplastic encephalomyelopathy / sensory neuropathy ( P E M / S N )
- Hu family of RBPs
The paraneoplastic Hu syndrome encompasses a clinically diverse set of neurologic

degenerative symptoms which may present as single or multifocal disorders (Dalmau e

al., 1992b). Neurologic dysfunction is most often localized to dorsal root ganglia (

of patients), but may also be found in the cerebellum, brainstem, limbic-, motor- or
autonomic nervous-system. Antisera from Hu patients recognize a nuclear and

cytoplasmic antigen which is pan-neuronal, but not present in other tissues (Dalmau

al., 1992a; Graus et al., 1985; Okano and Darnell, 1997). The first mammalian Hu fami

member to be identified, via expression cloning using patient antiserum, was HuD (S
et al., 1991). Three additional family members have subsequently been identified in
(HuA-HuC) (reviewed in (Brennan and Steitz, 2001; Keene, 1999)). HuB, C and D are

neuron-specific and display unique patterns of spatial and temporal expression (Oka
and Darnell, 1997). In addition, Hu transcripts undergo alternative splicing which

contributes to the potential for variability in function and/or targets of this fam
proteins.
All Hu proteins harbor three RNA recognition motifs (RRMs) of the type found in
a number of RNA binding proteins, including several involved in RNA splicing (for

example sex-lethal (Sxl), ASF/SF2 and polypyrimidine tract binding protein (PTB)). Th
best understood function of Hu proteins is a cytoplasmic role in the stabilization
messages encoding several cytokines, lymphokines and protooncoproteins via specific

binding to AU-rich elements (AREs) in the 3'UTR (reviewed in (Keene, 1999), (Brennan

and Steitz, 2001)). While there has been no demonstration that Hu proteins are invol

in splicing in mammals, H u D shows remarkable homology to the Drosophila proteins
ELAV (embryonic lethal abnormal visual system) and the well characterized splicing

factor Sxl (Szabo et al., 1991). ELAV is essential for neurogenesis (Robinow et al.,
and has been suggested to regulate alternative splicing of several transcripts in
Drosophila (Koushika et al., 1996; Koushika et al., 2000; Lisbin et al., 2001). Thus

remains an intriguing possibility that Hu proteins also play a role in splicing reg

neurons in addition to the suggested roles in early development of postmitotic neur
(Okano and Darnell, 1997).
Hu RBPs also play an important role in the nuclear export of certain mRNAs.
HuR (or HuA) has been shown to bind to specific sequences in the 3' UTRs of mRNAs

such as c-fos and to be necessary for their nuclear export (Brennan et al., 2000; G

and Steitz, 2001). Shuttling of HuR between the nucleus and the cytoplasm is mediated
by a novel shuttling domain, the HNS (Fan and Steitz, 1998a; Fan and Steitz, 1998b)

specific interactions with proteins including pp32 and APRIL (acidic protein rich i

leucine) which in turn interact with the nuclear export factor CRM1 (chromosomal re
maintenance protein l)(Brennan et al., 2000).
Immune targeting of Hu proteins in paraneoplastic disorder has been associated

with a diverse set of neurological symptoms, perhaps reflecting targeting of differ

family members in different patients. While the exact mechanisms of pathogenesis ar

not yet clear, Hu disease antisera recognize a discrete target epitope in HuD (Manl

al., 1995), suggesting that immune targeting of Hu protein contributes to neurologic
dysfunction.
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Paraneoplastic opsoclonus m y o c l o n u s ataxia ( P O M A ) - N o v a family
of RBPs

The Nova family of proteins was identified as the target antigens in paraneoplastic
opsoclonus myoclonus ataxia (POMA). POMA patients exhibit a loss of inhibitory
control of motor neurons in the spinal cord and brainstem. Two members of the Nova
family of RNA binding proteins have been cloned. Nova-1 expression is entirely

restricted to the diencephalon, brainstem and motor neurons of the ventral spinal co

correlating with regions implicated in the disease phenotype (Buckanovich et al., 19
Nova-2 expression is largely reciprocal to that of Nova-1. High levels of Nova-2

expression are observed in the cerebral cortex, hippocampus and dorsal spinal cord (
et al., 1998). A subset of POMA patients develop encephalopathy and dementia which
may be the result of immune targeting of Nova-2 expressing cells.
The Nova proteins belong to a growing class of RNA binding proteins containing
KH type (for hnRNP K homology) RNA binding domains. KH domain containing
proteins have been show to play roles in a number of aspects of RNA processing
including mRNA stability and translational control (hnRNP K and hnRNP E1/E2

(Kiledjian et al., 1995; Ostareck et al., 1997)) and subcellular localization of RN

specific sites in the cell cytoplasm (ZBP-1, Vera (Deshler et al., 1998; Ross et al.

Fragile-X mental retardation syndrome is associated with a lack of or mutation in t

domain containing protein FMR-l(De Boulle et al., 1993; Pieretti et al., 1991). A nu

of KH containing proteins have also been implicated in RNA splicing, including KSRP

(Min et al., 1997) and SF1 (Anting et al., 1996) in mammals, PSI (Siebel et al., 199
Drosophila and MER-1 in yeast (Engebrecht et al., 1991). Nova proteins are sequence-
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specific R B P s which have been s h o w n to recognize sequences present in introns adjacent
to alternatively spliced exons in at least two pre-mRNAs (Buckanovich and Darnell,
1997), as will be discussed in detail in Chapter 3. This suggested that Nova proteins were
candidates for mammalian tissue-specific splicing regulators.

Summary

The importance of RNA-binding proteins is the nervous system is highlighted by the
existence of many human disorders where the function of a specific RBP is affected.
Alternative splicing appears to be of particular importance in neurons both as a
mechanism to generate the enormous complexity of proteins and networks in the brain,
and as a mechanism to respond on a cellular basis to neurological activity. Alternative
splicing is highly prevalent in the central nervous system, including the existence of a
number of neuron-specific exons in widely expressed transcripts. Very little is understood
about how alternative splicing is regulated in the mammalian brain and in particular how
tissue specificity is achieved. A common theme in the study of alternative splicing
regulation in other tissues and organisms is that regulation is often achieved through
interaction of accessory factors with the core basal splicing machinery. This thesis is
aimed at determining whether Nova-1 can act as a regulator of alternative splicing in
vivo, thus becoming the first neuron-specific splicing factor to be identified in mammals,
and to determine the targets and mechanisms by which Nova-1 regulates alternative
splicing.
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C h a p t e r 2 - Materials a n d

Methods

DNA preparation and restriction digest analysis
Unless otherwise stated, all plasmid D N A was prepared using Spin mini-prep kits
(Qiagen) and analyzed by restriction digestion using enzymes, buffers and protocols
supplied by N e w England Biolabs. D N A was separated by electrophoresis in standard lx
TBE/1-1.5 %

agarose gels and photographed under U V light. Plasmid D N A for

transfections into cell lines was prepared by a modified cesium chloride method
(Molecular Cloning, by Sambrook, Fritch and Maniatis, Cold Spring Harbor Laboratory
Press, 1989), and dialyzed against lxTBE.

Plasmid constructs
The G A B A A R y 2 minigene containing full-length introns was generated by long-range
P C R using primers y2 G A B A F and y2 G A B A R on a subclone derived from mouse
B A C 6 0 8 F 8 (Research Genetics) and cloned into p C D N A 3 (Invitrogen). Exonuclease III
digests were performed according to the manufacturer's instructions (Amersham). The (3globin minigene was generated by P C R using primers glo-KpnF and glo-Rc using
plasmid sp64-H(3A6 (a kind gift from A. Krainer) as template, and cloned into p C D N A 3
(Invitrogen). Exon 2 was shortened by PCR. Heterologous minigene constructs were
generated by PCR.
c D N A s encoding T 7 tagged Nova-1 with and without exon H and T 7 tagged
h n R N P El were cloned into pCI-neo (Promega). All D N A constructs generated by P C R
or site-directed mutagenesis were sequenced in their entirety. Truncated Nova-1
expression plasmids were generated from the full length construct including exon H by
restriction digest with BbvCI and Sail (AKH3) or Xcml and Sail (AspKH3), blunt ending
using pfuTurbo (Stratagene) and religation with T 4 D N A ligase (New England Biolabs).
Mutations of both minigene and Nova-1 expression constructs were made with the
QuikChange Site-directed Mutagenesis Kit (Stratagene) and specifically designed
primers (Operon).
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R N A preparation
Total R N A was extracted from mouse tissues using a modified guanidine-acid phenol
protocol (Chomczynski and Sacchi, 1987). For S A B R E , tissues were frozen in liquid
nitrogen and stored at -80°C prior to R N A extraction. R N A from tissue culture cells was
purified using the RNeasy Mini kit system (Qiagen), including on the column DNase 1
digestion.

RT-PCR
Purified R N A was reverse transcribed using random hexamers and Superscript II reverse
transcriptase (Invitrogen). c D N A products were amplified using PfuTurbo (Stratagene)
with 40 pmol each primer, and 0.5 pmol of one y-32P-ATP-labeled primer. P C R products
were separated by denaturing P A G E ( 6 % acrylamide/7M urea) and confirmed by
sequencing. Quantitation was performed using a Molecular Dynamics Storm
Phosphorimager and ImageQuant software. P C R was linear with respect to input c D N A
and cycle number (data not shown).

RNase protection assays

RNase protection assays were performed using the RPA II kit (Ambion) according to t
manufacturer's instructions. For GlyRa2 probes and control R N A s , E2-3A-4 and E2-3B4 R T - P C R products were T A cloned into pGem-T Easy (Promega) using P C R primers
E 2 F and E 2 R and AmpliTaq polymerase (Perkin Elmer). Plasmids were linearized by
digest with Ncol or Spel and in vitro transcribed using T7 or Sp6 R N A polymerase (New
England Biolabs) for sense or antisense R N A s . Probes for G A B A A R y 2 and ClaB were in
vitro transcribed using T 7 R N A polymerase from gel-purified P C R products generated
using primers gaba-rpa-F and -R and cla-rpa-F and -R. Transcription templates were
confirmed by sequencing. Probes were labeled by incorporation of a32P-CTP.

Primer Extension
Primer extension was performed using Superscript II reverse transcriptase (Invitrogen)
according to the manufacturer's protocol. 2|ig total R N A and lpmol y-32P-ATP-labeled
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primer EGFP-4 ( 5 ' - C G T C G C C G T C C A G C T C G A C C A G ) were used in a final reaction
volume of 20,ul.

Cell transfection

N2A and 293T cells were grown to 60% confluence in 6-well plates or chamber slides
1 0 % F B S / D M E M with penicillin/streptomycin. For in vivo splicing assays, 2.25u.g of
total D N A , comprised of 0.25ug of the appropriate minigene, and variable amounts of
pNova-1 and empty pclneo vector, were incubated with 95ul of D M E M

and 5^1 of

Fugene6 (Roche) for 15 minutes at room temperature. The mixture was then added to the
cells in a total volume of 2 ml 1 0 % F B S - D M E M . After 40 hrs the cells were washed with
lxPBS, collected by scraping and halved for R N A extraction and protein extraction.
Transfection in chamber slides was performed by adding a mix of 0.25jig of plasmid,
48ul of D M E M and 2ul of Fugene6 to cells in a total volume of 1 ml 1 0 % F B S - D M E M .
293T cells ( A T C C ) are a primary human embryonal kidney cell line transformed with the
S V 4 0 T antigen. N 2 A cells ( A T C C ) are a mouse neuroblastoma cell line.

Western blot analysis
Tissue culture cells were lysed in P X L lysis buffer (lxPBS, 0.1% SDS, 0.5% D O C , 0.5%
NP-40). Proteins were separated by 10 %

S D S - P A G E and transferred to P V D F

membranes (Millipore). Equal loading of total protein was determined by Bradford
assay. Membranes were blocked for one hour at room temperature in 5 % non-fat milk in
R buffer (0.15 M NaCl, 10 m M Tris-Cl, 1 m M E D T A , 0.1 % Triton X-100), incubated
with HRP-conjugated anti-T7 tag monoclonal antibody (Novagen) in 5 % milk in R
buffer at 4°C overnight and washed four times with alternating high salt (1 M NaCl, 20
m M Tris-Cl, 0.1 % Triton X-100) and high detergent (0.15 M NaCl, 5 m M E D T A , 50
m M Tris-Cl, 1 % Triton X-100, 0.05 % S D S ) buffers. After a finalrinsewith R buffer,
signal was detected by chemiluminescence (NEN).

The membranes were wrapped

(SaranWrap) and exposed on Biomax M R film (Kodak).
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F u s i o n protein synthesis
Full-length recombinant T7/His tagged Noval fusion protein was produced and purified
as previously described (Lewis et al., 1999). Full-length Nova-1 c D N A including
alternative exon H was cloned into pET21a (Novagen) and transformed into BL21
competent cells, followed by standard IPTG-induction and purification by nickelchelation chromatography. Nova fusion protein was assessed for purity by S D S - P A G E
and Coomasie blue (BioRad) staining. The Nova-1 expression plasmid was made by A.D.
Polydorides.

Nitrocellulose Filter Binding Assays

Labeled RNA (100-200 nmol preheated to 75°C and bench-cooled 5 min) was incubated
with the indicated concentrations of protein. Protein-RNA mixes were incubated in a total
volume of 50 ixL S B B (200 m M K O A c , 10 m M TrisOAc [pH 7.7], and 5 m M

MgOAc),

S B B 500 (500 m M K O A c , 10 m M TrisOAc [pH 7.7], and 5 m M M g O A c ) or SBBhep
(SBB + lmg/ml heparin) for 10 min at room temperature. Binding solutions were passed
through MF-membrane filters (0.45 H A , Millipore) and washed with 5 ml S B B (or
SBB500). Data were plotted as percentage of total R N A bound versus log of the protein
concentration, and Kds were determined with Kaleidograph software (Synergy Software).
S B 2 R N A was synthesized as previously described (Buckanovich and Darnell, 1997). 9C
wild-type and mutant R N A s were transcribed using T7 R N A polymerase and gel-purified
P C R templates generated using primers T 7 - G A B A - 9 C F and xR' (wildtype, 159nt R N A )
or i9AtoCR2 (mutant, 156nt R N A ) and G A B A A R y 2 minigenes as P C R templates. Glo
R N A was transcribed using T7 R N A polymerase directly from minigene glo2A digested
with Bbsl, to yeild a 175nt R N A .

Boundary Mapping
Boundary mapping was performed as described (Fitzwater and Polisky, 1996), with the
following modifications. In vzYro-transcribed 9C R N A (60 pmol) was 3' end-labeled with
T 4 R N A ligase (New England Biolabs) and [32P]pCp (NEN). 9 C R N A (40 pmol) was 5'
end-labeled with T 4 polynucleotide kinase (New England Biolabs) and [-32P]ATP.
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Following gel purification, R N A was digested with 2 /il RNase Tl (GIBCO-BRL, 1180
units//xl) for ladder. Following alkaline hydrolysis, R N A was resuspended in 20 [il D E P C
H 2 0 and used in filter binding assays (SBBhep) with or without Nova-1 FP.

Immunofluorescence of cell cultures

For immunofluorescence of cell cultures, cells were plated onto chamber slides (Nal
Nunc), transfected where appropriate, and two days later rinsed with PBS, fixed (10
minutes in 2 % paraformaldehyde in P B S at room temperature), washed, permeabilized
(10 minutes in 0.5 % NP-40 in P B S at room temperature), washed again, blocked (1 hour
at room temperature in P B G : 0.2 % gelatin and 0.5 % bovine serum albumin in PBS) and
stained overnight with primary antibody in P B G at 4°C. After three washes in P B G ,
slides were incubated with fluorochrome-conjugated secondary antibodies in P B G for 1
hour at room temperature in the dark. Slides were then washed three times in P B G , once
with D A P I in PBS, and once in P B S alone. Slides were left at room temperature to dry
and then covered with mounting medium (Biomeda) and a coverslip (Fisher) before being
sealed with nail polish.

The slides were observed under multiple wavelength

fluorescence from a mercury lamp (AttoArc), in an upright microscope (Zeiss Axioplan).
Pictures were taken with a digital camera (Hamamatsu Orca), using Openlab software
(Improvision) and presented with Photoshop software (Adobe).

Immunofluorescence of tissue sections
Mice were deeply anesthetized with chloroform and perfused intracardially with 4 %
paraformaldehyde (PFA) in 0.1 M PBS, p H 7.2. Spinal cords were removed and postfixed overnight at 4°C in 4 % P F A in PBS. Vibratome sections (50 \xm) were collected in
cold P B S then incubated for 20 min in 50 m M N H 4 C 1 in P B S to quench the free
aldehyde groups. After P B Srinses(3 x 10 min), sections were preincubated for 10 min in
0.1% Triton X-100 and 0.1% bovine gelatin in PBS. Primary antibodies were incubated
in the same buffer overnight at 4°C. Sections were then rinsed in P B S (4 x 10 min) and
incubated for 2 hr at room temperature with fluorescent secondary antibodies (in 0.1%
bovine gelatin in PBS). After washes in P B S (4 x 10 min), sections were mounted on
slides with Vectashield (Vector Laboratories) and observed by confocal microscopy
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(Zeiss). Controls included the independent omission of each single major step of the
immunocytochemistry protocol, one at a time.

cDNA Arrays
Mouse A T L A S ™

cDNA

arrays (Clontech) were screened according to the

manufacturer's protocol. Total R N A was extracted from the spinal cords of a P12 Nova-1
null mouse and a wild-type littermate or from the pooled hindbrains of 20 PO Nova-1 null
and 20 wild-type (litter matched) mice, followed by polyA-i- purification using oligo-dT
coupled magnetic beads according to the manufacturer's protocol (Dynal). 1.5u.g polyA+
R N A per filter was used to make radiolabeled (oc32P-dATP) probe.

Selective amplification via biotin- and restriction-mediated
enrichment ( S A B R E )
Total R N A was extracted from the pooled spinal cords or hindbrains of 20 PO Nova-1
null and 20 wild-type (litter matched) mice, followed by polyA-l- purification using oligodT coupled magnetic beads according to the manufacturer's protocol (Dynal). 2.0 ug
polyA+ R N A per sample was used for S A B R E as described (Lavery et al., 1997) with the
following modifications: Linker oligos: Ll

5 ' - G G T C C A T C C A A C C - 3 ' , L 2 5'-

p h o s p h a t e - G A T C G G T T G G A T G G A C C G T - 3 ' . After linker ligation, the reactions
were loaded onto a 1 % agarose minigel and c D N A pools ranging from 150 bp to 2 kb
were isolated. Tester c D N A was P C R amplified with a 5'-biotinylated primer containing
a B a m H I restriction site. Driver c D N A from was P C R amplified with a non-biotinylated
primer containing a mutated B a m H I restriction site. Tester primer, Tl 5'-C(9)-biotinC C A G G A T C C A A C C G A T C - 3 ' ; Driver primer, D l 5 ' - G G T C C A T C C A A C C G A T C - 3 ' .
P E R T hybridization was performed according to Miller and Riblet (Miller and
Riblet, 1995). Following hybridization, single-stranded c D N A was digested with SI
nuclease and the whole reaction was mixed with 50 -ul of Dynal M-280 streptavidin
magnetic beads. After 2 h incubation at room temperature on a wheel, the beads were
extracted using a magnetic concentrator and tester homohybrids were removed by 5 a m H I
digestion. After five consecutive cycles of selection and amplification, the products were
loaded on a sequencing gel and selectively amplified c D N A bands were cut out of the gel
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and cloned into pGEM-Teasy (Promega). Following transformation of bacteria, plasmid
inserts were sequenced from plasmid minipreps using T 7 or M 1 3 R primers.

P C R Primers
The primers used were:
E2F
E4R

5'-AGCTTTCTGCAAAGACCATGAC
5' - G A A G A T C T C C A A A T C C A A G G A A T C A T C T G G G

a2glyR E3 A
a2glyR E 3 B
a2glyR E 4
Actin F

5' -C A T G G T G G T T T C T G T G A C T G A T C
5' -C A T T G T A G T T T C T G C T A T T G A C C C A A A G
5' -TCC A A A T C C A A G G A A T C A T C T G G G
5' - G T G G G C C G C T C T A G G C A C C A

Actin R

5'-CCCCCCTGAACCCTAAGGCCAACCG

mGluRIF

5'-CCTGGGGTGCATGTTTACTCC

mGluRlR

5'-AGGCCGTCTCGTTGGTCTTCA

ICH-1 F

5'-GTCTCATCTTCATCAACTCC

ICH-1 R

5'-ATGCTAACTGTCCAAGTCTA

ClaB F

5'-ACCGAACAGGAGTGGCGGGAG

ClaB R

5'-GGGGTCTCCTCCTTGGATTCT

y2 G A B A F

5'-GTATGGCACCCTGCATTATTTTGTC

y2 G A B A R

5'-TTGAATGGTTGCTGATCTGGGACG

Ch A T F

5' - A T G C C T A T C C T G G A A A A G G T C C C

Ch A T R

5' - A G T G C T C C G A G C A A A G A T C A C A G

src-F

5'-CCAAGCTCTTCGGAGGCTTCAACTC

src-R

5' - C A C A T A G T T G C T G G G G A T G T A A C C G

agrin F

5' - G G G A T A G T T G A G A A G T C A G T G G G G G

agrin R

5' - C G A A G C C A G C G G T T G G T G T T G

gaba-rpa-F

5' G A A A T T A A T A C G A C T C A C T A T A G G G A G T T G A A T G G T T G C T G
ATCTGGGACG

gaba-rpa-R

5' T C C C G C T C G T C G T C T G G T A T G G C A C C C T G C A T T A T T T T G T C

cla-rpa-F

5'- G A A A T T A A T A C G A C T C A C T A T A G G G A G G G G G T C T C C T C C
TTGGATTCT
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cla-rpa-R

5'- T C C C G C T C G T C G T C T G A C C G A A C A G G A G T G G C G G G A G

glo E1F

5'- C T G A G G A G A A G T C T G C C G T T A C T G

glo E3R

5' - C A G C A C A C A G A C C A G C A C G T T G

T7-GABA-9CF

5'- G A A A T T A A T A C G A C T C A C T A T A G G G A G C A G C T G C A
CTGCTTAAGCGC

xR'

5'- T T T T G C T A G C C A C A A T G T C A T C A A T G A G A T G A T G

i9C-A R 2

5' - G T A C T T C C A C A A T G T C A T C A A T T A G A T T A T T A A T C T G A A A A
TTAGTATTCAGAAAATTGCTT

glo-KpnF

5'- A T G G T A C C T G A C T C C T G A G G A G A A G

glo-Rc

5'- C C A C T T T C T G A T A G G C A G C C

Antibodies
The following primary antibodies were used throughout this work:
human P O M A patients' Ri serum (1:500, IF). (Buckanovich et al., 1993).
mouse monoclonal HRP-conjugated anti-T7 (1:5,000, W ) . Novagen.
mouse monoclonal anti-T7 (1:2,000, IF). Novagen.
mouse monoclonal anti-MAP2 (1:100, IF). Sigma.
rabbit polyclonal anti-coilin p80 (1:100, IF). R288, generously provided by Dr.Gall.
rabbit polyclonal anti-Noppl40 (1:1000, IF). RF12, generously provided by Dr. Meier.
mouse monoclonal anti-SIP-1 (1:100, IF) generously provided by Dr. Dreyfuss.
mouse monoclonal anti-Sm (1:100, IF). Y12, generously provided by Dr. Gall.
mouse monoclonal anti-SC35 (1:100, IF) generously provided by Dr. Gall.
mouse monoclonal anti-CTD domain of R N A polll (1:100, IF). 8 W G 1 6 , Santa Cruz.
A variety of HRP-, Cy2-, Cy3- and Cy5-conjugated species-specific secondary antibodies
were used as appropriate, following dilutions suggested by the manufacturer (Jackson
Immunoresearch). D A P I stain (Sigma) was used at 0.1 u.g/ml to visualize cell nuclei.
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C h a p t e r 3 : D e f i n i n g N o v a a s a s p l i c i n g f a c t o r in

vivo- Analysis of Nova null mice

Introduction

In vitro analysis of Nova binding

Differing approaches based on RNA selection have led to the demonstration that
Nova proteins act as sequence specific RNA-binding proteins. Through in vitro RNA
selection, a method whereby a random pool of RNA targets is subjected to selection

through binding to recombinant Nova-1 protein, a consensus binding sequence has bee

elucidated which consists of a stem-loop RNA containing (UCAUY)3 in the loop region

(Buckanovich and Darnell, 1997). This binding is sequence specific as mutagenesis of
this core to (UCUUY)3 abolishes RNA binding. Furthermore, mutagenesis and binding

studies showed that the third KH domain of Nova-1 is necessary and sufficient for h

affinity RNA binding to this sequence. Similar studies with Nova-2 yielded a consen

of GAGUCAU in a stem-loop, and whilst both proteins can bind the selected targets o

the other in vitro, subtle differences in the affinities to these RNAs were observe

et al., 1998). These results imply that Nova-1 and Nova-2 preferentially bind simila
perhaps overlapping, but not identical sets of RNA targets.
Studies using the third Nova KH domains in isolation revealed high affinity

targets containing a single UCAY element, again within a hairpin loop context (Jens
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al., 2000b), and allowed solution of the X-ray structure of a Nova K H 3 / R N A co-crystal.

The crystal structure reveals that the 20 nucleotide RNA is in the predicted stem-l
conformation, and that the protein grips the core UCAY of the RNA in a "molecular

vice" formed by a cleft between the variable and invariant protein loops of the Nova

domain (Lewis et al., 2000). Within the RNA, a segment of the single stranded region

AUCAC, accounts for the vast majority of RNA-protein contacts within the co-crystal.

The 5' A residue interacts with both N- and C-terminal amino acids in the protein v

non-specific stacking interactions. The CA dinucleotide forms contacts with the pro

to create pseudo-Watson-Crick base pairs and predicts that these residues are absol
necessary for binding to occur. Both the first and last positions of the UCAY

tetranucleotide could be filled by either pyrimidine according to the crystal struc

would not be compatible with a larger purine in these positions due to steric const
These predictions agree precisely with Nova KH3 domain/RNA binding studies in
which RNA mutations still conforming to the consensus HYCAY (where H denotes A, C

or U, Y denotes C or U) are tolerated (Jensen et al., 2000b). The stem region of the
appears to be important in constraining the conformation of the loop, retaining the
core within the single-stranded loop.

The information gleaned from these selection studies was used to search

several databases including one of neuron-specific alternatively spliced exons (Sta

al., 1994). These searches identified two potential in vivo Nova binding sites based
RNA sequence. One is present in the inhibitory neurotransmitter receptor GlyRa2
subunit pre-mRNA, 80bp upstream of an alternatively spliced exon, E3A, which is
spliced in a mutually exclusive manner with a downstream exon, E3B (Kuhse et al.,
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1991). The functional significance of the two resulting forms of the protein remains

unknown, however these exons encode part of the extracellular domain of the recepto

and thus may be involved in ligand binding (Kuhse et al., 1991). The second putative

Nova binding site is located in the Nova-1 pre-mRNA itself, 8 bp downstream of exon
also an alternatively spliced exon. This exon contains a number of potential sites
phosphorylation by serine/threonine protein kinases. Exon H may also alter protein

turnover since it contains amino acid residues reminiscent of PEST sequences (enric

in proline (P), glutamic acid (E), serine (S) and threonine (T) (Rogers et al., 198

are thought to lead to rapid intracellular degradation of the proteins containing t
including nuclear proteins (Chevaillier, 1993).

In vitro binding assays demonstrated that Nova is capable of binding RNAs

corresponding to these regions with high affinity, and that this binding is both se
specific (mutations of the UCAU repeats abrogate binding) and can be blocked
specifically by POMA disease antisera, which suggests that these antibodies may be
responsible for the development of neurological symptoms in POMA patients through
abrogation of Nova-1 RNA-binding activity in vivo (Buckanovich et al., 1996).
Moreover, native Nova protein in mouse brain lysates coimmunoprecipitates with
GlyRa2 and Nova-1 pre-mRNAs (Buckanovich and Darnell, 1997) and can be UVcross-linked to an RNA encoding a region of GlyRa2 intronic sequence, but not a
corresponding RNA in which the UCAU repeats have been mutated to UAAU (Jensen et

al., 2000a). These results demonstrate that these interactions are likely to occur i

also, and the proximity of the putative binding sites to alternatively spliced exon
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cases suggested that Nova-lmay play a role in the regulation of alternative splicing in
vivo.
Minigene constructs were generated to test whether Nova-1 is able to directly act
on GlyRa2 pre-mRNA to regulate alternative splicing of E3A and E3B. Cotransfection
with a Nova-1 expression plasmid caused a dose-dependent increase in E3A inclusion

relative to E3B in three separate cell lines (Jensen et al., 2000a). Mutation of the

binding element in this context abolished the increase in E3A inclusion upon the ad

of Nova-1, and paradoxically caused an increase in E3B inclusion relative to E3A. On

possible explanation for this observation is that the UAAU mutation allowed detecti

a cryptic Nova-1 binding site able to mediate action on E3B splicing. Taken togethe

these experiments demonstrate that Nova-1 is able to act directly to enhance the in

of GlyRa2 E3A in cell lines and that this action is dependent on the integrity of th
intronic UCAU Nova binding site.

N o v a null mice
Nova-1 null mice were generated by targeted disruption following extensive mapping
the Nova-1 gene. The first two coding exons of Nova-1, including the initiating

methionine, were replaced by an IRES-x-lacZ cassette resulting in the generation of

completely deficient in Nova-1 expression. At the phenotypic level these mice appea
normal at birth, but grow much less than their littermates and display progressive
weakness culminating in death on average by postnatal day 7-10. Heterozygous mice
harboring only one copy of the Nova-1 gene are phenotypically normal. Subsequently

these mice were bred into a CD1 genetic background resulting in mice able to surviv
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average 2-3 weeks after birth. These mice also display a severe phenotype, being

markedly smaller than their wild type littermates after as little as 3-4 days postwell as displaying symptoms of motor impairment such as motor weakness and action-

induced tremulousness as well as atrophy in the hind limbs, which are most pronounc

by approximately P7-P10. As a result, these mice are unable to walk well, dragging t

hind legs and spontaneously falling to the side, however there appear to be no sens
deficits.

Gross structure and histology appears normal in Nova-1 null mice at birth,

however signs of neuronal degeneration become evident during the first post-natal w
A four-fold increase in the number of pyknotic cells in the ventral spinal cord is
null mice compared to wild-type littermates at P5 (Jensen et al., 2000a). Neuronal

degeneration is particularly evident in brainstem motor nuclei and in motor neurons
the spinal cord, which correlates with regions of Nova-1 expression. There is no
evidence for such neuronal degeneration within the cortex, hippocampus, or sensory

neurons of the brainstem or spinal cord. These pyknotic cells corresponded to cells
undergoing apoptotic cell death, as assessed by TUNEL staining. Thus Nova-1 is
essential for survival but not development of subcortical motor neurons.

Nova-2 null mice have subsequently been generated and these mice display an

overt phenotype remarkably similar to that of Nova-1 nulls. Nova-2 null mice are al

born phenotypically identical to their littermates, but fail to grow as well, appear

markedly smaller by approximately P5. Nova-2 is also essential for viability, howev

a similar mixed genetic background, Nova-2 null mice survive slightly longer than t

Nova-1 null counterparts, an average of 14-17 days post-birth. Crosses into a numbe
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stable genetic backgrounds are in progress (M. Ruggiu, personal communication). Again,

heterozygous mice appear identical to their wild-type littermates, and null mice di

difficulty walking or righting themselves, however in contrast to Nova-1 nulls, Nova
null mice do not display action-induced tremors.

To assess the function of Nova proteins in vivo, proposed targets of Nova-1

alternative splicing regulation were examined in Nova-1 null and heterozygous mice.

These results demonstrate that Nova-1 regulates neuron-specific alternative splicin
GlyRa2 in vivo, in a manner consistent with previous biochemical and cell culture
analyses. A survey of neuronal exon usage in Nova-1 null mice revealed a defect in
inclusion of the GABAAy2L cassette exon and thus led to the identification of an

additional Nova-1 target. Finally, Nova-1 alternative splicing was analyzed in Nova

heterozygous and Nova-2 null mice on the basis of previous sequence analysis, and w
also found to be regulated in vivo by Nova proteins.

Results

Assay Development
Figure IA shows a schematic representation of GlyRa2 alternative splicing and two
complementary methods that were developed to assess GlyRa2 splicing in Nova-1 null
mice. First, RNA was RT-PCR amplified using primers specific to GlyRa2 exon 2 (E2)

and GlyRa2 exon 4 (E4). Reaction products were then digested with restriction enzym
that recognize sites either in E3A (Sspl) or E3B (BspMI, not shown) (with >98%
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specificity, Figure IB). In a second method, E 3 A and E3B-specific primers were used

under reaction conditions in which each primer showed absolute specificity for thei
respective exon (Figure IC). Quantitation of splicing using linear PCR reaction

conditions gave highly reproducible results over a range of reaction conditions (in
RNA, PCR cycle number) and between animals.
In a third set of experiments, RNase protection assays were performed. Since

GlyRa2 exons E3A and E3B are so similar (identical in 55 of 68 nucleotides), control
experiments were again performed to ensure that the assay conditions used enabled

absolute discrimination between the two spliced products. Figure 2A shows a schemat

representation of the probes used. Figure 2B shows that in an experiment where in v

transcribed RNAs were mixed in known ratios, absolute discrimination is achieved us
either an RPA probe specific for E3A- or E3B-containing messages.

GlyRcc2 Splicing in Nova-1 null mice

Preliminary experiments demonstrated that the ratio of E3A/E3B splicing was
decreased in Nova-1 null mice relative to wild-type littermates (Figure 1B,C). To
determine the reproducibility of these observations, splicing to E3A and E3B was

examined in 8 Nova-1 null mice from 6 different litters, and the results compared t
splicing in normal littermates. In every case, RNA from Nova-i null mice showed a

decrease in the utilization of E3A relative to E3B (Figure 3). These results are co
with the transfection data discussed above, in which Nova-1 acts to enhance the

utilization of GlyRa2 E3A, while in the absence of Nova-1 in vivo there is a relati
deficit in the ability of neurons to utilize the E3A splice site.
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Specificity of Splicing Defects in N o v a - 1 null m i c e .

The specificity of the defect in GlyRa2 splicing was examined by comparing the

splicing efficiency of six previously described alternatively spliced neuronal tran

(Figure 4). Splicing of five of these transcripts was unchanged in Nova-1 null mice

relative to their littermates, including clathrin light chain B (ClaB), agrin, mGluR
1 and n-src. However, alternative splicing of the GABAA receptor y2 subunit was

significantly altered in Nova-1 null mice. The GABAARy2 transcript is widely expres
in the brain, but the pre-mRNA is alternatively spliced to include a cassette exon,
preferentially in brainstem and spinal neurons (Zhang et al., 1996). Examination of
brainstem and spinal cord RNA revealed a two-fold difference in the E3yVE3B GlyRa2
splicing ratio and nearly a three-fold difference in the Y2L/y2S GABAARy2 splicing

in wild-type versus Nova-1 null mice, averaged over 11 and 9 litters, respectively (
4).
These observations were confirmed by RNase protection assays (Figure 5). By
this method, the difference between GlyRa2 and GABAARy2 splicing ratios was

calculated to be approximately 1.4-fold and 1.9-fold, respectively. These results w
reliable than RT-PCR in quantitating the low abundance splice variants in a tissue
of high complexity, as anticipated (Foley et al., 1993), which most likely accounts

difference in values. It is clear from these experiments however that Nova-1 null m
show a deficit in inclusion of the GlyRa2 E3A and GABAARy2 exon 9 alternatively
spliced exons.
In addition to differences in splicing, the steady-state level of GlyRa2 mRNA is

altered in Nova-1 null mice. Approximately 2.5-fold higher levels of GlyRa2 mRNA ar
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seen in the spinal cord of Nova-1 null mice compared to littermates (Figure 5C). This is

somewhat surprising, especially given the death of Nova-1 expressing neurons seen b

histological studies which would perhaps predict a decrease in the overall level of
neuronal messages in Nova-1 null mice. Whilst the mechanism underlying this

observation is not clear, one possible explanation could be that as a result of the
of Nova-1, processing of the RNA subsequent to splicing is altered. Recent evidence
suggests splicing in the nucleus is coupled to mRNA export, and can subsequently

influence stability (especially nonsense-mediated decay) and translatability in the
cytoplasm (reviewed in (Reed and Hurt, 2002)). Failure to interact with Nova-1 may
cause retention of the spliced RNA in the nucleus or incorrect processing in the

cytoplasm and, thus accumulation in null animals. No difference in steady state lev

seen for the GABAARy2 (or Cla-B) messages, which argues against a global upregulati
of transcription of inhibitory neurotransmitter receptors as a result of neuronal
dysfunction. If indeed GlyRa2 mRNA accumulates as a result of incorrect posttranscriptional processing in Nova-1 null mice, this would imply that GlyRa2 and
GABAARy2 RNAs are handled somewhat differently by these cells, since no change in
GABAARy2 steady state mRNA level is observed.
Although the GlyRa2 and GABAARy2 genes are expressed throughout the brain,

Nova-1 expression is relatively absent in rostral structures including the forebrai

sensory thalamus (Buckanovich et al., 1996; Yang et al., 1998). If aberrant GlyRa2 E

and GABAARy2L splicing results directly from the lack of Nova-1 in neurons, splicin
these RNAs should be relatively normal in the forebrain and abnormal in the spinal
of individual Nova-1 null mice. Specific abnormalities in GlyRa2 and GABAARy2
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splicing were found in the spinal cord and hindbrain but not the forebrain (Figure 6). In

forebrain of wild-type versus null mice no differences in alternative splicing for G

GABAARy2L, or clathrin-B mRNA, nor in steady state levels of actin or the spinal mo
neuron marker ChAT were observed (Figure 6). These results indicate that Nova-1

mediates a specific effect on the alternative splicing of GlyRa2 and GABAaRy2 recep
pre-mRNAs in a cell autonomous manner.

Genotype and developmental profile of splicing changes.

The level of Nova-1 protein varies in a dose-dependent manner in wild-type mice rel
to Nova-1 heterozygous and null mice (Jensen et al., 2000a). To assess whether the
splicing defects of GlyRa2 and GABAARy2 RNAs are dependent on the level of Nova-1

protein, the utilization of these exons in mice as a function of Nova-1 gene dosage
examined. The GABAARy2L splicing defect varied from 1.5 fold in heterozygous mice
to a 3 fold change in Nova-1 null littermates Q7igure 7A-B). GlyRa2 E3A utilization

only abnormal in Nova-1 null mice, suggesting differences in the degree to which the
Nova-1 protein is rate limiting for proper splicing of GlyRa2 and GABAARy2 premRNAs.
When alternative splicing was examined as a function of age, utilization of the
GABAaRy2L increased in wild type mice during the first three weeks of post-natal
development (Figure 7C), consistent with previous analyses (Wang and Grabowski,

1996; Zhang et al., 1996). A deficiency in exon utilization first becomes apparent a
Nova-1 null mice (Figure 7C). In Nova-1 heterozygous mice, there was again an
intermediate deficit in GABAaRy2 usage evident at P7. The GlyRa2 E3A/E3B ratio was
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unchanged in P0-P4 Nova-1 null mice (<10% difference across multiple littermates), and
thereafter differed by approximately two-fold.

Nova-1 exon H Splicing in Nova-1 heterozygous and Nova-2 null mice
A putative Nova-1 binding element containing four YCAY motifs is present eight
nucleotides downstream of Nova-1 exon H, which is conserved between mouse and

human (Figure 8A). Nova-1 alternative splicing was assessed in spinal cords of Nova

heterozygous and wild-type littermate mice (Figure 8B,C). In all litters tested over
age of P12, exon H inclusion was decreased in wild-type mice compared to

heterozygotes. This implies that in addition to mediating alternative exon inclusio
was seen for GlyRa2 and GABAARy2, Nova-1 can also act in a negative fashion to
mediate alternative exon skipping. The magnitude of the effect, whilst small, is

comparable to the difference seen in GABAaRy2 splicing between wild-type and Nova-1
heterozygous mice (Figure 8D).
Nova-1 exon H alternative splicing was also examined in Nova-2 null mice. In
both spinal cord and midbrain/hindbrain preparations, Nova-1 exon H inclusion was

decreased in a manner consistent with a dose-dependent effect of Nova-2 to decrease

exon H inclusion. Regional differences in exon H inclusion were also observed, rang
from approximately 19% inclusion in midbrain/hindbrain to 88% in cerebellum. No

difference was seen in exon H splicing between wild-type and Nova-2 null mice in th

cerebellum, however any increase in exon H inclusion in the null mice would be diff

to detect given the high level of exon inclusion in wild-type cerebellum. Taken tog

these results imply that Nova-1 can autoregulate alternative splicing of its own me

and that this splicing decision can also be regulated by Nova-2. If the effects on s
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are a direct result of Nova binding to its o w n message, these results imply that Nova-1
and Nova-2 share at least one target in common, and that Nova-1 and Nova-2 are coexpressed in at least a subset of Nova-expressing cells. Regional differences exist
level of exon H inclusion, perhaps indicative of differences in the amount of Nova

proteins (perhaps relative to other splicing regulators) in neurons in different re
the brain.

Discussion

Nova-1 regulates tissue specific alternative splicing of 3 distinct premRNAs
Genetic approaches have been used to demonstrate that Nova-1 functions to regulate

alternative splicing in neurons. Combined with previous biochemical approaches, this
provides strong evidence that Nova-1 functions to regulate alternative splicing in

by binding pre-mRNA in a sequence-specific manner to activate exon inclusion. In co
transfection assays, GlyRa2 pre-mRNAs harboring (UCAUY)3 sequence show a Nova-1

dose-dependent increase in utilization of the alternatively spliced E3A, while muta
mRNAs harboring the (UAAUY)3 point mutant do not show this effect (Jensen et al.,

2000a). Consistent with this, in Nova-1 null mice, there is a reciprocal two-fold de
in the ratio of GlyRa2 E3A relative to E3B splicing. These data provide converging

of evidence that Nova-1 regulates GlyRa2 splicing by directly binding to the pre-mR
in neurons.
A second specific defect in alternative splicing in Nova-1 null mice was also

identified by surveying a number of messages known to be alternatively spliced in t
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brain, deficient inclusion of the G A B A A R y 2 L exon. The defective exon utilization of y2L

and GlyRa2 E3A in Nova-1 null mice, suggests that Nova-1 most likely acts to activa
GlyRcc2 E3A and GABAARy2L exon inclusion in neurons. An alternative, and not

entirely exclusive possibility, is that Nova-1 activates splicing indirectly, by co

with a splicing inhibitor. Such an interpretation would be consistent with the obse

that Nova action can be antagonized by a recently discovered brain-enriched variant
PTB (Polydorides et al., 2000). However, a strictly indirect action of Nova appears

unlikely, since the action of Nova-1 to activate GlyRa2 E3A splicing in transfected

is abolished by mutation in an intronic RNA element (Jensen et al., 2000a). Experime
designed to assess whether Nova-1 also regulates GABAARy2L exon inclusion in a
sequence-specific manner are reported in Chapter 4.
These studies also provide evidence that Nova proteins regulate alternative

splicing of a third pre-mRNA. In contrast to the two previous examples, Nova null a

heterozygous mice show a relative increase in alternative splicing to Nova-1 exon H

compared to their wild-type littermates. Thus, it is proposed that high levels of No

cause a decrease in the inclusion of exon H. Again, it is unclear from the analysis

mice whether this regulation of alternative splicing is due to an indirect action o

for example Nova may alter exon H inclusion by inhibiting a splicing factor require

efficient utilization of this exon. However, it is intriguing that a putative Nova-b

element is located only 8bp downstream of exon H in the adjacent intron. This point

hypothesis whereby Nova-1 splicing regulation is also regulated by sequence specifi

binding of Nova protein to the pre-mRNA. The difference in the resulting effect (No

mediates exclusion rather than inclusion of this exon) may relate to the position o
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N o v a binding site relative to the exon involved. Chapter 4 begins to address s o m e of
these questions.
The identification of the glycine and GABAA receptor pre-mRNAs as well as the
Nova-1 pre-mRNA itself as Nova-1 targets raises the question of the extent to which
Nova proteins are used to regulate alternative splicing in neurons. A cursory examination
of transcripts known to be alternatively spliced in the brain was performed, the results of
which revealed that absence of Nova-1 does not globally alter splicing regulation, thus it
appears that Nova is involved in only a subset of splicing decisions that are made in a
single cell. How this specificity is achieved is not entirely understood, however sequence
specific RNA binding and perhaps specific protein-protein interactions are both likely to
contribute. The mechanism by which Nova-1 regulates alternative splicing is also not
well understood. Detailed analysis of the sequence elements required for Nova's action
on the two additional targets (GABAARy2 and Nova-1 exon H) has been undertaken in an
attempt to begin to understand the mechanism by which Nova-1 regulates alternative
splicing by comparison with studies of GlyRa2 E3A splicing.

Nova-1 mediated splicing regulation and neuronal dysfunction.

Nova-1 expression is not only specific to neurons, but to a subset of neurons in
the hypothalamus, brainstem and spinal cord (Buckanovich et al., 1993; Buckanovich et

al., 1996; Jensen et al., 2000a). Therefore the identification of Nova-1 as a splicing factor
provides a mechanism by which individual neurons can differentially regulate splicing in
a qualitatively distinct manner from other cell types. GABAARy2L is preferentially
included in the hypothalamus, midbrain, brainstem and spinal cord (Zhang et al., 1996),
and this correlates precisely with the pattern of Nova-1 expression, supporting our
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finding of a role for Nova-1 in generating the y2L splice variant in vivo. This study also

shows that Nova-1 exon H inclusion varies regionally within the brain. It remains t

seen whether this could also be explained in part by a correlation with Nova protei
levels, or expression levels of other splicing factors in these regions.
Analysis of Nova-1 null mice has shown that Nova-1 is essential for neuronal
viability in mature neurons in postnatal mice (Jensen et al., 2000a). The defect in

neuronal viability suggests either a loss of function, such as a failure of mechani

necessary to insure survival of mature neurons, or a gain of function, such as acqui
of a new toxic activity that mediates neuronal death in Nova-1 null neurons. For

example, aberrant splicing of the a1A calcium channel in mice is believed to result

gain of function mutation which leads to a delayed onset neurologic disorder manife
ataxia, motor seizures and absence seizures (Fletcher et al., 1996). In Nova-1 null
defects in inhibitory receptor splicing could lead to a gain of function such that
and/or GABA receptors become toxic, for example by creating imbalances between
neuronal inhibition and excitation that lead to excitotoxic cell death.
Patients with POMA have symptoms that suggest abnormal inhibitory control

over brainstem and spinal motor pathways (Luque et al., 1991). Moreover, mice with t

spasmodic mutation (Ryan et al., 1994; Saul et al., 1994) and humans with hyperekpl

(Shiang et al., 1993) harbor defects in inhibitory glycine receptors and suffer fro
myoclonic syndromes that bear marked similarities to the motor symptoms evident in

Nova-1 null mice and in POMA patients. Thus the defects in splicing of the inhibito
glycine and GABA receptors in Nova-1 null mice suggest a reasonable model for the
mechanism of motor dysfunction in both the murine and human systems. In POMA,
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immunologic targeting of N o v a protein m a y lead to defects in inhibitory receptor
function and thereby to the excess motor activity evident in the disorder.
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Figure 1: R T - P C R assays to assess GlyRa2 E3A/E3B alternative splicing.

(A) Schematic representation of GlyRoc2 E3A/E3B alternative splicing. The primers
described below are depicted as colored arrows, stars denote 32P-labeled primers.
(B) I. Specificity of the restriction digest assay. P C R of a c D N A encoding the mature
E2-E3A-E4 m R N A or the E2-E3B-E4 m R N A using 32P-labeled E 2 primer and
unlabeled E 4 primer was digested with Sspl. Phosphorimage analysis of the data
revealed that > 9 8 % of the E2-E3A-E4 D N A was digested, while < 2 % of the E2-E3BE 4 D N A was digested. II. R T - P C R analysis of G l y R a 2 E 3 A and E 3 B splicing
utilization. Spinal cord R N A from a P16 Nova-1 null mouse and a wild-type
littermate was analyzed by RT-PCR using the same conditions as in (I.) followed by
Sspl restriction digestion and autoradiography.
(C) I. Specificity of the E3A/E3B primers assay. c D N A clones encoding the mature
E2-E3A m R N A or the E2-E3B m R N A were P C R amplified with 32P-labeled E 2 and
either E3A- or E3B-specific, unlabeled primers.

Analysis of this data on a

phosphorimager revealed that E2-E3A or E2-E3B products could not be detected
using the mismatched primer pair (E2-E3B or E2-E3A primers, respectively). II. R T P C R analysis of GlyRcc2 E 3 A and E 3 B splicing utilization. Spinal cord R N A
from a P18 Nova-1 null mouse and a wild-type littermate was analyzed by R T - P C R
using 32P-labeled E 2 primer and unlabeled E 3 A or E 3 B primer followed by
autoradiography.
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Figure 2: RNase protection assay controls.
(A) Schematic representation of G l y R a 2 probes used for RNase protection
assays. Body-labeled antisense R N A probes complementary to E2-E3A-E4
m R N A or E2-E3B-E4 m R N A result in protected fragments of 288bp when
hybridized to their own sense message, or 132nt when hybridized to the
alternative splice form.
(B) Probes differentiate between E 3 A and E 3 B . Template R N A was in vitro
transcribed from c D N A clones encoding the mature E2-E3A m R N A or the E2E3B m R N A and mixed in precise ratios. These mixes were hybridized to bodylabeled antisense R N A probes as described in (A), followed by RNase digestion
and the results analyzed by denaturing P A G E and autoradiography.
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Figure 3: Aberrant GlyRcc2 splicing in Nova-1 null mice

Reproducibility of the GlyRcc2 splicing defect in Nova-1 null mice. Spinal cord RNA
from Nova-1 null mice and their littermates with indicated genotypes were analyzed as in
Figure 1(C) for the presence of GlyRa2 E 3 A and E 3 B isoforms. Data is presented as the
ratio of E 3 A to E3B exon usage in each animal. P C R results were linear with respect to
R N A input and cycle number. Actin R N A levels were measured in each sample by R T PCR, and differed by ~ 5-10% between littermates.
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Figure 4: Specific abnormalities in alternative splicing of GlyRcc2 and G A B A A R y 2
transcripts in Nova-1 null mice.
(A)

Schematic representation of the assay used to assess alternative splicing of
messages other than GlyRa2. Primers to exons surrounding the alternatively
spliced exon were used to RT-PCR both exon included and excluded forms of the
messages. One primer was 32P-labeled (star) and the products separated by
denaturing P A G E and visualized by autoradiography.

(B)

R T - P C R analysis of alternative splicing utilization. R N A isolated from a P16
Nova-1 null mouse and a heterozygous littermate was analyzed by R T - P C R with
primers specific to the indicated genes. All P C R reactions were performed in
duplicate using minus-RT reactions (not shown). y2L includes and y2S excludes
exon 9 in G A B A A R y 2 mRNA(Whiting et al., 1990). L C B 2 includes and L C B 3
lacks the neuron-specific E N exon in the clathrin light chain B (ClaB) m R N A
(Wang and Grabowski, 1996). Agrin0 lacks and agrin19includes both Z-site exons
(Ferns et al., 1992). mGluRla lacks and mGluRip contains an additional exon in
the metabotropic glutamate receptor m R N A (Hollmann and Heinemann, 1994).
ICH-1S includes and ICH-1L lacks an additional exon in the IL-1(3 converting
enzyme m R N A (Wang et al., 1994). n-src m R N A includes a neuron-specific
exon in the c-src message [Martinez, 1987 #632

(C)

Quantitation of the data presented in (B) together with additional R N A
samples (the number of litters examined is indicated by (n)). The ratio of
long:short alternatively spliced products measured in wild-type animals relative
to the respective ratio in the corresponding Nova-1 null littermate is presented.
For GlyRa2, the ratio of E3A/E3B in wild-type versus Nova-1 null littermate is
depicted. The bars represent the average change in wild-type:null exon usage for
the number of litters examined; error bars represent the standard deviation.
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Figure 5: Confirmation by RNase Protection Assay.
(A) R P A analysis of alternative splicing utilization. Schematic representation of
the body-labeled antisense R N A probes used for RNase protection assays and the
resulting product sizes used for quantitation are shown on the left. Spinal cord
R N A isolated from P16 (GlyRcc2 analysis) and P13 ( G A B A A R y 2 and Cla B )
Nova-1 null mice and their littermates with indicated genotypes was analyzed by
RNase protection assay. Autoradiographs are shown on the right.
(B) Quantitation of the data presented in (A) together with additional R N A
samples (the number of litters examined is indicated by (n)). Products were
quantitated by phosphorimager and corrected for the expected number of labeled
nucleotides (Cs). The ratio of long:short alternatively spliced products measured
in control animals relative to the respective ratio in the corresponding Nova-1
null littermate is presented. For GlyRa2, the ratio of E3.A/E3B in control versus
Nova-1 null littermate is depicted. The bars represent the average change in
wild-type:null exon usage for the number of litters examined; error bars represent
the standard deviation.
(C) R P A analysis of steady state m R N A levels. Quantitation of the data presented
in (A) together with additional R N A samples (the number of litters examined is
indicated by (n)). Products were quantitated by phosphorimager and corrected
for the expected number of labeled nucleotides (Cs). The total of both
alternatively spliced products measured in control animals relative to the total
m R N A level in the corresponding Nova-1 null littermate is presented. The bars
represent the average change in wild-type:null m R N A level for the number of
litters examined; error bars represent the standard deviation.
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Figure 6: Regional specificity of splicing defects

GlyRoc2 and GABAARv2 alternative splicing defects are restricted to Nova-1
expressing regions of brain in Nova-1 null mice. Spinal cord or forebrain R N A was
isolated from a P18 (P7 for G A B A A R y 2 ) Nova-1 null mice and a wild-type littermate and
analyzed for the indicated splicing products by RT-PCR. Data is presented as in Figure
3. Unlike the spinal cord, quantitation of phosphorimager data using R N A from
forebrain revealed no differences in the ratio of G l y R a 2 E3A/E3B and y2L/y2S
GjABAARy2 exon usage between Nova-1 null animals and wild-type littermates. Clathrin
B light chain alternative splicing showed no null:wild-type difference in either spinal
cord or forebrain. Quantitation revealed no differences in the steady-state levels of R N A
encoding the motor neuron marker choline acetyltransferase (ChAT) or actin in Nova-1
null spinal cord relative to wild type.
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Figure 7: Changes in GlyRcc2 and G A B A A R y 2 Alternative Splicing as a Function of
Gene Dosage and Development.
(A)

G A B A A R y 2 , GlyRcc2, and c-src alternative exon usage in the spinal cords of a
P16 Nova-1 null mouse and its heterozygous and wild type littermates were
analyzed. There was a significant difference in alternative exon utilization in both
the null and heterozygote mice for the G A B A A R y 2 message, whereas the GlyRa2
E3A/E3B ratio is only disturbed in the null mouse. Alternatively spliced n-src
m R N A is unchanged in all three genotypes.

(B)

Data obtained from (A) and the indicated number of additional litters is shown.
GlyRct2, G A B A A R y 2 and n-src alternative exon usage in Nova-1 null and
heterozygote mice is plotted using the alternative exon ratio of the wild-type
mouse set to 1. Bars represent the average of the normalized exon use ratio; error
bars indicate the standard deviation.

(C)

Developmental change in the G A B A A R y2L/y2S exon use ratio. Points represent
single measurements at the indicated developmental times.
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Figure 8: Nova-1 alternative splicing is altered in Nova-1 heterozygous mice.
(A) Alignment of Nova-1 genomic sequence downstream of exon H from mouse
(mus) and human (hum). Non-conserved nucleotides are depicted in gray, Y C A Y
motifs in red.
(B) R T - P C R analysis of exon H utilization. R N A isolated from Nova-1 null,
heterozygous and wildtype littermates at the indicated ages was analyzed by R T P C R with primers specific to exons surrounding exon H. Analysis of null mice
confirms that these mice do not express Nova-1 m R N A , and confirms the
specificity of the primers used.
(C) Quantitation of the data presented in (B). Data is presented as the ratio of exon
H included (+H) to excluded (-H) for each heterozygous and wildtype animal.
(D) Data obtained in (C) from four litters aged P12 and over presented with data from
Figure 7(B). Alternative exon usage in Nova-1 null and heterozygote mice is
plotted using the alternative exon ratio of the wild-type mouse set to 1. Nova-1
data is presented as the fold increase in alternative exon inclusion in
heterozygous compared to wildtype mice, all other data represents fold decrease.
Bars represent the average of the normalized exon use ratio; error bars indicate
the standard deviation.
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Figure 9: Nova-1 alternative splicing is altered in Nova-2 null mice.
(A) R T - P C R analysis of exon H utilization. R N A isolated from the indicated tissues
of P16 Nova-2 null, heterozygous and wildtype littermates was analyzed by R T P C R as in Figure 8(B).
(B) Quantitation of the data presented in (A). Alternative exon H usage is plotted
using the exon H included:excluded ratio of the wild-type mouse set to 1.
Differences in exon H alternative splicing are seen in heterozygous and Nova-2
null mice compared to wildtype littermates in R N A isolated from spinal cord and
midbrain/hindbrain.
(C) Quantitation of the data presented in (A). Exon H inclusion is plotted as a
percentage of total spliced Nova-1 m R N A . The level of exon H inclusion is
similar in spinal cord and midbrain/hindbrain ( 2 3 % and 1 9 % in wildtype,
respectively), but much greater in cerebellum (88% in wildtype).
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C h a p t e r 4 - Characterization of N o v a action

on

Defined pre-mRNAs

Introduction

GABAARy2 alternative splicing.

The GABAA receptor is an important mediator of synaptic inhibition in the central
nervous system. A number of studies have shown that alternative splicing of the y2
subunit of GABAAR alters the pharmacological properties of GABAA receptor channels
(Krishek et al., 1994; Wafford et al., 1993). y2L and y2S forms of this subunit are

generated by alternative splicing of a cassette exon, E9, inclusion of which adds a

additional eight amino acids to an intracellular loop of the protein, and generates

which can be phosphorylated by PKC (Krishek et al., 1994). Further evidence that thi

splice choice is functionally important comes from analysis of mice engineered to o

express the short form of the GABAaRy2 subunit, (y2S). y2L -/- mice display a higher

level of anxiety than control mice as measured by both the number of entries onto t

open arms of an elevated plus maze and the time spent on open arms (Homanics et al.,

1999). In addition, these mice display increased sensitivity to benzodiazapines (Qui
et al., 2000).
Splicing to GABAaRy2 exon 9 is neuron specific, and the level of inclusion of

this exon varies both regionally within the brain and in a developmentally regulate
manner (Wang and Grabowski, 1996). Studies aimed at trying to understand the
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mechanism behind regulation of this splicing decision have shown that nucleotides within
the exon and the adjacent splice sites are essential for neuron-specific regulation as
assessed by quantitation of the level of exon inclusion in a neuronal versus a nonneuronal cell line (Zhang et al., 1996). In addition, PTB has been shown to inhibit
splicing to this exon, which has led to the hypothesis that splicing is regulated by a
mechanism involving derepression of splicing at this site in neurons of the CNS (Ashiya
and Grabowski, 1997; Zhang et al., 1999). This hypothesis implies a requirement for a
tissue-specific factor which would alleviate the repression of splicing by PTB in the brain
either through competition for RNA binding and/or through interactions with PTB which
prevent its repressive action. The finding that Nova-1 null mice show a decrease in the
level of inclusion of exon 9 suggests that Nova-1 likely plays a role in regulation of
GABAARy2 alternative splicing, possibly through an interaction with PTB. In keeping
with this hypothesis, Nova-1 has been shown to interact with a brain-enriched variant of
PTB, brPTB in yeast-2-hybrid assays and this interaction antagonizes the ability of Nova1 to enhance splicing to E3A of GlyRa2 pre-mRNA (Polydorides et al., 2000).
Alternatively, Nova-1 may act to enhance E9 splicing by sequence-specific binding to the
RNA independent of any interaction with PTB.

Nova-1 exon H alternative splicing.

Nova-1 alternative splicing is by definition an additional example of neuronspecific splicing as this message is transcribed exclusively in neurons. Very little is
known about either the function or regulation of alternative splicing of Nova-1 exon H.
This exon contains a number of putative phosphorylation sites and preliminary evidence
suggests that this region of the protein can be phosphorylated in vivo (G. Stefani and R.
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Darnell, unpublished data). Analysis of Nova-1 heterozygous and Nova-2 null mice, as

well as the existence of a putative Nova binding site in the adjacent intron provid

tantalizing evidence that Nova proteins may autoregulate splicing of the Nova-1 pre
mRNA. If this is indeed the case, then Nova-1 is able to act as both a positive and

negative regulator of alternative exon inclusion. SR proteins have been shown to ac

both positive and negative regulators of alternative splicing depending on the posi

the relevant binding site within the pre-mRNA (Kanopka et al., 1996). In addition, T
activates female-specific splicing of dsx RNA by enhancing splice site recognition

through recruitment of general splicing factors (reviewed in (Lopez, 1998)) but rep
splicing of the Ml intron within its own pre-mRNA (Mattox and Baker, 1991). Further
evidence for a direct action of Nova on alternative splicing of both GABAaRy2 and

Nova-1 alternative splicing and information regarding the sequence requirements for
an action would help to elucidate the mechanism by which Nova-1 acts as a tissue
specific regulator of alternative splicing in vivo.

Results

Nova regulates GABAARy2 alternative splicing in cell lines
To assess the sequence requirements necessary for Nova-1 action on GABAaRy2
alternative splicing, a minigene construct was generated which contains the entire

genomic region surrounding the alternatively spliced exon, E9, and extends into the
adjacent exons, E8 and E10. This was cloned into the mammalian expression construct

pcDNA-3, under transcriptional control of the CMV promoter (see schematic, Figure 10

A). This construct was transiently transfected into N2A or 293T cells. Total RNA was

65

isolated 40 hours post-transfection and used for R T - P C R analysis of spliced products

using PCR primers to E8 and E10. Figure 10 B,C show initial experiments performed i
N2A cells which were used to optimize PCR conditions. Cycle number and input cDNA

volumes demonstrated to be within the linear range of amplification in this experim
were used in subsequent studies (28 cycles, 3|J,1 cDNA unless otherwise noted).
Cotransfection of a T7-tagged Nova-1 expression vector with the GABAaRy2

minigene in mammalian cell culture recapitulated the splicing effects seen in Nova-

mice (Figure 11). Addition of Nova-1 plasmid caused a dose dependent increase in E9

inclusion, resulting in a roughly four-fold increase in the ratio of E9 included (y

excluded (y2S) splice forms upon the addition of 2.0u.g of Nova-1 plasmid in N2A ce

(Figure 11A). Similar results were seen in a second cell line, 293T, where a five-fo

increase in exon 9 utilization was observed (Figure 1 IB). Analysis of mock transfe
cells showed that neither cell line expresses endogenous GABAaRy2 mRNA (lanes M,
Figure 11 A.I, B.I) meaning that any spliced products detected are derived from
transfection of the minigene. Interestingly, the level of E9 inclusion without the

of exogenous Nova-1 was substantially different between the two cell lines. The rat

y2L/y2S splice forms was approximately 10 fold higher in N2A cells than in 293Ts. T

may reflect the fact that N2A cells express endogenous Nova proteins whereas 293T c

do not, although there are likely to be many other variables that also come into pl
Similar cotransfection experiments were also performed using a T7-tagged
hnRNP-El mammalian expression vector. Addition of exogenous hnRNP-El caused a
modest decrease in the utilization of GABAaRy2 exon 9 (Figure 11 A, B). Comparable

expression levels of the two proteins was confirmed by Western blot (Figure 11 A.II
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B.ll). hnRNP-El, like Nova, contains three KH-type R N A binding domains, the second

two of which are separated by a spacer region. This result demonstrates that the ac
Nova-1 in this assay cannot be replicated by another KH-domain protein, which is

consistent with the hypothesis that sequence-specific interactions between Nova-1 a

GABAaRy2 RNA are necessary. As an additional control, fixed cells were stained with

anti-T7-tag monoclonal antibody and visualized with Cy3-conjugated secondary antibo

to confirm that both T7-tagged proteins are able to localize to the nucleus, and th
result is not due simply to the fact that the exogenous hnRNP-El was spatially
constrained (on a cellular level) from effecting splicing (Figure 11 C,D).

Defining the region of GABAARy2 RNA necessary for regulation by
Nova-1
Given that Nova-1 regulates alternative splicing of GlyRa2 pre-mRNA via binding to
intronic YCAY repeats, the available genomic sequence surrounding GABAaRy2 exon 9

from three organisms (human, mouse and rat) was examined in order to identify putat
conserved Nova-1 binding sites. Within approximately 170 nt upstream and 100 nt
downstream of exon 9 (Figure 12, yellow rectangle), only 2 YCAY motifs conserved

between human and mouse were found (Figure 12, red underline). Within this region, t
additional motifs were found in each species which were not conserved (Figure 12,
purple underline).
The conserved YCAY motifs, plus a nearby (within lOnt) CA dinucleotide were
mutated as indicated in Figure 12 in the context of the GABAaRy2 minigene to test
whether Nova-1 action to increase splicing to E9 requires these sequence elements.
Figure 13A shows that the mutation within intron 8 has no effect on splicing of E9
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or without the addition of exogenous Nova-1 in N 2 A cells. T h e mutation in intron 9,
however, had a dramatic effect on splicing to E9, resulting in a decrease in the ratio of
y2L/y2S of approximately 15-fold in N2A cells (Figure 13A). Similar results were seen in
293T cells (Figure 13B). Again, mutation of intron 8 had no effect, but mutation of intron
9 reduced E9 inclusion approximately 5-fold, down to barely detectable levels. Despite

this, addition of Nova-1 still leads to an increase in E9 inclusion in both cell lines (Figure
13A,B) of similar magnitude to the wild-type minigene. Thus this mutation likely
disrupts an intronic splicing enhancer necessary for efficient utilization of E9, but is not
at the site of Nova-1 action.
Since the introns surrounding GABAaRy2 exon 9 are quite large (approximately
2.3kb and 1.4kb), identification of a suspected intronic Nova-1 binding site is difficult.
To overcome this difficulty, exonuclease was used to generate a number of deletion
minigene constructs with introns of varying lengths. These were then analyzed in the
same manner as the full-length minigene in the hopes of identifying an even smaller
region of sequence necessary for Nova-l's action on E9 splicing, and which would be
more amenable to biochemical studies of Nova-1 binding in vitro, and to a more thorough
mutagenesis approach. Figure 14A illustrates the approach used to generate such a library
of constructs: the minigene was cut with restriction enzymes within either of the two
introns. The introns were then shortened by bi-directional digestion using exonuclease III
for varying lengths of time. A fraction of the products were resolved on agarose gels to
confirm reduction in plasmid size (Figure 14B). The remaining products were
recircularized and transformed into E. coli. Individual clones were screened by restriction
digest to determine approximate insert size (Figure 14C), then sequenced.
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A selection of the minigenes generated in this manner were then cotransfected

into N2A cells with or without the addition of Nova-1 expression plasmid. Figure 14

shows the results of a number of these experiments. Although a large amount of vari

was seen in both the level of E9 inclusion in the absence of Nova-1 addition, and th

degree to which Nova-1 alters splicing, there did not appear to be a distinct cut-o

between constructs regulated by Nova, and those that were not. The only minigenes t

displayed an increase in E9 inclusion of less that 2-fold upon Nova addition were t

which did not splice correctly to E9, presumably because the branch-point adenosine

intron 8 was deleted in these cases (constructs D3 and Dil). However, there was a d
(to < 3-fold) in Nova's effect upon deletion of sequences within 200bp upstream of
(Figure 14D, minigenes Al-30, Al-44, Al-43, A2-38). This region is rich in YCAY

repeats as will be discussed below. Further attention was drawn to this region by t
results of transfection of minigenes Al-20 and particularly Al-21 which show an
increase in the magnitude of the Nova-1 effect.
A drop in Nova-1 effect was also seen upon deletion of sequences within lOObp

upstream of E9 (compare constructs D7, D17, D12 to D4, Figure 14D). This region doe

not contain a single YCAY repeat in mouse (see Figure 12), but may contain a cryptic

Nova binding site or another sequence necessary for the effect, but not directly bo
Nova.

To facilitate further investigation, especially in the region around E10, a truncat
minigene was made by combining of constructs D12 and 2A2 (Figure 14D) which is

depicted in Figure 15A (D12/2A2). In addition a minigene was constructed using the f

3 exons of the human p-globin gene and the entire intervening sequences ("glo", Fi
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15A) with the aim of generating an unrelated construct not regulated by Nova-1 which

could be used as a negative control and for the construction of chimeric minigenes.
central exon of this construct was uniformly included in the spliced product upon

transfection into N2A or 293T cells (data not shown). It has been well established t

size of an exon can directly influence the efficiency of splicing to that exon (Ber
1995; Dominski and Kole, 1991). In order to make a minigene more comparable to
GABAaRy2, the central region of (3-globin exon 2 was deleted ("glo2A", Figure 15A)
give a central exon size of 28nt.
Figure 15B shows that the truncated GABAaRy2 minigene D12/2A2 behaved in a

manner analogous to the full-length construct, showing increased E9 utilization upo

addition of Nova-1 and a lower level of basal E9 inclusion in 293T cells compared to
N2A cells. Quantitation of the results revealed that addition of 2.0u,g of pNova-1

in an almost 6-fold increase in E9 inclusion in N2A cells, and a roughly 14-fold in

in 293T cells (Figure 15C), even more robust effects that were seen with the full-l

construct. Minigene glo2A showed a similar level of alternative exon (E2A) inclusio
the GABAaRy2 construct in N2A cells (Figure 15B,C), but was not regulated upon the
addition of exogenous Nova-1 in either cell line.
To address which regions of GABAaRy2 sequence remaining in the truncated

minigene are necessary for the regulation of alternative splicing by Nova-1, chimeri
constructs were generated incorporating regions of GABAaRy2 and (3-globin sequence

(depicted in Figure 16A) and tested in cell transfection assays. The results displa

Figure 16A and quantitated in Figure 16B show that the central 12Int region surroun
and including GABAaRy2 E9 is not sufficient to mediate the level of Nova-dependent
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splicing as seen with the G A B A a R y 2 minigene truncate, either in the presence or absence

of the upstream exon and intronic region (compare construct a. to b. and d., Figure
Surprisingly, inclusion of an additional 43nt upstream of E9 (Figure 16, construct

not restore the effect as may have been expected from comparison of constructs D4 a
D12 in Figure 14C, making it unlikely that a cryptic Nova-1 binding site exists in
location.
Consistent with the observations made from analysis of the GABAaRy2 deletion

constructs (Figure 14D), the sequence element upstream and extending into the 5' en

the constitutively spliced exon E10 is necessary for the robust Nova-dependent effe

alternative splicing (compare constructs d. and e., Figure 16B). In order to furthe

the sequence sufficient for Nova-dependent regulation of GAB.\aRy2 alternative spli

additional chimeric constructs were generated and are illustrated in Figure 17A. Co
transfection of these constructs with Nova-1 demonstrated that the region upstream
and including exon 10 that was shown to be necessary for Nova-dependent splicing

(Figure 16 construct e.) is also sufficient to mediate the effect (Figure 17, const
Furthermore, the exon E10 included in the GABAaRy2 minigenes is neither necessary
nor sufficient for Nova-dependent splicing (Figure 17, construct g. and h.). These
were consistent in both cell lines tested: N2A (Figure 17B) and 293T cells (Figure
Thus the 21 Int intronic element situated immediately upstream of exon E10 in

GABAaRy2 pre-mRNA is sufficient to mediate Nova-dependent regulation of alternative
splicing of a heterologous exon (Figure 17, construct g.).
This intronic element contains seven YCAY repeats (Figure 18, red underlines)
and is highly conserved between mouse and human sequences; where there are
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differences between the two species in the regions of these repeats, the variation is in
which pyrimidine residue is used at either end of the motif, thus maintaining the
consensus YCAY, or in one instance a repeat is shifted by two positions in human
compared to mouse (purple underlines, Figure 18). Mutations were made in the first
(Figure 19A, denoted by green star), last four (red star), or all seven (green + red
mutating YCAY repeats to YAAY in the context of the chimeric minigene construct g
(Figure 17A). Figure 19B-I shows that in N2A cells, mutation of the first three or

four YCAY motifs reduces the effect of Nova addition by approximately 2.4-fold, whi
mutation of all seven repeats abrogates it to a level similar to that seen for the
negative control (-c, Figure 19). The effects of these mutation were recapitulated

cells (Figure 19B-II). The results from Figure 19B are graphed again in Figure 19C a

change in ratio of long to short spliced forms (L/S) upon the addition of Nova-1, t

basal level of E9 inclusion without the addition of exogenous Nova is set to 1. Thi

of presentation makes the effect of the mutations even more apparent. The results s

that intact YCAY repeats are necessary for Nova-dependent regulation of alternative
splicing in the context of the chimeric minigene.
Identical mutations were made in the full-length GABAaRy2 minigene (Figure
20A) to determine whether the presence of these YCAY repeats is necessary for Nova-

dependent regulation in this context. Co-transfection of these plasmids with pNova-

293T cells yielded very similar results to those seen for the chimeric construct (F

20B, quantitation is shown in Figure 20C). Again mutation of the first three or las
YCAY repeats had a dramatic effect on Nova-dependent regulation, but did not

completely abolish it. Mutation of all seven YCAY repeats resulted in a paradoxical
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decrease in the inclusion of E9 upon the addition of Nova-1. These results indicate that

these repeats are indeed vital for the regulation of GABAaRy2 E9 alternative splici
Nova-1.

In vitro analysis of Nova binding to GABAARy2 RNA
An RNA corresponding to the region of the GABAaRy2 pre-mRNA harboring all

seven YCAY motifs shown to be necessary for Nova regulation of alternative splicing
was synthesized in vitro (RNA 9C, arrows Figure 18). Nitrocellulose filter binding
were performed to determine whether purified Nova-1 fusion protein (NFP, Figure 21

Fraction 2 was used) is capable of binding to this sequence with high affinity in v
These results show that full-length Nova-1 fusion protein is capable of binding to

sequence with affinity similar to that of binding to an RNA purified by RNA selecti

(SB2) under similar conditions to those used for the selection (lxSBB) (Buckanovich

Darnell, 1997) (Figure 21B-I). This binding is severely abrogated by the mutation of

YCAY repeats to YAAY (9Cmut, Figure 21), to a level similar to the binding of NFP to

an irrelevant (3-globin (glo) RNA of a similar length. Addition of heparin to the r
both increases the binding affinity of the target RNAs to Nova-1 and decreases nonspecific binding to the mutant RNA and (3-globin RNAs (Figure 21B-II). This binding

severely though not entirely disrupted by high salt conditions (500mM KOAc) (Figure
21B-ni).
To determine the minimal RNA sequence necessary for high affinity Nova-1

binding, the 5' and 3' boundaries of the RNA that bound to Nova-1 fusion protein we

mapped (Figure 22). Full-length 9C RNA was labeled with 32P at either the 5' or 3'e
and subjected to mild alkaline hydrolysis. This RNA was then incubated with Nova-1
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fusion protein and bound R N A s captured by filtration through nitrocellulose filters,
eluted and analyzed by denaturing PAGE. The results suggest that a minimum of 4-5
YCAY repeats are necessary for binding of the RNA to Nova-1. Alternatively, the
minimal sequence between the 2 boundaries may be all that is required for Nova-1
binding in this instance, although this has not been addressed directly.
To correlate the in vitro binding studies with the function of Nova-1 on the
regulation of alternative splicing, additional minigenes were assayed in cell culture
transfection assays which contained smaller GABAaRy2 intronic elements of varying
lengths (Figure 23A, lines are color coded to match the schematics shown in 23B). The
results of cotransfection of these constructs with Nova-1 into 293T cells are shown in
Figure 23B. Figure 23C displays the quantitation of these results and clearly indicates
that constructs w and x containing only 114 and 68nt of sequence derived from
GABAaRy2, respectively are regulated to the same degree by Nova as the control,
construct g. Reduction of this element to only 39, or even 24nt (constructs y and z,
respectively, Figure 23) corresponding to the region bound by Nova-1 established by the
boundary mapping experiment and a total of four YCAY motifs is sufficient to mediate
alternative splicing regulation of a heterologous minigene construct by Nova-1, although
the effect is slightly diminished. Taken together with the in vitro binding studies, these
results are consistent with the hypothesis that Nova-1 binding is necessary and sufficient
for regulation of alternative splicing in a the context of a heterologous minigene.
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Analysis of the r e g i o n s of N o v a - 1 protein required for regulation of
GABAARy2 alternative splicing.

Truncated versions of pNova-1 expression plasmid were generated to assess whether
KH3 and the spacer region contribute to Nova-1 function in regulating GABAaRy2
alternative splicing. Figure 24A illustrates the deletions that were made and the
GABAaRy2 minigene target, D12/2A2, that was used in the assay. Deletion of KH3

reduced the effect of Nova-1 on E9 splicing by approximately 2-fold in both N2A (Fi
24B) and 293T cells (Figure 24C), but does not completely abrogate the effect. This
implies that KH3 likely contributes to the binding of Nova-1 to GABAaRy2 RNA, but
that other regions of the protein, presumably KH1 and KH2, also contribute to the

binding. Deletion of the spacer region plus KH3 results in the production of a trun

protein with no effect on the alternative splicing of GABAaRy2 E9 in N2A cells (Fig
24B). This shows that the spacer region is necessary for regulation of alternative

by Nova-1, possibly through interactions with other proteins. Attempts to express th

protein in 293T cells resulted in very low or undetectable levels of exogenous prot
expression, so these results were not included.
To address the role of exon H in GABAaRy2 splicing and to ask which KH

domains contribute to alternative splicing regulation, Nova-1 expression plasmids w

lack exon H or harbor a single point mutation within one of the KH domains were use

cotransfection assays with a minigene target. Mutations were made in residues of th
domains believed to be important for RNA binding from analysis of the Nova KH3/RNA

co-crystal structure and comparisons to FMRP (Lewis et al., 2000). Mutations at thes
positions in KH1 and KH3 have been shown to greatly reduce binding of the isolated
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domains to poly-rG in vitro (Buckanovich et al., 1996). Figure 25B shows that expression
of the Nova-1 isoform lacking exon H had the same effect on GABAaRy2 alternative
splicing as Nova-1 including exon H. However, single point mutations in any of the

domains resulted in a decrease in the effect of Nova-1 on E9 inclusion. Quantitatio

these results (shown in Figure 25C) indicated that the magnitude of the decrease wa

roughly 2-fold. This is within the same range of effect as was seen upon truncation
entire KH3 domain, and thus is consistent with the mutations resulting in complete
abolition of RNA binding by that KH domain. Attempts to express a Nova-1 protein

harboring all 3 KH mutations resulted in poor expression levels, so the results wer
included in this study.

Autoregulation of Nova-1 alternative splicing

To investigate the role of Nova-1 on its own alternative splicing, two reporter pla

were constructed harboring a Nova-1 minigene EGFP expression cassette (Figure 26A).

The minigenes are composed of the first coding exon of Nova-1, exon E, which suppli
an initiating methionine and a splice donor, and approximately 400bp of downstream

intronic sequence. Exon E also contains the putative Nova-1 NLS. This fragment is t
joined to a region of genomic DNA surrounding the alternatively spliced exon, exon
which includes approximately 500bp of intronic sequence either side of the coding
region. A lbp insertion has been made in the 72bp exon such that inclusion of this

will change the reading frame of downstream coding sequences. Finally the first 30b
the terminal coding exon, exon I, along with 800bp of 5' intronic sequence has been

fused to an EGFP reporter in either of two frames. The resulting plasmids are desig

such that the EGFP portion of the coding sequence is in frame if exon H is included
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out of frame if exon H is spliced out in one instance, or vice versa for the other plasmid.

These proteins will not contain any of the Nova-1 KH domains, and thus are not expe
to contribute to RNA-binding function in these assays.
Figure 26B demonstrates that cotransfection of the minigene (designated pG-)

which expresses functional EGFP when exon H is excluded from the spliced product wi
increasing amounts of pNova-1 results in increasing numbers of cells expressing
detectable levels of EGFP protein. No change in EGFP expression was seen upon the
cotransfection of exogenous Nova-1 with the parental EGFP expression plasmid (data
shown). Thus addition of exogenous Nova-1 causes a decrease in the level of exon H

inclusion. This is consistent with the results shown in Chapter 3 (Figure 8s and 9)

Nova-1 heterozygous and Nova-2 null mice show an increase in the level of Nova-1 ex
H inclusion compared to their wild-type littermates.
Mutations (YCAY to YACY) were made in pG- to disrupt the putative Nova-1

binding site immediately downstream of exon H and are depicted in Figure 27A. In or

to avoid issues of primer competition since primers to exonic regions within the mi
would also amplify the Nova-1 cDNA from the pNova-1 expression plasmid, spliced
products were analyzed by primer extension using a 32P-end labeled primer specific
EGFP, as well as by EGFP protein expression. Figure 27B shows that mutation of the
YCAY repeats downstream of exon H did not effect exon H splicing in the presence or

absence of exogenous Nova-1. Quantitation of the results (Figure 27B) showed that t

mutations decreased the basal level of exon H inclusion by about 2-fold, but that N

was still able to mediate a robust decrease in exon inclusion. The magnitude of the
of exogenous Nova expression on exon H splicing is shown in Figure 27D by
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presentation of the results after normalizing the basal level of exon H inclusion to 1, and

indicates that the mutations had no effect on the ability of Nova-1 to regulate spl

its own alternative exon. Thus if Nova acts to regulate alternative splicing of its
message by directly binding to the RNA, as has been shown to be the case for GlyRa2
and GABAARy2, binding is not likely to occur within this region.
An approach similar to that used to assess the sequences necessary for Nova-

dependent regulation of GABAARy2 alternative splicing was also undertaken to analyz

Nova exon H splicing. Figure 28A shows the sequence of the entire region surroundin
and including exon H that was present in the pG- minigene. Chimeric minigenes,

depicted in Figure 28B, were constructed harboring exon H and various lengths (mark

by arrows in Figure 28A) of the surrounding intronic sequences between human (3-glo

exons 1 and 3. Figure 28C clearly shows that chimeric minigenes containing exon H p

as little as 69 and 47nt of Nova-1 intronic sequence 5' and 3' respectively are sti

robustly regulated by cotransfection with Nova-1 in both N2A and 293T cells. This d

was quantitated and is presented graphically in Figure 28D). Further chimeric minig

(illustrated in Figure 29A) were constructed to assess whether this effect was medi

through intronic or exonic sequences. Figure 29B shows that exon H sequence alone i

sufficient to mediate Nova-l's effect on alternative splicing to this exon in a het

context, and that the intronic regions have no effect on splicing of a heterologous

exon. Examination of the sequence revealed that exon H contains five YCAY motifs (i
red, Figure 29A). Mutation of these as depicted in Figure 29A abrogates this Novadependent splicing to this exon (Figure 29). Thus Nova-1 likely binds to this exon

manner consistent with previous studies (i.e. via YCAY motifs), however binding to t
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region causes skipping of this alternative exon in contrast to the effects on G A B A a R y 2 or
GlyRoc2 alternative splicing.

Discussion

The results presented in this chapter provide further evidence that Nova-1 regulate
alternative splicing of at least two pre-mRNAs, those encoding GABAaRy2 and Nova-1

itself, in a sequence specific manner. Minigenes were constructed which recapitulat

findings in Nova-1 null mice: Nova-1 enhances splicing to GABAaRy2 E9 and represses
splicing to Nova-1 exon H. Nova-1 has been shown to enhance inclusion E3A of GlyRa2

by specific interaction with the pre-mRNA. By analogy, it was hypothesized that Nov

regulates alternative splicing of GABAaRy2 by directly binding to the pre-mRNA in a
sequence specific manner. Chimeric minigenes were then analyzed in order to define
sequences necessary for Nova-dependent regulation of alternative splicing of these
messages.

Nova-dependent regulation of GABAARy2 E9 alternative splicing.

Consistent with a previous report comparing GABAaRy2 E9 splicing in a

neuronal versus non-neuronal cell line (Zhang et al., 1996), large regions of the in
surrounding E9 were dispensable for neuron-specific splicing of GABAaRy2 minigenes

(Figure 14D). This group also showed that particular nucleotides within and upstrea

E9 were essential for neuron specific splicing in their system (Zhang et al., 1996)

PTB plays a negative role in regulation of splicing to E9 via sequences located nea

splice site (Ashiya and Grabowski, 1997). It is clear that a number of sequence elem

influence splicing of E9, not the least of which are the small exon size and relati
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weak 5' splice site. In contrast to the experiments discussed above, in the experiments
shown here increased inclusion of E9 was mediated solely by the co-transfection of

single factor, Nova-1, into cultured cells. The goal here was to try to separate non
specific effects from specific effects of Nova-1 on splicing of GABAaRy2 E9. The

experiments shown in Figure 13 indicate that this is feasible. The mutation made in

9 caused a dramatic decrease in the basal level of E9 inclusion. Interestingly, thi

sequence resembles that of intronic enhancer elements found in a number of messages

including fibronectin, fibroblast growth factor receptor 2 (FGF-R2) and src (Carste
al., 1998; Huh and Hynes, 1994; Modafferi and Black, 1997). However, addition of

Nova-1 was still able to mediate an increase in E9 incorporation of approximately t
same magnitude as was achieved with the wild-type minigene (Figure 13).
The majority of splicing regulatory sequences that have been characterized lie

within or close to the exon that they regulate (Smith and Valcarcel, 2000). Combined

with the results discussed above, it was therefore somewhat surprising to find that
region surrounding and including E9 could be replaced with heterologous sequence
containing a short exon not normally regulated by Nova, and retain Nova-dependent

regulation (Figure 16). This regulation was then shown to require a 2lint stretch o

sequence normally present approximately 1.3kb downstream of E9, adjacent to the nex
ubiquitously included exon, E10.
Several lines of evidence were gathered consistent with a direct action of Nova-1

on this element via sequence specific RNA binding. First, this 211 nt segment conta
YCAY motifs (Figure 18) which are known to be the preferred RNA sequence for Nova

KH domain binding (Buckanovich and Darnell, 1997; Jensen et al., 2000b; Lewis et al.
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2000). Second, mutation of these Y C A Y motifs to Y A A Y completely abrogated Nova's

effect in the context of the chimeric minigene (Figure 19), and more importantly th
length minigene (Figure 20), indicating that these motifs are necessary for Nova-

dependent splicing regulation. Mutation of the first three, or more dramatically, t

four motifs reduces the Nova effect but does not abolish it. Third, Nova binds with

affinity to the wild-type but not the mutated sequence corresponding to this region

(Figure 21). Boundary mapping experiments indicated that this binding abruptly drop

the sequence contains less than 4 UCAY repeats (Figure 22). Furthermore a 24nt elem

spanning the last four YCAY repeats, which appear to be the most important given th
minigene mutagenesis and boundary mapping studies, is sufficient to mediate Novadependent E9 inclusion (Figure 23).
In addition, deletion of KH3 or mutation of any single KH domain diminishes the
effect of Nova-1 on GABAaRy2 E9 splicing to a similar degree, implying that each KH

domain contributes to GABAaRy2 binding to approximately the same degree (Figures 24

and 25). Taken together, these results suggest that alternative splicing regulation
GABAaRy2 is mediated through the binding of multiple KH domains to multiple YCAY
repeats within the RNA. It was recently demonstrated by X-ray crystallography that

tandem KH domains within a single protein can concurrently bind to a single nucleic

molecule with only a short (5 nt) linker between the bound nucleotides (Braddock et
2002). This suggests that a single Nova molecule may bind up to three YCAY motifs
within one RNA. In addition Nova proteins can multimerize as evidenced by yeast-2-

hybrid and GST-pulldown assays (Polydorides et al., 2000) thus several Nova protein
molecules may co-operatively bind an RNA target. Both of these mechanisms would
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effectively increase the affinity of binding to an R N A target, and help to explain the
requirement for several YCAY motifs in the GABAaRy2 pre-mRNA for regulation of
alternative splicing by Nova.

Autoregulation of Nova-1 alternative splicing

The results presented here and in chapter 3 demonstrate that Nova proteins repress
alternative splicing to Nova-1 exon H. A minigene was constructed in which splicing to

the alternative exon creates a frame-shift in the resultant protein. By precise fusion to an
EGFP reporter this allows the degree of splicing to be assessed by the level of
fluorescence within these cells. Similar constructs have also been made incorporating
EBFP or ERFP as the marker (not shown) so that the protein products of both splice
forms may be visualized and distinguished in the same sample. This strategy could be
extended for in vivo use, for example via incorporation into BAC transgenic animals.
This would be very useful for assessing the regional distribution of alternatively spliced
forms of a message within an organism, even at the single cell level. Similar constructs
could also be used to extend the transfection studies reported here by analysis of splicing
of mutated constructs within an in vivo setting.
This Nova-1 minigene was initially tested in tissue culture cells. As predicted, the
expression of EGFP was consistent with repression of Nova-1 exon H inclusion upon the
addition of exogenous Nova-1 protein (Figure 26). It was initially predicted that Nova-1
may autoregulate its own splicing by sequence specific interactions with a region rich in
YCAY repeats immediately downstream of exon H (Buckanovich and Darnell, 1997).
Figure 27 shows that this is not the case. Mutation of these repeats, whilst slightly
altering the basal level of exon H inclusion, did not change the magnitude of the effect of
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Nova-1 on its o w n splicing (figure 27). Moreover, presence of the intronic regions
surrounding exon H did not result in Nova-dependent changes in splicing to a
heterologous exon (Figure 29).
Nova is capable of binding to sequence corresponding to this intronic region in

vitro, and this binding is abolished upon mutation of the YCAY repeats (Buckanovich

and Darnell, 1997). It is not clear, however, whether Nova binds to this exact regio
vivo, since the co-immunoprecipitation of Nova-1 RNA reported in (Buckanovich and

Darnell, 1997) may have been the result of Nova binding to the nearby exonic sequen

which is also rich in YCAYs. In fact, this exon is necessary and sufficient for Nova
dependent regulation of alternative splicing, as shown in Figure29. This effect is
completely abolished by mutation of the YCAY repeats within the exon.
These results indicate that the presence of YCAY repeats capable of binding to
Nova-1 in vitro in the vicinity of an alternatively spliced exon is not sufficient

dependent regulation of splicing to that exon. Intervening or surrounding nucleotid
within the YCAY-rich elements defined in GlyRa2 and GABAaRy2 introns and Nova-1
exon H may be necessary but not sufficient for Nova binding to the element in the

context of a larger RNA molecule, perhaps through contributions to secondary struct
in ways that are not apparent in vitro. Alternatively, position relative to nearby
intron/exon junctions, which was carefully conserved in the generation of chimeric

GABAARy2 / (3-globin minigenes, may be critical for either Nova binding or Nova eff
on splicing. Indeed position of the Nova-binding element within the pre-mRNA may
explain the opposite effect of Nova addition on splicing of GlyRa2 and GABAaRy2
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exons compared with Nova-1 exon H. This model for the mechanism of Nova regulation

of alternative splicing of these messages will be discussed in more detail in Chapt
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Figure 10: G A B A A R y 2 minigene assay development.
(A) Schematic representation of the G A B A A R y 2 minigene containing the full mouse
intronic regions surrounding and including exon 9 plus shortened exons 8 and 10
constructed for transient transfection assays. The primers used for R T - P C R
analysis are depicted as arrows, the star denotes the 32P-labeled primer.
(B) RT-PCR was performed on R N A isolated from N 2 A cells transiently transfected
with the minigene depicted in A. I A P C R master mix was prepared and
aliquotted into 9 identical 20,ul reactions (template amount was equivalent to 3fxl
per 20(xl reaction). 1 reaction tube was removed and stored on ice after every 2nd
cycle starting at the completion of cycle 20. Products (4|0,1) were separated by
denaturing P A G E . II. Quantitation of data from (I). P C R amplification is linear
for both products throughout most of the range of cycle numbers tested (20-36).
Note that for cycle 26, slightly less product was loaded on the gel due to a
pipetting error, however the ratio of the 2 products remains the same. 28 P C R
cycles (red arrow) were used for subsequent studies unless otherwise noted.
(C) RT-PCR was performed on R N A isolated from N 2 A cells transiently transfected
with the minigene depicted in A. I. A P C R master mix was prepared without
template c D N A and aliquotted into 5 tubes containing from 1 to 5u.l of template
c D N A (made up to 5u.l with H20; final reaction volume, 20(il). Reactions were
cycled for 28 cycles and products (4uJ) separated by denaturing P A G E . II.
Quantitation of data from (I). P C R amplification is linear for both products over a
range of c D N A input from 1 to 4u.l. 3/al of template c D N A (red arrow) was used
for subsequent studies unless otherwise noted.
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Figure 11: Nova-1, but not hnRNP-El, enhances G A B A A R y 2 L splicing in
heterologous cell lines.
(A) I. R N A from N 2 A cells transiently transfected with the G A B A A R y 2 minigene
shown in Figure 10(A) and the indicated amounts of Nova-1 or hnRNP-El
mammalian expression plasmid was analyzed by R T - P C R as in Figure 10. M =
mock transfected cells. All P C R reactions were performed in duplicate using
minus-RT reactions, representatives of which are shown (-RT). II. Western blot
using anti-T7 tag antibody showing the titration of T7-tagged Nova-1 and
hnRNP-1 protein levels after transfection. Plasmid concentrations were chosen
which would lead to roughly equivalent levels of protein expression for the two
T7-tagged proteins. III. Quantitation of the data presented in (A.I.) plus 2
additional independent transfections (n= 3). Data is presented as the ratio of
y2L/y2S products.
(B) I. R N A from 293T cells transiently transfected with the G A B A A R y 2 minigene
and the indicated amounts of Nova-1 or hnRNP-El mammalian expression
plasmid was analyzed by R T - P C R as in B. II. Western blot using anti-T7 tag
antibody showing the titration of T7-tagged Nova-1 and hnRNP-1 protein levels
after transfection. Plasmid concentrations were chosen which would lead to
roughly equivalent levels of protein expression for the two T7-tagged proteins.
III. Quantitation of the data presented in (B.I.) plus 2 additional independent
transfections (n= 3). Data is presented as the average ratio of y2L/y2S products;
error bars represent standard deviation.
(C) N 2 A cells were fixed post-transfection and stained with anti-T7-tag monoclonal
antibody and visualized with Cy3-conjugated anti-mouse secondary antibody
(red, first column). The cells were also stained for D A P I to visualize cell nuclei
(blue, second column). The third column is a merged image of the first two.
Nl=cells transfected with pNova-1, El= cells transfected with p-hnRNP-El.
(D) 293T cells fixed post-transfection and stained as per (C).
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Figure 12: Sequence comparison of intronic regions surrounding G A B A A R y 2 exon 9
Genomic sequence surrounding and encompassing G A B A A R y 2 exon 9 (yellow box) from
human (hum), mouse (mus) and rat was aligned by ClustalW alignment (MacVector).
Conserved Y C A Y motifs are underlined in red, non-conserved Y C A Y motifs in purple.
Mut8 and Mut9 represent mutations made in the mouse minigene within introns 8 and 9
respectively (see Figure 13).
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Figure 13: Mutations within the surrounding introns do not interfere with Nova's
ability to regulate G A B A A R y 2 exon 9 alternative splicing.
The mutations depicted in Figure 12 were made in the G A B A a R y 2 minigene, either
individually or in combination and the resulting minigenes cotransfected with increasing
amounts of pNova-1. Spliced products were measured by R T - P C R and phosphorimage
analysis as in Figure 10, the data is presented as y2L/y2S exon use ratio. The titration of
transfected Nova-1 expression was monitored by western blot (not shown). (A) N 2 A , (B)
293T.
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Figure 14: Generation of shortened minigenes by Exonuclease III digestion.
(A) Schematic representation of the approach taken to produce G A B A A R y 2 minigene
deletion constructs. To shorten intron 8; the full length G A B A A R y 2 minigene was
digested with unique restriction enzymes (Pacl + X c m l , followed by bluntending with pfu polymerase to remove 3' overhangs), then incubated with
Exonuclease III for varying lengths of time (aliquots were removed at 10 second
intervals).
To shorten intron 9; a clone with blunted Pacl/Xcml sites religated was
digested with PpuMl (now unique), followed by incubation with Exonuclease in
(PpuMl generates 5' overhangs, therefore blunting was not required in this case)
(B) A fraction of the Exolll digested plasmid from each time point was run on a 1 %
agarose gel. The remaining reaction was re-circularized with T 4 D N A ligase.
(C) Clones were digested with EcoRI to estimate insert size, then sequenced.
(D) Survey of ExoIII generated minigene constructs. 0.25.ug of minigene was
cotransfected with 1.0u.g of pNova-1 or empty vector into N 2 A cells grown in 6well plates. Cells were harvested 40 hours post-transfection and analyzed by RTP C R as in Figure 10. The average ratio of y2L/y2S products over the number of
trials (n) is shown on the left ± standard variation (or deviation from the mean for
n=2). The average increase in this ratio upon cotransfection of Nova-1 is listed in
the next column. Minigenes are shown as schematic representations (not to
scale), with the length of intronic sequence (in bp) remaining either side of the
deletion point noted above.
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Figure 15: Alternative splicing of a severely truncated G A B A A R y 2 minigene is still
regulated by Nova-1: narrowing down the sequence elements required.
(A) Schematic representation of minigene constructs generated for this study. A
truncated G A B A A R y 2 minigene was generated by fusing constructs D 1 2 (5'of
E9) and 2 A 2 (3' and including E9). A human B-globin minigene was constructed
using the first 3 exons of the human gene and the entire intervening sequences.
Subsequently the central region of B-globin exon 2 was deleted producing a
version which is alternatively spliced in cell culture transfection assays. The sizes
of the exonic and intronic sequences contained in the minigenes are noted above
(in bp). B-globin exon 2 A retains lOpb 5' and 18 bp 3' of the deletion site.
(B) Minigenes were cotransfected with increasing amounts of pNova-1 and spliced
products measured by RT-PCR and phosphorimage analysis as in Figure 10. The
titration of transfected Nova-1 expression was monitored by western blot using aT7tag antibody (lower panel).
(C) Quantitation of the data presented in (B) plus additional experiments (n=4 for
D12/2A2, n=5 for glo2A). The data is presented as v2L/y2S exon use ratio.
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Figure 16: Sequence surrounding G A B A A R v 2 E 9 is not sufficient for regulation of
alternative splicing by Nova-1 - sequence around E10 is necessary.
(A) Schematic representation of minigene constructs generated for this study.
Chimeric constructs were made by ligating portions of the G A B A A R y 2 (blue and
green) and B-globin (yellow) constructs shown in Figure 15. gloyD4 (construct
c.) was derived from the ExoIII deletion construct D 4 (Figure 14C). Minigenes
were cotransfected with increasing amounts of pNova-1 and spliced products
measured by R T - P C R using primers specific for the outside exons and
phosphorimage analysis as in Figure 10 (right panel). The titration of transfected
Nova-lexpression was monitored by western blot (not shown).
(B) Quantitation of the data presented in (A). Since the baseline level of alternative
exon inclusion varies widely between these constructs, the data is presented
as the change in y2L/y2S exon use ratio upon addition of Nova-1 (i.e. the ratio of
y2L/y2S with no added Nova is normalized to 1).
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Figure 17: Intronic sequence upstream of G A B A A R y 2 E10 is sufficient for
regulation of alternative splicing by Nova-1.
(A) The chimeric minigenes depicted on the left were cotransfected with increasing
amounts of pNova-1 and spliced products measured by R T - P C R

and

phosphorimage analysis as in Figure 10 (right panels). The titration of transfected
Nova-lexpression was monitored by western blot (not shown).
(B) Quantitation of the N 2 A data presented in (A). The data is presented as the
y2L/y2S exon use ratio.
(C) Quantitation of the 293T data presented in (A). The data is presented as the
y2L/y2S exon use ratio.
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Figure 18: Sequence comparison of intronic regions upstream of G A B A A R y 2 E10.
Genomic sequence upstream of G A B A A R y 2 exon 10 (blue box) from mouse (mus) and
human (hum) was aligned by ClustalW alignment (MacVector). Conserved Y C A Y
motifs are underlined in red, non-conserved motifs in purple. The green box denotes the
putative branch-point adenosine based on sequence analysis. Blue arrows indicate the
region corresponding to in vitro transcribed R N A 9 C (see Figure 21). Mutations (C to A )
in Y C A Y repeats used in following experiments are shown in red.
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Figure 19: Mutagenesis of the Y C A Y repeats abrogates Nova-dependent regulation
of chimeric minigene alternative splicing.

(A) Schematic representation of minigenes used in (B). The DNA sequences derived
from G A B A A R y 2 intron 9 contained within the chimeric minigene is shown. The
green star denotes one set of 3 C to A mutations (green As), the red star denotes a
second set of 4 C to A mutations (red As) made in the minigene.
(B) Minigenes depicted in (A) were cotransfected into I. N 2 A or II. 293T cells with
2.0u.g of pNova-1 or empty vector and spliced products measured by R T - P C R
and phosphorimage analysis as in Figure 10 (shown on the left). The transfected
Nova-lexpression was monitored by western blot (not shown). Quantitation of
the data is presented on the left as the ratio of L/S spliced products.
(C) Presentation of the data shown in (B) as the change in the ratio of L/S spliced
products upon addition of Nova-1 (i.e. the ratio of L/S with no added Nova is
normalized to 1).
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Figure 20: Mutagenesis of the Y C A Y repeats close to E10 abrogates Novadependent regulation of G A B A A R y 2 minigene alternative splicing.

(A) Mutations were made (depicted by starts) within the intronic region of the
G A B A A R y 2 minigene upstream of E10. The D N A sequence in the region of the
mutations is shown. The green star denotes one set of 3 C to A mutations (green
As), the red star denotes a second set of 4 C to A mutations (red As) made in the
minigene.
(B) Minigenes depicted in (A) were cotransfected into 293T cells with increasing
amounts of pNova-1 and spliced products measured by R T - P C R

and

phosphorimage analysis as in Figure 10. The titration of transfected Novalexpression was monitored by western blot (not shown).
(C) Quantitation of the data presented in (A) presented graphically as the ratio of
y2L/y2S spliced products.

95

2.3 kb

1.4 kb

tt

irk

CTGCACTGCTTAAGCGCAAAATCTGAAACCTGCAACTGTGCTATCTTTCTGAGTT
* A A A A
CAATTTTACCATCGTAAGATCACGATGTCATAAGCAATTTTCTGAATACTCATTTT
•fa
A A A
CAGATTCATCATCTCATTGATGACATTGTGGAAGTACTGTGTTATATAGCTCCAG
TATAACTA CTTTGCTCTCTCTCCTTACCTACCTTGTCTCAgI

B
wt
p-Nova-1 l~~o
(ng)

ol

ti
2~l H )

y2L
Y2S

P-N1 (ng) ,0
minigene

0.5

2

0^5

+
2~~' l~~0

tiJC
2~~l H )

51

minigene
2~~l

Figure 21: Nova-1 binds with high affinity to G A B A A R y 2 R N A in vitro

(A) His-tagged Nova-1 fusion protein was over expressed in E.coli and purified over
a nickel column. The protein was eluted from the column and collected in 2
fractions. Aliquots of increasing concentrations were analyzed by S D S - P A G E
followed by staining with Coomassie stain. Fraction 1 contained higher
molecular weight contaminants in addition to Nova fusion protein. Fraction 2
appeared to be much more pure, so was used for subsequent experiments.
M=full-range rainbow markers, C L = column load, NFP=Nova-l fusion protein.
(B) Nitrocellulose filter binding assays were performed using Nova-1 fusion protein
shown in (A) and four in vitro transcribed R N A s . 9C = R N A corresponding to
the region of G A B A A R y 2 intron 8 highlighted in Figure 18 with the addition of
the sequences G G G A G at the 5' end and C U A G C A A A at the 3' end derived
from the P C R primers used to amplify the template prior to in vitro transcription.
9Cmut = R N A identical to 9C with the exception of 7 C to A mutations as shown
in Figure 18. SB2 = R N A purified by S E L E X with Nova-1 (Buckanovich and
Darnell, 1997). glo = R N A derived from human B-globin which spans regions of
exon 1 and intron 1, and contains no Y C A Y motifs.
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Figure 22: Mapping the boundaries of Nova-1 binding to G A B A A R y 2 9 C R N A

9C RNA was labeled with 32P at either the 5' or 3'end and subjected to mild alkaline
hydrolysis (AH). The R N A was then incubated with Nova-1 fusion protein at a final
concentration of lOnM or 7 5 n M and protein:RNA complexes captured by filtration
through nitrocellulose filters. Bound R N A s were eluted and analyzed by denaturing
P A G E . The ladders represent the position of G residues (determined by RNase Tl
digestion). Boundaries are highlighted by arrows and indicated on the 9 C R N A sequence
shown at the bottom. Small letters represent sequence derived from primers.
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Figure 23: 24nt intronic sequence is sufficient for regulation of alternative splicing
by Nova-1.

(A) DNA sequences derived from GABAARy2 intron 9 contained within the chimeric
minigenes shown in B. The colored lines highlight the region cloned into the Bglobin minigene labeled in the corresponding color in B.
(B) The chimeric minigenes depicted on the left were cotransfected into 293T cells
with increasing amounts of pNova-1 and spliced products measured by R T - P C R
and phosphorimage analysis as in Figure 10 (right panels). The titration of
transfected Nova-lexpression was monitored by western blot (not shown).
(C) Quantitation of the data presented in (A). The data is presented as the ratio of L/S
spliced products.
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Figure 24: K H 3 and the spacer region contribute to the function of Nova-1 in
regulating alternative splicing.

(A) Schematic representation of Nova-1 protein, and the GABAaRy2 minigene used
in this experiment. Mammalian expression constructs were generated which
express truncated forms of Nova-1 which lack K H 3 (AKH3) or K H 3 and the
spacer region (AspKH3).
(B) N 2 A cells were cotransfected with the truncated G A B A a R y 2 minigene D12/2A2
and increasing amounts of plasmids expressing full-length or truncated Nova-1
cDNAs. Spliced products were analyzed by RT-PCR and phosphorimage analysis
as in Figure 10. The titration of transfected Nova-lexpression was monitored by
western blot (not shown). The data is presented as the ratio ofy2L/Y2S spliced
products. Error bars for addition of 0 and 1.0(ig pNova represent deviation from
the mean in 2 separate trials.
(C) 293T cells were transfected and the spliced products analyzed as in (B). Error
bars represent deviation from the mean in 2 separate trials.
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Figure 25: All 3 K H domains contribute to the function of Nova-1 in regulating
alternative splicing.

(A) Mammalian expression constructs were generated which either lack exon H or
harbor point mutations in one of the K H domains as noted. These were used in
cotransfection experiments with the minigene depicted.
(B) 293T cells were cotransfected with the chimeric minigene and increasing
amounts of Nova-1 expression plasmid. Spliced products were analyzed by R T P C R and phosphorimage analysis as in Figure 10. The transfected Novalexpression was monitored by western blot (not shown).
(C) Quantitation of the data presented in (B), plus 2 additional experiments. The data
is presented as the average ratio of L/S spliced products over the three trials, error
bars display the standard deviation.

100

exon H
KH1
l-N

[ | jlKH2

|

spacer

| KH3

* V-N

L-N
211

•

B

p-N1

0

- •

•

-H

KH1*

0 'o.5 2 "0.5

2M0.5

,0.5 2 ,

,0.5 2 |

p-N1

-H

KH2*

2 "0.5

KH3*

2 "0.5

2' (ng)

,0.5 2 |

,0.5 2 ,

KH1*

KH2*

,0.5 2 | (ng)
KH3*

Figure 26: Nova-1 regulates alternative splicing of its o w n message in tissue culture
cells.

(A) Schematic representation of a Nova-1 minigene generated for this study. Details
of the construction of the minigene are discussed in the text.
(B) A version of the minigene which results in the expression of in-frame E G F P if
exon H is excluded (pG-) was transfected into N 2 A cells with increasing amounts
of p-Nova-1 expression plasmid. Cells were fixed and analyzed for E G F P
expression by fluorescence microscopy.
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+ H = G F P out of frame
- H = G F P in frame

B

Figure 27: Mutations within the downstream intron do not interfere with Nova's
ability to regulate exon H alternative splicing.

(A) The mouse genomic Nova-1 sequence immediately downstream of exon H
contains four Y C A Y repeats (red). Mutations made in this region of the minigene
are shown in orange and green.
(B) N 2 A cells were cotransfected with the wildtype or mutated minigenes and
increasing amounts of Nova-1 expression plasmid. Spliced products were
analyzed by primer extension using a labeled primer to E G F P and phosphorimage
analysis. The transfected Nova-1 expression was monitored by western blot (not
shown).
(C) Quantitation of the data in (B). Bars represent the ratio of exon H included (+H)
to excluded (-H) spliced forms.
(D) Presentation of the data shown in (B) as the change in the ratio of +H/-H spliced
products upon addition of Nova-1 (i.e. the ratio of +H/-H with no added pNova1 is normalized to 1).
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Figure 28: Alternative splicing of a truncated Nova-1 minigene is still regulated by
Nova-1 protein: narrowing d o w n the sequence elements required.

(A) Mouse genomic Nova-1 sequence surrounding exon H (red box) which is
included in the minigene shown in Figure 26. Y C A Y repeats are shown in red.
Chimeric constructs were generated containing this entire region or the sequences
contained between the arrows.
(B) Schematic representation of the minigenes used in this experiment. Sizes of
exonic or intronic regions are shown in bp.
(C) Minigenes depicted in (B) were cotransfected into N 2 A or 293T cells with
increasing amounts of pNova-1. R N A was harvested 40 hours post-transfection
and analyzed by R T - P C R using primers to globin exons 1 and 3, followed by
phosphorimage analysis.
(D) Quantitation of the data presented in (C). Bars represent the fraction of messages
containing exon H as a percentage of the total spliced products.
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gatccctaaattcatgtggaatcagcttgttggtgatgttcaacatattaagtaggtgga
tacttttatgccaaagtaaacttcatttcaccacttcttcaaatctccgactgtattcatt
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Figure 29: Sequence within Nova-1 exon H is necessary and sufficient for
autoregulation of alternative splicing.

(A) Schematic representation of the minigenes used in this experiment. The sequence
of exon H is shown in the red box. Y C A Y repeats are shown in red, mutations in
green. The blue G indicates the lbp insertion made in the original minigene
construct (Figure 26) in order to create a frame shift.
(B) Minigenes depicted in (A) were cotransfected into 293T cells with increasing
amounts of pNova-1. Spliced products were analyzed as in Figure 28.
(C) Quantitation of the data presented in (B). Bars represent the fraction of messages
containing exon H as a percentage of the total spliced products.
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Chapter 5 -

Nova-1

subcellular

localization

Introduction

A number of distinct compartments have been visualized in the nuclei of mammalian
cells, using both electron microscopy and indirect immunofluorescence against the

proteins contained within them. Photobleaching and other live cell imaging experime

using GFP (and its variants) fusion proteins have shown that many of these structur
highly dynamic and feature rapid protein exchange between the compartment and the
nucleoplasm (reviewed in (Misteli, 2001)). It has been suggested that by analogy to

compartmentalized organization of the cytoplasm, the existence of numerous subnucle
compartments suggests that particular processes occur in specific locations within
nucleus (Misteli, 2001). In addition, most of these compartments disassemble during

phase of the cell cycle and reassemble rapidly in daughter cells, indicating high s

plasticity. Whilst the biological functions of many of these domains are unknown, m

information can be surmised from the types of proteins and nucleic acids that compr
them. Not surprisingly given the roles they play in nuclear processes, RNA binding
proteins are often key components of these structures.

Nucleolus

The nucleolus is formed by the clustering of ribosomal genes on different chromosom
into chromosomal loci called nucleolar organizers. They are the site of rRNA

transcription, processing and assembly into ribosomal subunits, and their formation
both transcription and cell-cycle dependent. Nucleoli are generally not associated
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poly-A m R N A , however some transcripts including M y o D and N-myc have been

detected within them (Bond and Wold, 1993). In addition, mutations that interfere wi
mRNA transport, or heat shock result in poly-A mRNA accumulation in the nucleoli of

yeast (Schneiter et al, 1995), (Tani et al., 1995). Taken together with the observati
inactivation of nucleoli prevents export of nonribosomal RNAs in mammalian cells

(Harris et al., 1969), these results have led to the suggestion that the nucleolus m
be involved in mRNA export and/or degradation (Lamond and Earnshaw, 1998).

Cajal (coiled) bodies and gems (gemini of coiled bodies)
Cajal bodies (also known as coiled bodies) were first described by Ramon y Cajal in
vertebrate neural tissues. Although the function of these small nuclear organelles

largely unknown, they may play a role in snRNP transport, maturation, or both (Lamon
and Earnshaw, 1998) or in the assembly of RNA polymerase complexes (Gall, 2001). In

addition to snRNPs, they are highly enriched in basal transcription and cell cycle f

the nucleolar proteins fibrillarin (Raska et al., 1990) and Noppl40 ascent pre-mRNA
non-snRNP splicing proteins, thus they are unlikely to be sites of pre-mRNA

transcription or splicing. Coilin is often used as a marker of Cajal bodies which g
number between 1 and 10 per cell. Like nucleoli, Cajal bodies are associated with

specific genomic loci, in this case the snRNA and histone gene clusters (Gall, 2000).

Combined with the fact that Cajal bodies contain the U7 snRNP, which cleaves the 3'

of histone pre-mRNA, a role in histone 3' end processing has also been proposed (Fr
and Matera, 1995).
SMN, the target antigen of spinal muscular atrophy (SMA) localizes to nuclear
structures often paired with Cajal (or coiled) bodies. SMN interacts with both the
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class of snRNP proteins and SIP-1 (Liu et al., 1997), and the SMN-SIP-1 complex plays

an essentia] role in spliceosomal snRNP biogenesis (Fischer et al., 1997), as discus
Chapter 1.

Nuclear speckles (interchromatin granule clusters) and perichromatin
fibrils.

Pre-mRNA splicing factors accumulate in approximately 25-50 nuclear speckles (or
intrachromatin granule clusters), as well as being diffusely distributed throughout

nucleoplasm (Spector, 1993). The diffuse localization is attributed to snRNPs intera

with nascent RNAs. Nuclear speckles are highly dynamic and their components appear t

cycle between sites of active transcription and interchromatin granule speckles (Mi

al., 1997). This cycling may be dependent on phosphorylation since inhibition of kin

or phosphatase activities alters the appearance of the speckles (Misteli and Specto

1996), (Gui et al., 1994). Upon inhibition of transcription, the diffuse staining dis
and speckles become enlarged (Carmo-Fonseca et al., 1992; Spector et al., 1991).
Several functions have been proposed for nuclear speckles. For example, they
may play a role in mRNA transcription or regulation based on evidence that the mRNA

from some highly transcribed genes is enriched near speckles, or in mRNA export sin
they do not incorporate Br-UTP and lack detectable DNA, but do contain poly-A RNA
(reviewed in (Lamond and Earnshaw, 1998)). Alternatively, speckles have been

suggested to function as supply depots from which factors are recruited to sites of

transcription (perichromatin fibrils), or regions of accumulation of snRNPs bound ei

to excised introns after their release from the spliceosome, or partially spliced p

(Singer and Green, 1997; Spector, 2001). Not all splicing factors localize in an iden
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manner. For example, SC35 is highly concentrated in discrete regions within the nucleus,
in a pattern that is a distinct subset of that seen with anti-snRNP antibodies (Fu

Maniatis, 1990). Thus it was hypothesized that SC35 plays an active role in splicing

as a result is localized in perichromatin fibrils along with Pol II, whereas snRNPs
other SR proteins are mostly localized to nuclear speckles.

PML bodies

PML bodies are nuclear structures specifically disrupted in individuals suffering f
acute promyelocytic leukemia (APL). PML bodies ordinarily number 10-30 per cell
nucleus, however APL cells show a larger number of smaller PML-containing foci
resembling broken up PML bodies. This is the result of a translocation event which

the PML gene to the retinoic acid receptor alpha (RARa) gene (Goddard et al., 1991).

Treatment with retinoic acid triggers degradation of PML- RARa, restores PML bodies

and results in remission of the cancer. In addition to the RING-finger motif contai

protein, PML, these bodies contain a number of other proteins including the autoant
SplOO and SUMOl. The function of PML bodies in not known, though they have been

suggested to play a role in transcription regulation, and appear to be targets of v

infection (Spector, 2001). The PML protein itself exists in two forms, one of which i

dispersed throughout the nucleoplasm. The other is a form conjugated to SUMOl (smal

ubiquitin-like modifier), which is exclusively localized to PML bodies (Muller et al
1998).
In order to gain additional insight into the function of Nova, analysis of the
subcellular localization of Nova by immunofluorescent microscopy was undertaken to

108

assess whether Nova, like many other splicing factors, localizes to discrete compartments
within cell nuclei, and if so, is localization to a known compartment?

Results

Nova localizes to a novel subnuclear compartment.
Nova is a predominantly nuclear antigen that plays a role in alternative splicing

regulation. To determine the subnuclear distribution pattern of Nova, N2A cells, whi
express endogenous Nova proteins by western blot analysis (data not shown), were

analyzed by immunofluorescent microscopy. Nova resides in a number (usually 2-10) o

distinct, heavily staining foci as can be seen in the first column of Figure 30 (gre

These foci are not seen by staining with secondary antibody alone, or in cell lines
not express Nova (data not shown). These cells were co-stained with antibodies to

proteins known to reside in particular subnuclear compartments. In the first row ce
co-stained with an antibody which recognizes the core Sm proteins of spliceosomal

snRNPs (sm), and thus stains nuclear speckles, in addition to diffuse staining thro
the nucleoplasm. The merged panel shows that whilst both antibodies show punctate

staining within the nucleus, they clearly recognize distinct foci, thus Nova does no
localize to classical nuclear speckles.
Nova also does not reside in gems, despite the similarity in the size and numbers

of foci recognized by the two antibodies in the second row (Sip-1). Nova does not co

localize with the splicing factor SC35, or in PML bodies and is clearly excluded fr

nucleoli as can be seen by co-staining for the nucleolar protein, Noppl40, and by th

presence of unstained regions within the nucleus of some cells (particularly eviden
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first (Sm) row). In addition, Nova does not reside in Cajal bodies (p80 coilin) or in
perichromatin fibrils (Pol II). Thus Nova in N2A cells localizes to a subnuclear

compartment distinct from nucleoli, Cajal bodies, gems, nuclear speckles, PML bodies
perichromatin fibrils.

Actinomycin-D disrupts Nova foci.

Inhibition of transcription by agents such as actinomycin-D, a-amanitin and D, 5,6-

dichloro-1-P-D-ribofuranosylbenzimadizole (DRB) cause significant redistribution of
many nuclear factors and alter the morphologies of nucleoli and nuclear speckles

(Carmo-Fonseca et al., 1992; Spector et al., 1991). These agents cause enlargement o

nuclear speckles and SC35 containing bodies (Fox et al., 2002). To determine whether
transcription inhibition has a similar effect on Nova foci, cells were treated with

actinomycin-D (5 u.g/ml) for 3 hours prior to fixation (Figure 3IB). Untreated cell

received fresh medium. Cells were also treated with cyclohexamide (20 pg/ml, 3 hours

to determine whether blocking protein synthesis had any effect on Nova localization

or actinomycin-D together with cyclohexamide (D). In contrast to other splicing fact
Nova bodies disperse upon actinomycin-D treatment, in the presence or absence of

cyclohexamide, consistent with the hypothesis that the formation and maintainance o
Nova foci is transcription dependent. Actinomycin D has also been shown to inhibit

nuclear import of some shuttling proteins, including hnRNP K (Michael et al., 1997).

Thus another possibility is that Nova foci are dependent on the presence of a prote
normally shuttles in a transcription-dependent manner, which gets trapped in the

cytoplasm upon actinomycin D treatment. Alternatively, Nova itself could shuttle in
transcription-dependent manner resulting in dispersion of foci on actinomycin D
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treatment. Cyclohexamide treatment had little or no effect on Nova distribution indicating

that rapid new synthesis of proteins is not required for maintenance of Nova contai
bodies.

Transfection of a splicing target does not disrupt Nova foci.

If Nova bodies act as reservoirs for the storage of inactive splicing factors as ha

proposed for the role of nuclear speckles, high levels of transcription of a Nova t
could be expected to disrupt Nova localization. To test this hypothesis, N2A cells
transfected with a region of GABAARy2 RNA known to contain a Nova-binding site and

to be regulated by Nova-1 at the level of alternative splicing. The GABAARy2 region
the minigene D12/2A2 (Figure 15A) was cloned into a different parental vector, but
under the control of a CMV promoter. On the same construct, EGFP was expressed from

an SV40 promoter in order to easily identify cells that had been transfected with t
plasmid. Similar to the original minigene construct, GABAARy2 E9 inclusion was

enhanced by the addition of exogenous Nova-1 (data not shown). As a control, cells w
also transfected with the parental vector to ensure that any changes seen in Nova
distribution could be attributed to GABAARy2 minigene expression. A schematic

representation of these constructs is shown in Figure 32A. Figure 32B shows that th
morphology of Nova foci is not changed upon high levels of transcription of a Nova

target, or due to EGFP expression under the conditions tested. No difference was se

cells analyzed 12 hours after transfection when EGFP expression is barely detectabl
shown), or 36 hours post-transfection (Figure 32B).

Ill

N o v a forms subnuclear foci in m o u s e spinal cord

To determine whether Nova localizes to discrete foci in tissue, mouse spinal cord se

were stained with human anti-Nova serum and analyzed by confocal microscopy. Figure

33 shows that distinct, brightly staining foci (arrows) were detected in the nuclei

positive cells in the ventral spinal cord, often in the vicinity of the nucleolus. S

the staining pattern in N2A cells, Nova appears to be completely excluded from nucle
These foci were much more difficult to detect in these cells compared to N2A cells,

part due to a higher level of diffuse Nova staining in tissue. In addition, fewer fo

most 2 per cell) were seen in tissue compared to N2A cells. However, the visualizati

these foci in tissue implies that the localization observed in cell cultures corres
biologically significant process observable in the context of the whole brain.

Discussion

The compartmentalization of the nucleus into discrete domains contributes to the
complexity of processes involved in gene expression and its regulation.

Immunofluorescent microscopy was used to determine that Nova in N2A cells localizes

to a subnuclear compartment distinct from known structures, including nucleoli, Caja
bodies, gems, nuclear speckles, PML bodies or perichromatin fibrils. Nova domains

become dispersed upon inhibition of transcription with actinomycin-D, unlike nuclea
speckles which harbor constitutive splicing factors and become enlarged upon

transcription inhibition. This finding is consistent with the hypothesis that the f
and maintainance of Nova foci is an active process and is transcription dependent.
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At least one other protein, YT521-B, which localizes to subnuclear bodies (called

YT bodies) disperses upon treatment with actinomycin-D, but not other transcription

inhibitors such as a-amanitin or DRB. Since actinomycin-D inhibits transcription by

binding to GC rich regions of double stranded DNA, preventing RNA elongation, it wa

suggested that YT bodies form independently of transcriptional activity, possibly t

a direct or indirect DNA-protein interaction (Nayler et al., 2000). Thus it would be

interesting to further elucidate the role of transcription in the appearance of Nov

using more direct inhibitors such as a-amanitin which inhibits transcription throug
direct inhibition of RNA polymerase II or DRB which blocks transcription through
inhibition of an upstream kinase of RNA polymerase II (Zandomeni and Weinmann,

1984). Experiments involving visualization of regions of transcription by analysis o

UTP incorporation could also be used to determine whether Nova- containing bodies a
recruited to sites of active transcription.
Transcription of a Nova target minigene from a highly active promoter (CMV)
did not result in alterations in the appearance of Nova foci in N2A cells 12 or 36

post-transfection. This does not rule out the possibility that transient disruption
that these domains become highly dynamic but do not disperse when presented with an
abundance of a pre-mRNA which is spliced in a Nova-dependent fashion. Live cell
imaging of cells transfected with GFP-tagged Nova proteins which also localize to

discrete foci in N2A cells (A. D. Polydorides and R.B Darnell, unpublished data), co
be used to address these concerns.
The results shown in this chapter, and the further studies suggested here are of

some importance since Nova is also seen in foci in tissue (Figure 33), implying tha
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localization observed in cell cultures corresponds to a process of biological significance
in the context of the whole brain. Thus information regarding the localization and
dynamics of Nova foci and their role in nuclear processes could be extended (cautiously)
to the role of Nova in the brain.
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Figure 30: Nova localizes in to a novel subnuclear compartment.

N2A cells were fixed and stained with anti-Nova human serum and visualized with Cy2conjugated anti-human secondary antibody (green, first column). Notice the distinct, brightstaining intranuclear foci. Cells were also co-stained with a second primary antibody to the
proteins indicated which was visualized using the appropriate Cy3-conjugated secondary
antibody (red, second column), and counterstained with D A P I (blue) to visualize cell nuclei. The
third column is the merged composite of all three channels. The antibodies and concentrations
used and the specific proteins recognized by each are listed in Chapter 2 (Materials and
Methods).
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Figure 31: Actinomycin-D disrupts Nova-containing foci, cyclohexamide does not.

N2A cells were fixed and stained with anti-Nova human serum and visualized with Cy2conjugated anti-human secondary antibody (green, first column) after the following treatments:
(A) Untreated.
(B) Actinomycin-D: 5u.g/ml, 3hours.
(C) Cyclohexamide: 20p.g/ml, 3hours
(D) Actinomycin-D + cyclohexamide: as in (B) and (C).
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Figure 32: Transfection of a splicing target does not disrupt Nova foci.

(A) Schematic representation of plasmids used in this study. pCMS-y contains the trunc
G A B A A R y 2 minigene region from plasmid D12/2A2 (see Figure 15A) inserted into the
multiple cloning site of p C M S - E G F P (Clontech). The Nova target (minigene) R N A is
transcribed from a C M V promoter. Transfected cells express E G F P from an SV40
promoter contained within the same construct.
(B) N 2 A cells were grown on chamber slides and transfected with pCMS-y or the parental
vector p C M S - E G F P . 12 hours (not shown) or 36 hours post-transfection, cells were
fixed and stained with anti-Nova human serum and visualized with Cy3-conjugated antihuman secondary antibody (red, second column). E G F P expression is shown in the first
column (green). Cells were also counter-stained with D A P I to visualize cell nuclei. The
third column is the merged composite of all three channels.
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Figure 33: Nova forms subnuclear foci in mouse spinal cord.

Confocal laser image of Nova expression pattern in P5 {check} mouse ventral spinal cord
Horizontal spinal cord sections were stained with anti-Nova human serum and visualized with
Cy5-conjugated anti-human secondary antibody (red). Co-staining is with anti-MAP2 antibody
and Cy2-conjugated secondary antibody (green). Heavily staining Nova foci are highlighted by
arrows. The boxed area (dashed lines) is shown at higher magnification on the right.
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Differential g e n e

expression

screens

Introduction

Differences in gene expression underlie a vast number of cellular processes from fa

determination and specification of cell type to formation and maintenance of synaps

the brain. In addition stimuli such as drug exposure, environmental changes, depriva

of required factors can all influence gene expression which may in turn exert drama

changes on cellular phenotype, fate and function, so it is not surprising that comp

of gene expression between populations of cells is of great interest in many biolog

systems. Numerous different methods have arisen which aim to identify these genes i

order to better understand the processes involved at a molecular level. The various

methods differ in their applicability to different systems, their ease of execution
sensitivity and reliability.

Non-selective methods:
1) Differential screening involves screening a library (or libraries) in duplicate

with cDNA probes generated from two different RNA populations of interest. Colonies

or plaques harboring clones representing differentially expressed RNAs should hybri

differentially to the two probes and thus can be isolated and analyzed further. Thi
approach is readily available, rapid and relatively inexpensive and has been used

successfully even at the single cell level (Dulac and Axel, 1995). However, differen
screening is relatively insensitive, so it can only be used in situations when the
involved are abundant and the differences in expression level are high.
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2) Serial analysis of gene expression (SAGE), developed by Velculescu et al.
(Velculescu et al., 1995) allows quantitative and simultaneous analysis of a large

of transcripts. Briefly, double stranded cDNA is generated using biotinylated oligo

primer and cleaved with a frequently cutting restriction endonuclease (i.e. one wit

recognition site). The 3'-most fragment of each transcript is then isolated by bindi
streptavidin coated beads. This pool is then divided in half and ligated to one of

linkers containing the recognition site for a restriction enzyme which cleaves at a

distant from its recognition site. Cleavage with this enzyme results in the release

the beads of the linker with a short piece of the cDNA, generating sequence tags. Th
tags are then amplified, concatenated, cloned and sequenced. Comparison of the

frequency of each tag in each of two populations then forms the basis of the analys

differential gene expression. The disadvantages of this technique, however, are that

requires a dedicated sequence facility and also biases towards the 3' ends of cDNAs
3) cDNA arrays are becoming more widely available for these types of studies

and offer a rapid method of screening a vast number of discrete sequences. These ma
take the form of membranes or chips spotted with an array of different cDNAs or
oligonucleotides (either commercially available or custom made). The use of chips
allows orders of magnitude more sequences to be analyzed at one time and detection
usually more sensitive than that achieved with membrane arrays, however the cost
involved is also orders of magnitude higher! In addition, arrays are not currently
useful for distinguishing between alternative spliced forms of mRNAs.
4) For differential display (DDRT-PCR) (Liang and Pardee, 1992) random PCR

primers are used to generate a series of bands which are then separated in polyacry
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gels. B a n d s differing in intensity between two populations are isolated from the gel,
cloned and sequenced. In order to cover a statistically significant portion of the
population, a large number of primer pairs and sequencing gels are involved making this
technique quite labor intensive. Abundant non-differentially expressed species can also
obscure the detection of other species of interest, and high rates of false positives have
been reported (Wan and Erlander, 1997).

Selective Methods

1) Subtractive hybridization is the basis behind the first selective methods

reported for isolating differentially expressed genes (for review see (Milner et al., 1995)).
Two single stranded cDNA or RNA libraries are generated; one from the population of
interest (the "tester") and a second, complementary (antisense) library from the control
("driver") population, and mixed such that the driver is in excess. Hybridization of the
two libraries is followed by subtraction of double stranded hybrids which represent
species shared by the two populations. This is achieved either using hydroxyapatite
columns (Wan and Erlander, 1997) or by tagging the driver cDNA with biotin and
removing the driver-containing species through streptavidin binding and organic
extraction (Akopian and Wood, 1995; Sive and St John, 1988). The remaining single
stranded species of the sense strand are then either used as probes for library screening or
converted to double stranded cDNA and cloned. Although highly successful for some
applications for example cloning of the T-cell receptor (Hedrick et al., 1984) and
identification of genes that are activated at the gastrulation stage of Xenopus laevis
(Sargent and Dawid, 1983) there are two primary drawbacks to subtractive hybridization.
Firstly, small differences in abundance will not be detected because if the fold increase of
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a particular species in the tester population is less that the fold excess of driver used in
the hybridization reaction, these species will be lost during the selection procedure.
Secondly, the selection procedure is a negative one, that is unwanted species are removed
from the reaction rather than desired species being positively selected. If the selection
does not proceed with 100% efficiency, which is likely since hybridization kinetics
approach but never reach completion, unwanted species will be retained in the selected
population resulting in a higher rate of false positives and possible masking of desired
species of low abundance.
2) Suppression hybridization kits are available commercially (eg. PCR-Select,
Clontech) in which abundant species, deemed to be of less interest, are suppressed by
selective PCR of single-stranded species after hybridization of tester and driver
populations. This then allows rare differentially expressed species to be identified by
traditional non-selective methods somewhat more easily and with less false positives
(Diatchenko et al., 1996; von Stein et al., 1997), however there is the risk of losing
modest differences which are suppressed.
3) Competitive hybridization. In this instance double stranded tester and driver
populations are hybridized together rather than single stranded libraries, so there is
competition between the formation of heterohybrids deriving one strand from each of the
tester and driver populations, and homohybrids containing either two tester strands or two
driver strands. Assuming random assortment, molecules more abundant in the tester
population will form a higher proportion of tester homohybrids relative to tester/driver
heterohybrids than molecules which are expressed equally in both species. Selection of
tester homohybrids thus results in an enrichment of species more abundant in the tester
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population. Enrichment of such species will occur even in instances w h e n the difference
in abundance is less than the excess of driver to tester used, a clear advantage over
subtractive hybridization approaches. Enrichment to detectable levels, especially of rare
species, is achievable but may require several rounds of selection and PCR amplification
which in itself can also introduce problems. Several methods of selection of tester
homohybrids after competitive hybridization have been published. These include:
(a) Biotinylation of the driver species followed by streptavidin binding and organic
extraction (Wang and Brown, 1991).
(b) Enzymatic degradation selection (EDS) in which tester molecules are tagged with
thiolated nucleotides, thus rendering tester homohybrids resistant to digestion with a
combination of exonucleases III and VII (Zeng et al., 1994).
(c) Cloning of only tester homohybrids by the presence of compatible restriction site
overhangs only on tester molecules (Klickstein, 1995).
(d) Representational difference analysis (RDA) (Lisitsyn and Wigler, 1993). PCR
primers are ligated only to tester molecules which results in exponential amplification of
tester homohybrids only.
(e) Biotin and restriction enrichment (SABRE) (Lavery et al., 1997). Tester homohybrids
are selected by biotin/streptavidin binding and restriction enzyme reconstitution.
The first two selection methods suffer from the issues of negative selection
discussed above for non-selective procedures, (c) and (d) are positive selection
procedures, but both require substantial manipulation between rounds of selection. For
competitive hybridization to be successful hybridization must be efficient to avoid the
loss of rare species, in addition, like all methods utilizing PCR amplification of the
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populations, bias can be introduced through preferential amplification of some species.
The SABRE system developed by Lavery et al (Lavery et al., 1997), addresses these

problems whilst still benefiting from the advantages of competitive hybridization f

isolation of rare species displaying moderate to low (less than ten-fold) differenc
abundance.
Two of these methods, screening of nylon cDNA arrays and SABRE, were
undertaken to identify mRNA species differentially expressed in Nova-1 null mice

compared to their wild-type littermates. The SABRE technology is of particular inte
as it has the potential to identify changes in only a region of a message which is
differentially expressed, for example an alternative exon whose level of inclusion

between the two populations being tested. Several species cloned after SABRE select
appear to fall into this category and warrant further investigation.

Results

cDNA Arrays
ATLAS™ cDNA expression arrays (Clontech) containing 588 mouse cDNAs
spotted in duplicate were screened using RNA isolated from the spinal cords of P12

Nova-1 null and wild-type littermate mice, or the hindbrains of PO mice. Both region
express Nova-1 at high levels and are thus likely to show greatest changes in gene

expression in Nova-1 null mice. Uniformly labeled single stranded cDNA was generated

using primers supplied in the kit specific for the range of genes to be screened us

polyA+ RNA as a template. The resulting libraries of fragments were size fractionat

via column elution then used to probe identical blots. Figure 34 shows the results a

124

hybridization of the P12 spinal cord probes. Some differences in gene expression can be
detected readily by eye, for example the cDNA spots corresponding to insulin-like
growth factor binding protein 2 (IGF-BP2) appear darker on the blot probed with the

library generated from wild-type mice, indicating that this message occurs with low
abundance in Nova-1 null mice.
Quantification was performed by phosphorimager analysis including

normalization with respect to a selection of housekeeping genes (bottom row of spots

Figure 34), the levels of which are assumed to be the same in the two RNA populatio

A summary of the differentially expressed genes detected by this method is listed i
Table 1. Only positions which showed moderate to high levels of hybridization, and

where differences in hybridization signals between Nova-1 null and wild-type probes
were apparent are shown. Care was taken to ensure that any differences were indeed

result of higher levels of hybridization to both of the duplicate spots on one filt

compared to the other for a particular gene, not the result of high levels of backgr

labeling in a particular region of one filter. No dramatic differences (>2 fold cha

both experiments) were seen in the expression of any genes represented on the filter
the five messages (shown in bold in Table 1) which showed differences in abundance
both tissues tested, PO hindbrain and P12 spinal cord, four showed modestly higher
abundance in wild-type tissues compared to those from Nova-1 null mice. The fifth,
BAG-1, was decreased in wild-type PO hindbrain, but increased in P12 spinal cord

compared to Nova-1 null tissues. This could be the reflection of differences in cel
responses to a lack of Nova-1 in the two different tissues or at the two different
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more likely, the result of natural variation between individual mice. Further analysis is
required to confirm or deny these results.

SABRE (Selective amplification via biotin- and restriction-mediated
enrichment)

SABRE was performed using libraries prepared from the hindbrains, and

separately the spinal cords, of PO Nova-1 null and wild-type mice in order to assess

differential gene expression of the whole complement of transcripts expressed in No

rich regions of the CNS. This methodology was also chosen as it has the potential t

in identification of additional candidate messages regulated by Nova-1 at the level

alternative splicing. PO mice were chosen because at this age no neuronal degenerat

evident in Nova-1 null mice and thus changes in gene expression detected are less l
to be due downstream effects of neuronal dysfunction, and thus more likely to be a

result of the absence of Nova-1. Figure 35 outlines the protocol used. Double strand

cDNA libraries were generated from RNA extracted from spinal cords or hindbrains of
20 Nova-1 null or wild-type littermate mice. The cDNA was then digested with Sau3A,

ligated to linkers of fixed sequence, and size selected by agarose gel electrophores

These libraries were then amplified by PCR using primers specific to the linker reg
each library was amplified using either the tester-specific (BamHI containing,
biotinylated) primer Tl, and the driver-specific primer Dl, in separate reactions.
Following amplification, the two populations were mixed with a 30-fold excess of
driver, ethanol precipitated and resuspended in hybridization buffer. Hybridization

performed using a modification of the phenol emulsion reassociation technique (PERT
developed by Miller and Riblet (Miller and Riblet, 1995) in a thermal cycler. Under
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these conditions D N A

reassociation equivalent to that achieved after one w e e k of

hybridization under standard conditions in drawn out capillary tubes is achieved
overnight. At the end of the hybridization procedure, single stranded (unhybridized)
species were digested with SI nuclease and the mixture was incubated with streptavidin
coated magnetic beads. The beads were washed to remove unbiotinylated species, thus
retaining only hybrids harboring at least one strand derived from the tester population.
Further enrichment was achieved by eluting only tester-tester homohybrids by restriction
digest with BamHI. This population was then further amplified using primer Tl for use
in successive rounds of selection.
To minimize false positives introduced as a result of preferential amplification of
certain sequences by PCR, and other manipulations, a control hybridization and selection
reaction is performed using the control population (the driver in the experimental
hybridization) as both driver and tester. This population is used as the driver in
subsequent rounds of selection. In theory, this population should be identical to the
starting population. By comparing experimental and control populations after selection,
species with an increased concentration in both populations can be excluded from further

analysis.
Selection in this manner was performed such that RNA species whose steady state
levels are increased or decreased will be detected by using the Nova-1 null libraries as
either the tester population, or alternatively, as the driver population. Figure 36A shows
the results of one such experiment using spinal cord cDNA libraries and selecting for
species of higher abundance in the Nova-1 null mice. A fraction of both the experimental
(or tester, T) and control (driver, D) reactions was body labeled with a3:P-dATP during
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P C R amplification after each round of selection and separated by denaturing P A G E .

Species enriched in the tester but not the driver population after five rounds of s
were excised from the gel, PCR amplified, cloned and sequenced. Figure 36B shows a

region of the gel from which 3 enriched species were identified. The identification

of these bands as LacZ was highly encouraging given that this gene is driven from t

Nova-1 promoter in the null mice. Table 2 lists the species identified in this manne

enriched in Nova-1 null (A,B, spinal cord and hindbrain, respectively) or wild-type

spinal cord and hindbrain, respectively) tissues. Clones which corresponded to ribos
RNA or appeared in both populations (i.e. upregulated in Nova-1 null and wild-type
libraries) were not included. These comprised approximately 20% of the independent
clones sequenced.
Confirmation of these results by Northern blot, RT-PCR or RPA is required.
Figure 37 shows RT-PCR confirmation of clone 1H36 which corresponds to contactin

associated protein 1 (Cntnapl), a neurexin-like axonal transmembrane molecule mainly

localized at the paranodal junction. Cntnapl (also called neurexin IV or Paranodin)
mRNA level is increased in the hindbrains of Nova-1 null mice compared with
heterozygous or wild-type littermates by a factor of 1.64 fold (±0.22, n=6). Taken

together with the identification of LacZ, these results indicate that the SABRE proc

was successful in identifying all-or-none differences in gene expression between tw
samples (i.e. LacZ which is only expressed in null mice, not wild-types) and subtle
alterations as was seen for Cntnapl.
Database searches using sequences obtained from SABRE clones showed that a
number of these clones correspond to one of two or more alternative isoforms of the
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m R N A identified. For example, M A P 1 A m R N A is transcribed from 2 alternative

promoters, generating a long and a short transcript (Nakayama et al., 2001). Clone 2S

matches a region of the gene which is specific to the long transcript and extends i

region common to both (depicted in Figure38A). Attempts to assess Nova's effect on t
levels of these two transcripts by transfection of N2A cells (which express both

transcripts, (Nakayama et al., 2001)) with exogenous Nova-1 were complicated by the
fact that the ratio of the two mRNA forms was altered by transfection of the empty
expression vector (data not shown).
Clone 1H60 matches a region of a large intron present in rat Shank3a. When this
rat mRNA sequence is compared to mouse sequences in the database (by BLAST
analysis), the closest match is a transcript, Shank3b, which is almost identical to

sequence, but lacks this large exon (exon 8A, Figure 38B). Since this clone was sel

from a mouse library, it is hypothesized that this may represent an alternatively s
exon in mice. RT-PCR using primers to exons 8 and 9 or exons 8A and 9 confirmed the

existence of both species in mouse hindbrain (not shown). Further analysis by Northe

blot or RPA is required to determine whether the enrichment of this clone during th
SABRE procedure is the result of a difference in overall message level, or a change

alternative splicing of this exon. Analysis of splicing by RT-PCR similar to the app

used to assess GABAARy2 alternative splicing would not be appropriate given the lar
size (2.3kb) of the exon to be spanned.
EST data suggests that clone 1H53 also corresponds to one of two alternative
isoforms of an mRNA encoding a protein of unknown function. In this instance, it

appears that the clone extends into one of two alternative 3'-terminal exons as dep
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Figure 3 8 C . N o E S T s or other c D N A sequences were found that contained both exon 6 A
and exon 7 in the same transcript, however these two exons lie within close proximity in
genomic DNA (Celera). Again, further analysis by is required to determine whether the
enrichment of this clone is the result of a difference in alternative splicing of this exon,
overall message level of both transcripts.

Discussion

Differential gene expression screens are powerful tools for comparing the mRNA profiles
of two or more populations. As discussed in the introduction of this chapter, there are
many methodologies for performing such screens, each with their own set of advantages
and disadvantages and the use of several of these techniques to address a specific
question can be particularly powerful. cDNA libraries prepared from Nova-1 null and
wild-type littermate mice were screened using two of these methods; cDNA arrays and
SABRE. The steady state levels of a number of transcripts were found to be different in
the two populations.
Differential gene expression screens are usually employed to detect differences in
the level of transcription of messages in different biological samples; however, what they
really detect is differences in the steady state levels of messages. RNA processing events
in the nucleus and cytoplasm are linked in ways that are just beginning to be explored.
Alterations at any step of the process can have profound effects on the downstream
processing of a transcript. For example, splicing of non-coding regions of a transcript can
result in incorporation of different signals in the form of sequence or associated proteins
which result in altered stability, polyadenylation, nuclear export and/or translation of a
message, and ultimately changes in steady state mRNA level. Thus analysis of Nova-1
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null mice by these approaches not only assesses the transcriptional alterations, some of

which are most likely due to indirect effects of the lack of Nova-1 expression such

neuronal dysfunction and degeneration, but also the downstream effects of misregula
of Nova-1 target RNAs. The accumulation of GlyRa2 mRNA in Nova-1 null mice

detected during experiments presented in chapter 3 is hypothesized to be the result

incorrect processing of this message, perhaps inefficient nuclear export, as a resul
lack of Nova regulation of alternative splicing. Similarly, other messages may be

incorrectly spliced and as a result incorrectly processed, and detected by the meth
described in this chapter.
Interestingly, at least 3 of the clones isolated during the SABRE screen appear to
correspond to alternative isoforms of the mRNA identified. In one instance (Shank),

difference between the two transcripts appears to be at the level of alternative sp

consistent with the known role of Nova-1 in neurons. A second difference is detecte
transcript (clone 1H53, unknown function) with an alternative 3'-terminal exon and

at the level of both alternative splice choice and regulation of polyadenylation. P

been shown to regulate both exon inclusion and polyadenylation of the alternative 3
terminal exon, exon 4 of CT/CGRP (Lou et al., 1999), so by analogy Nova-1 may also

play a dual role in splicing and polyadenylation of the message corresponding to cl
1H53.
Finally, one clone corresponded to a message transcribed from an alternative

promoter (2S31, MAP1A). FMRP is predicted to regulate translation and/or stability b

binding to a region of the 5'UTR of the long transcript of MAP1B (Darnell et al., 20

and J.C. Darnell (personal communication), which has an almost identical gene struct

131

to M A P 1 A . B y analogy, the difference in steady-state level of this transcript in Nova-1

null mice may reflect specific association of Nova-1 with one of the alternative tr
and subsequent regulation of its post-transcriptional processing. Another formal

possibility is that Nova plays a role in the transcriptional regulation of one of t

transcripts. Although no role in transcription regulation has been suggested for No
proteins, other RNA binding proteins such as hnRNP K have been hypothesized to

function as transcriptional regulators (Takimoto et al., 1993). In addition, spliceo
snRNPs have been shown to promote transcriptional elongation, probably through
interactions with the elongation factor TAT-SF1, leading to the hypothesis that

recruitment of U snRNPs near the elongating polymerase is important for transcripti
(Fong and Zhou, 2001).
In addition to identifying a number of interesting candidate Nova-1 targets, this

work has paved the way for additional, more complicated experiments to be performed

These experiments, which are currently ongoing in the laboratory, incorporate addit
manipulations in order to address the aim of identifying Nova-1 RNA targets more
directly, but are in essence very similar to the screens discussed here. One such

experiment involves the co-immunoprecipitation of Nova, followed by assessment of t

bound RNAs by microarray analysis. A similar technique has been used successfully i
the identification of RNA targets of FMRP (Brown et al., 2001). A second approach
involves the cross-linking of Nova to target RNAs in vivo by UV irradiation and the

subsequent co-immunoprecipitation, isolation and identification of cross-linked spec

These approaches, combined with those presented in this chapter should yield valuab
information regarding additional Nova targets and thus Nova function in vivo.
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Figure 34: c D N A expression arrays

Duplicate cDNA arrays (Clontech) were probed using uniformly labeled single strande
c D N A libraries generated from R N A isolated from Nova-1 null (top) or wildtype
littermate (bottom) mice at ages PO (hindbrain, not shown) and P12 (spinal cord, shown).
Each c D N A is spotted in duplicate. Quantification was performed by phoshorimager
analysis with normalization to a selection of housekeeping genes, the levels of which are
assumed to be the same in the two populations. Regions displaying different levels of
hybridization to the two different probes allow identification of messages which are
differentially regulated in the two populations, for example insulin-like growth factor
binding protein (IGF-BP2) (inset, highlighted by arrows).
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Table 1: Differentially expressed genes identified using Clontech c D N A arrays.
Quantitation of the data presented in Figure 34, and from arrays probed with libraries
generated from the spinal cords of PO mice. Only positions which showed moderate to
high levels of hybridization, and where differences in hybridization signals between
Nova-1 null and wildtype probes were apparent are shown.
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Figure 35: Selection of tester homohybrid species by S A B R E

Tester DNA, biotinylated at each 5' end (yellow star) and with a BamHI restriction
each primer sequence, is hybridized with an excess of driver D N A , which is
unbiotinylated and contains a mutated B a m H I site in the primer sequence. Three types of
double-stranded molecules are formed: tester homohybrids, driver homohybrids, and
driver-tester heterohybrids. Tester homohybrids and driver-tester heterohybrids are
purified by capture of biotin-containing hybrids on streptavidin (green)-coated magnetic
beads. Next, digestion with B a m H I specifically releases the tester homohybrids from the
beads. The released molecules are then reamplified by P C R for further analysis and
selection. Figure adapted from (Lavery et al., 1997).
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Figure 36: Enrichment of c D N A fragments overexpressed in spinal cords of Nova-1
null mice.

(A) Representative autoradiogram showing enrichment of specific bands following
successive rounds of S A B R E selection. S A B R E was performed on Sau3Adigested c D N A libraries from spinal cord m R N A samples isolated from either
homozygous Nova-1 null (-/-) or wild-type (+/+) mice, with -/- c D N A as tester
and +/+ c D N A as driver (lanes marked T). Control hybridizations were performed
with +/+ c D N A as tester and +/+ c D N A as driver (Lanes marked D ) . After five
selection rounds, several prominent species enriched in the experimental -/- vs.
+/+ selection (round 5, lane T) but not in the control +/+ vs. +/+ selection (round
5, lane D ) were cloned and sequenced.
(B) Region of the gel shown in (A), enlarged (Lanes T and D, round 5). Indicated
bands were identified by sequence analysis.
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Table 2. Differentially expressed genes identified by S A B R E selection.
Summary of differentially regulated genes identified by this method. Identity of
fragments cloned after S A B R E was performed on:
(A) Spinal cord c D N A s . Tester = -/-, Driver = +/+.
(B) Spinal cord c D N A s . Tester = +/+, Driver = -/-.
(C) Hindbrain c D N A s . Tester = -/-, Driver = +/+.
(D) Hindbrain c D N A s . Tester = +/+, Driver = -/-.
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A . mKJNj/Vs increased in F U N o v a - 1 null spinal cord
Clone ref
ISI
1 llkJX
1S6

Identity
LacZ
1^1A w**rtP»-rt»»

1S42
1S46

ii\j uiau,u
Rattus norvegicus m R N A for beta-tubulin T betal5.Mus musculus,
Similar to tubulin, beta polypeptide.
0 1 0 R F 2 . Unknown
protein phosphatase 2, regulatory subunit B (B56), beta isoform

1S47
1S49
1S121
IS 142

mPer.
M u s musculus hypothalamus c D N A clone. Unknown.
M u s musculus c D N A clones H o m o sapiens partner of R A C 1 (arfaptin 2)
M u s musculus adult C b c D N A . Unknown.

B . m R l N A s increased in F U JNova-1 null hindbrain
Clone ref
1H15
iiti^:
1H18
1H30
1H32

1H35
1H36
1H37
IH53
1H60
1H64
IJioS
Itt/U
1H73
1H87

Identity
N-myc downstream regulated 2 (Ndr2)
i it_i
r> ii
:„i
~i

Unknown. Match to region of human genome with no known genes
(UCSC).
rilwsomal
protein Ll 1
[ M u s musculus dishevelled segment polarity protein homolog (Dvl-1)
T M S - 1 m R N A / transfer RNA-Ser synthetase (SERS)
M u s musculus apolipoprotein E
A M u s musculus contactin associated protein 1 (Cntnapl)
H o m o sapiens guanosine-diphosphatase like protein m R N A (mus
•
. . . . .
.
. .
il pnii/»i*w%cipnpp» r*"ir»»iprMiw*iifir*j» — r e l a t e d '

Unknown. Chromosome segregation protein SMC-related
Rattus norvegicus Shank postsynaptic density protein 3a
double cortin and calcium/calmodulin-dependent protein kinase like 1
(Dcamkl 1) M u s musculus C P G 16
iofhivn

H o m o sapiens a disintegrin-iike and metalloprotease (reproiysin type)
with thrombosjx>ndin ty.pe 1 motif, 4 (,ADAMr.S4)
Unknown
Unknown

(J. m R N A s increased in F O wildtype spinal cord
Clone ref
2S1

Identity

2S5

M u s musculus c D N A clone similar to inositol polyphosphate 4phosphatase. V A V proto-oncogene related
M u s musculus alpha-mannosidase
M u s musculus carnitine acetyltransferase (Crat)
M u s musculus cyclin ania-6b (partial match)
M u s musculus potassium channel, subfamily K, member 2 (Kcnk2)/
T R E K - 1 K + channel subunit
H o m o sapiens OSBP-related protein 7 m R N A similar to oxysterolbinding protein; O R P 7
Ivlus musculus IvlORF-reiated °ene X •IvTr°xN*
M u s musculus kinesin family member 21B (Kiizib)
Unknown
M u s musculus microtubule-associated protein M A P 1 A (Mtapl) m R N A ,
alternative promoter product

2S6
2S8
2Si2
2S22
AljZtt

2S25
2S26
2S31

M u s musculus syndecan 3 (Sdc3)- transmembrane heparan sulfate
proteoglycan

TT 1
•LfliKIiUWIl
H o m o sapiens, myeloid leukemia factor 2

D . m R N A s increased in P O wildtype hindbrain
Clone ref
2H1
2H2
2H3
2H5
2K10
2H14
2H19
2H20
2H23
/ g~j /- "^

2H30
2H36

idennrv
M u s musculus similar to nischarin / M u s musculus nischarin (Nisch)
M u s musculus adult male hippocampus c D N A . Unknown.
Unknown
zincfingerprotein of the cerebellum 1 (Zicl)
Unknown
M u s musculus M R P L 4 m R N A for mitochondrial ribosomal protein L 4
Unknown
H o m o sapiens brother of C D O (BOC) m R N A - member of Ig superfamily
U n know n.
H o m o sapiens myotubuiarin related protein 7 m R N A
Rattus norvegicus plectin (Plecl), m R N A

Figure 37: R T - P C R confirmation of contactin associated protein 1 (Cntnapl, clone
1H36) upregulation in Nova-1 null mice.

RNA isolated from hindbrains of Nova-1 null and control (heterozygous or wildtype
littermates) at the indicated ages was analyzed by RT-PCR. Primers were designed to
recognize a region of the m R N A contained in the S A B R E clone, and to span 2 exon/exon
boundaries. PCRs were multiplexed with primers to P-actin m R N A ( Q u a n t u m R N A ™ 6actin Internal Standards, Ambion). Data was quantitated by phosphorimager analysis and
presented as the ratio of message in Nova-1 null samples vs. control (control level set to
1, indicated by thick line) after correction for actin.
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Figure 38: Several S A B R E clones correspond to alternative m R N A isoforms.

Schematic representations of the genomic regions of 3 genes identified by SABRE as
differentially expressed in Nova-1 null mice compared to wildtype littermates. Red bars
show regions contained within the S A B R E clones. Exon numbers were assigned based on
comparisons of c D N A and genomic sequences in the databases.
(A) S A B R E clone 2S31 (increased in wildtype spinal cord) spans 5 exons of the long
transcript of M A P 1 A . The two transcripts are generated from alternative
promoters (Nakayama et al., 2001).
(B) S A B R E clone 1H60 (increased in Nova-1 null hindbrain) is contained within a
large (2.3kb) exon (designated 8A) in rat Shank3a m R N A . B L A S T searches of
rat Shank3a m R N A against mouse sequences pulls out mouse Shank 3b which
lacks exon 8A.
(C) S A B R E clone 1H53 (increased in Nova-1 null hindbrain) spans 3 exons of a gene
of unknown function. Analysis of E S T data reveals the likelihood of 2 alternative
3'-terminal exons (and 2 polyA sites). Clone 1H53 extends into the first of these
exons.

139

A

MAP1A

short transcript

SABRE clone 2S31

long transcript

B

Rat shank 3a

SABRE clone 1H60

o n
M u s shank3b

c
Unknown
SABRE clone 1H53
polyA

Chapter 7 -

Discussion

Physiological consequences of Nova-dependent splicing

dysregulation.

Several reports have implicated splicing defects as a cause of motor neuron death i
spinal cord. Dreyfuss and colleagues have determined that a protein mutated in the

human disorder spinal muscular atrophy plays a critical role in the generation of s

and have suggested that the proper regulation of splicing is necessary for post-nat

survival of motor neurons (Fischer et al., 1997). In addition, Lin et al. have repor
splicing defects in the glutamate transporter, EAAT2, are associated with the motor

neuron disorder amyotrophic lateral sclerosis (Lin et al., 1998). The phenotype of N
null mice, which phenocopies many aspects of the human POMA syndrome, together

with the biochemical evidence presented here, provides a particularly compelling ca

illustrating splicing defects that are associated with neuronal death in the ventra
cord.
The symptoms of POMA patients and the phenotypes of Nova null mice share

many of the characteristic hallmarks of failure of inhibitory responses in the cent

nervous system. The finding that two of the known targets of Nova action on alterna

splicing are subunits of inhibitory neurotransmitter receptors, and the third is th

message itself (which may add further complexity to the regulation of the first two

targets), is very intriguing. Mice lacking the long splice variant of GABAARy2 (y2L)

display a higher level of anxiety than control mice (Homanics et al., 1999), and inc
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sensitivity to benzodiazapines (Quinlan et al., 2000). Targeted disruption of the entire

GABAARy2 gene results in benzodiazapine insensitive mice which, like Nova null mice

display retarded growth postnatally and drastically reduced lifespan in addition to
sensorimotor dysfunction (Gunther et al., 1995). Furthermore, epilepsy has been

correlated with mutations in the GABAARy2 gene (Baulac et al., 2001; Wallace et al.
2001), and altered ratios of y2L and y2S mRNAs in schizophrenics have also been
reported (Huntsman et al., 1998). Several human and animal disorders of glycine

neurotransmission, such as hyperekplexia, the murine mutations spastic, spasmodic a
oscillator, and the bovine, equine and possibly canine forms of myoclonus reflect

symptoms similar to POMA patients and to Nova null mice (glycine disorders reviewed
in (Rajendra et al., 1997)). These observations attest to the importance of correct

functioning of these receptors in vivo, and are consistent with the hypothesis that

of correct Nova-dependent processing of these messages may contribute, at least in p

to the neuronal dysfunction and phenotypes seen in Nova null mice and POMA patients
A delicate balance between different alternatively spliced forms of individual

messages is clearly important for correct functioning of the nervous system, as evi

by the finding of subtle alterations in splice site selection in FTDP-17, SMA, DM a

mouse model of POMA. The alterations in the ratio of alternatively spliced forms of

GABAARy2 and GlyRa2 in Nova-1 null mice are relatively subtle, however these ratios
were measured at the tissue level. Nova-1 is expressed in only a subset of neurons,
is overlapping with the subset of those neurons that express GABAARy2 and GlyRoc2

subunits. Thus it is likely that the differences at the single cell level are far m

profound. In agreement with this, the change in alternative exon usage in tissue cu
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cells transfected with minigenes with or without Nova is greater that that seen in Nova
null mice.
Splicing has also been linked to several downstream processes such as nuclear

export, translation and cytoplasmic localization. The failure of these RNAs to go th

a Nova-dependent splicing pathway could have even more profound effects on relative
protein levels or distributions. Nova protein and GlyRa2 mRNAs co-localize in the

dendrites of ventral horn spinal cord neurons of the adult rat (C. Racca, A. Trille
B. Darnell unpublished data). In addition, GlyRa2 and ol mRNAs differ in their

subcellular localization depending on the neuronal population suggesting that diffe
mechanisms for the localization of these messages are used by distinct populations
neurons (Racca et al., 1998). Furthermore, GlyRcc2 mRNAs are not transported to
dendrites in dorsal horn neurons of the spinal cord, cells in which Nova-2 but not

is expressed, which points at a possible functional difference between these two pr

Taken together, these observations suggest that Nova-1 may play a role in the dendr
localization of GlyRcc2, and by analogy, GABAARy2 mRNAs, and that this localization
may be splicing-dependent. Thus in Nova-1 null mice, these messages are spliced
independently of Nova-1, so may not acquire the appropriate hnRNP composition

necessary for dendritic localization, possibly including the deposition of Nova-1 i

onto the spliced message. Conceivably, Nova could be associated with one alternativ

spliced form of the message only. Thus a relatively subtle dysfunction in alternati

splicing in Nova-1 null mice could in fact reflect a much more dramatic effect on t
protein expression at distal sites.
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The observation that steady-state levels of GlyRa2 m R N A are increased the
spinal cords of Nova-1 null mice compared to wild-type littermates may also be the

of incorrect processing of these RNAs subsequent to splicing. Nova proteins may shu

between the nucleus and cytoplasm, and in doing so may facilitate the export of bou
mRNAs. A lack of Nova-1 may then result in accumulation of GlyRa2 message in the

nucleus. As a result of either a decrease in cytoplasmic turnover of these messages

positive feedback on transcription, or both, an overall increase in message level c
envisaged. The fact that a similar observation was not made in the case of GABAARy2

may reflect a difference in the processing of these messages, or in the physiologic
response to aberrations in their processing.

Proposed mechanisms of Nova-dependent splicing

regulation.

Several unanswered questions regarding tissue-specific splicing are addressed by

the finding that Nova-1 regulates alternative splicing in neurons. RNA binding prot
such as Sxl and Tra/Tra-2 in Drosophila, identified by genetic approaches, act in a

sequence-specific manner to regulate alternative splicing of specific target transc

However, genetics has not previously been applied to the study of RNA binding prote

in mammals, and biochemical studies applied to complex splicing problems have led n

to the identification of tissue-specific splicing factors, but to the identification
ubiquitously expressed RNA binding proteins. These studies have yielded one clear
model in which differential regulation of splicing in mammals is generated through

relatively subtle changes in the levels of such ubiquitous splicing factors. Changi
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ratio of the constitutively expressed h n R N P protein h n R N P A l to the S R protein

ASF/SF2 mediates quantitative changes, ranging from 1.25-fold to several-fold in ce

transfection studies, in the utilization of proximal versus distal splice site choi

alternatively spliced exons (Caceres et al., 1994). The data presented here demonstr

that in addition to the role general factors play in regulating alternative splicing

specific factors that recognize specific RNA ligands exist in mammals, and may conf
more robust changes than those seen with constitutive factors alone.
In previous studies of the mechanism of neuron-specific splicing, intronic
enhancer elements similar in nature to the GlyRa2 (UCAUY)3 sequences have been

identified in other transcripts. These include multiple elements that promote neuron

specific exon inclusion in the c-src, calcitonin/CGRP, GABAA y2 and agrin genes (Bl

1992; Lou et al., 1999; Wei et al., 1997; Zhang et al., 1996). Regulation of splicin
appears complex given that multiple elements, both positive and negative, influence

alternative splicing events. For example, in c-src, in addition to positive acting s
identified as targets of an RNA binding protein complex involving KSRP, hnRNP F and
hnRNP H (Chou et al., 1999; Min et al., 1997), negative elements are found in the

polypyrimidine tract upstream of the neuronal n-src exon, which interact with PTB (

and Black, 1997), and downstream of the n-src exon, which interact with brain-enrich
PTB (Markovtsov et al., 2000).
The mechanism of neuron-specific splicing in the GABAA y2 gene has similar

complexities (Ashiya et al., 1995; Zhang et al, 1996; Zhang et al., 1999). A number o
negative elements surrounding the y2 exon were found to bind PTB, and, evidence was
also found for positive acting splicing elements. These observations, together with

144

data, suggest that Nova-1 may act in concert with general factors such as P T B or brain-

enriched PTB to regulate GABAA y2L exon utilization, which would be consistent with
the finding that Nova interacts with brain PTB (Polydorides et al., 2000). The work

presented here has led to the identification of a sequence element necessary and su
for Nova-dependent enhancement of GABAARy2L exon utilization. This enhancer

element lies approximately 1,250 nt downstream of the alternatively spliced exon, E9
and 80 nt upstream of the next constitutively included (last) exon.
Several examples of downstream enhancer elements have been documented in the
literature. For example, as noted above, n-src splicing is regulated in part by the
of KSRP to the downstream control element (DCS), possibly by recruiting Ul snRNP to

the 5' splice site and enhancing removal of the downstream intron (Min et al., 1997)
processing of the CT/CGRP RNA, an intron enhancer is located downstream of the

regulated exon, exon 4, which is included in thyroid cells, but excluded in neuronal

Increasing PTB levels results in an increase in exon 4 inclusion (Lou et al., 1999).
enhancer contains a core element which resembles a pseudoexon, featuring all the
necessary splicing signals; 3' and 5' splice sites, polypyrimidine tract and branch

with 3' and 5' splice sites abutted such that they contain no internal sequences. P
binds to this pseudoexon element and excludes binding of U2AF, thereby preventing

sequestration of U2AF at the cryptic splice site, and favoring binding of U2AF to th
upstream splice site, and subsequent splicing of exon 4. If this site is mutated to

consensus U2AF65 binding site, enhancement of exon inclusion is prevented (Lou et al

1999). Thus although PTB acts as a splicing enhancer in this system, the mechanism o

action is very similar to the role of PTB in negative regulation of other alternativ
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namely G A B A A R y 2 L and src exon Nl. This mechanism of action is highly reminiscent of

the regulation of tra splicing by Sxl (Valcarcel et al., 1993); Sxl bind to an upstre
splice site in tra, which precludes binding of U2AF65 and thereby promotes U2AF*5
binding to the downstream, weaker 3' splice site.
The splicing of human nonmuscle myosin heavy chain (NMHC)-B neural-specific

alternative exon, N30, is also regulated by a downstream enhancer element (Kawamoto,
1996). This element, termed the intronic distal downstream enhancer (IDDE) resides

1.5kb downstream of the exon it regulates. In vitro splicing assays using substrate
containing only two exons, N30 and either the upstream or downstream exon,

demonstrated that this element facilitates splicing of the upstream intron, not the
which it resides (Guo and Kawamoto, 2000). This upstream intron contains a weak
polypyrimidine tract, optimization of which obviates the need for the downstream

enhancer for exon inclusion, and destroys neural specificity. This observation, com

with transfection experiments involving overexpression of a truncated U2AF65 lackin
the RNA binding domain which acts in a dominant negative fashion to inhibit N30

inclusion, led the authors to conclude that this enhancer element facilitates recog

the 3' splice site in the upstream intron via a series of protein-protein interacti

recruit U2AF to the suboptimal polypyrimidine tract. However, the nature of the fact

which directly bind to this element and the way in which neural specificity is achi
unknown.
An overriding theme in the regulation of alternative splicing is a balance between

positive and negative (or suboptimal) signals. It appears that in many instances th

limiting amounts of splicing factors that assemble on a pre-mRNA, and that weak spl
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sites may be skipped by default in situations where factors are limited. To tip the balance
between positive and negative signals several scenarios can be envisaged. One,
enhancement of splicing could be mediated through inhibition of a negative signal,

allowing a particular splicing event to occur - for example, PTB's action on CT/CGR

which involves the inhibition of a competing pseudoexon. Alternatively, enhancement
could be achieved by bona fide positive action on the mechanics of splicing such as

recruitment of essential splicing factors to an otherwise poorly utilized site, as h
proposed for KSRP enhancement of src Nl inclusion, or the action of the downstream

enhancer of (NMHC)-B N30 inclusion. These possibilities are not necessarily mutuall
exclusive.
The first scenario would predict that in the absence of the inhibitory signal, the

enhancer element would not be required, and in fact would fail to act as an enhance

finding that a small (as short as 24nt) sequence element corresponding to the regio
Nova-1 binding is sufficient to mediate Nova-dependent enhancement of an upstream
exon in a heterologous system (as was shown in Figure 21) would argue against this

hypothesis of Nova action on GABAARy2L exon utilization, unless this 24nt element a
harbored the inhibitory element, or Nova acts in a manner reminiscent of PTB as a

splicing inhibitor. This seems highly unlikely given the small size of the element,
of any obvious pseudo-splice site within the element (like that in CT/CGRP).
Nova-dependent enhancement of GABAARy2L exon utilization is more likely to
involve facilitation of splicing of an intron adjacent to E9. It is unclear as yet
facilitation involves the intron upstream (similar to (NMHC)-B N30) or downstream
(similar to KSRP/src Nl) of E9. In vitro splicing assays utilizing simple two exon
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substrates similar to those performed by G u o and Sawamoto (Guo and Kawamoto, 2000)
would be helpful in determining this. Comparison with Nova's action on GlyRoc2

splicing, however, would predict that Nova enhances splicing of the intron in which

resides. By binding to these intronic enhancer elements, Nova may facilitate spliceo
assembly. Yeast-2-hybrid results have indicated that Nova can bind to spliceosomal

elements present at both the 3' and 5' splice sites, namely U1-70K and U2AF65 as wel

some SR proteins, including SRp20 (G. Stefani and R.B. Darnell, unpublished results)
Through interactions such as these, Nova may serve a bridging function between the
nearby 3' splice site and the next upstream 5' splice site. Figure 39A illustrates
model.
The position of the Nova binding site so close to the splice acceptor signals of

exon 10 is intriguing. One other possibility for the mechanism of Nova action is th

Nova simply slows down the assembly of the spliceosome at exon 10 by interfering wi

binding or assembly of essential factors at this site. This could then enhance spli

E9 in a kinetic manner, essentially by allowing more time for assembly to take plac
otherwise weakly recognized site, and thus increasing the chances of recognition of

exon. This hypothesis does not require (though it also does not exclude) the need f

Nova to recruit or bind to other splicing factors. However, it is difficult to recon
hypothesis with what is known about Nova regulation of GlyRoc2 splicing. The Novabinding element shown to be necessary for enhancement of E3A inclusion is in a very

similar location with respect to the downstream exon, but in this instance the down

exon is the regulated exon (E3A). If Nova was to act on GlyRa2 in a manner similar t
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the hypothesis stated above, N o v a binding would be expected to result in a decrease in
E3A inclusion.
Splicing regulation of Nova-1 exon H is also likely to represent a balance between
positive and negative signals. In contrast to the two other known targets of Nova-1
splicing regulation, in this instance it appears that the default pathway involves exon H
inclusion and Nova acts as an inhibitor via binding to an exonic silencer sequence. Thus
Nova is a multifunctional splicing factor, able to act as both a repressor and enhancer of
alternative exons. The most obvious difference between the targets of Nova splicing
regulation is that in both instances where Nova acts to enhance alternative exon
utilization, the Nova-binding site lies within an intron, albeit in a different position
relative to the regulated exon, whereas the Nova-binding site in it's own message is
contained within exon H.
Position can have a profound effect on splicing enhancers. Changing their
location can alter their dependence on particular trans-acting factors. For example, Tra is
no longer required to activate female-specific splicing of exon 4 of dsx if the splicing
enhancer is moved closer to the 3' splice site (Tian and Maniatis, 1994). Sequences

identical to this dsx enhancer are also present in the gene fruitless (fru) where they direc
utilization of a downstream 5' splice site in females, a process also dependent on Tra
(Heinrichs and Baker, 1995). This difference implies that a particular type of splicing
enhancer complex can promote different outcomes on different genes, triggered by the
same developmental regulator, Tra, but involving a different range of molecular
interactions depending on the position within the pre-mRNA.
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Position can even transform a positive element into a negative one, as the data
presented in this work would suggest occurs for Nova regulation of it's own message
compared to that of GlyRcc2 or GABAARy2. For example, an SR-protein-binding site

positioned just upstream of a branch point causes splicing inhibition in an adenovi
mRNA by blocking access of U2snRNP The same element can act as an exonic splicing
enhancer if it is placed downstream of the 3' splice site (Kanopka et al., 1996).
Interestingly, this inhibition is dependent on phosphorylation of the SR proteins;
inhibition is relieved upon dephosphorylation of the bound SR proteins (Kanopka et

1998). Similarly, Nova-binding to the site in exon H may inhibit access of necessary

splicing factors such as SR proteins to this exon. Since Nova can be phosphorylated

vivo (G. Stefani and R. B. Darnell, unpublished data) the action of Nova on splicin
could also conceivably be influenced by phosphorylation state, though there is no
evidence to support this hypothesis yet.
Nova binding to exon H could inhibit splicing in a number of ways. Binding

could simply sterically inhibit the binding or association of other necessary compo

of the spliceosome at this exon, resulting in exon skipping, as illustrated in Figur

Alternatively Nova binding could lead to recruitment of constitutive factors, as wa

suggested for regulation of GlyRa2 and GABAARy2 alternative splicing, but to the wr

position relative to the RNA and thus in a manner inhibitory for exon inclusion. Fo

example, since KH binding to RNA is directional as evidenced by the co-crystallizat
of a Nova KH domain bound to a target RNA (Lewis et al., 2000), Nova binding to RNA

elements is restricted in a unidirectional fashion. If Nova interactions with other

factors are also directional, Nova could dictate the position of these factors rela
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R N A . By extension of the GlyRa2 / G A B A A R y 2 model shown in Figure 39A, if Nova is

only able to bind U170K on the upstream side and U2AF65 on the downstream side, this

would result in the recruitment of these factors to the wrong splice site if Nova w
bound to an exon, and hence exon exclusion (illustrated in Figure 39B.II).

Summary

A delicate balance between different alternatively spliced forms of individual pre-

mRNAs is clearly important for correct functioning of the nervous system, as eviden

by the finding of subtle alterations in splicing of particular messages in a number

neurological diseases. The mechanisms by which splicing is regulated so tightly and
specifically are not generally known, but likely involves both general factors and
specific (or enriched) factors. The finding that Nova-1 acts as a neuron-specific

alternative splicing factor is an important one, since it is the first example of s
found exclusively in the mammalian brain. Elucidation of the mechanism of Nova-

dependent splicing regulation through identification of splicing targets and the el
necessary and sufficient for Nova regulation of them, will help to understand the

exquisite control and complexity of gene expression in the brain. Ultimately, studi
as these will also aid in the understanding of a number of neurological diseases.
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Figure 39: M o d e l for N o v a regulation of alternative splicing.

(A) Nova (red ovals) binds to an intronic region in GlyRa2 and GABAARy2 preR N A s , near the 3' splice site. Binding m a y occur in either the intron upstream (as
is the case for GlyRoc2 E 3 A ) or downstream (as for G A B A A R y 2 E 9 ) of the
alternatively spliced exon. N o v a then bridges the interaction between the adjacent
5' and 3'splice sites via interactions with proteins at both sites, such as U 1 7 0 K , a
component of U l s n R N P (yellow octagons) at the 5' splice site and U 2 A F 6 5
(purple trapezoid) at the 3' splice site, thereby enhancing splicing of the intron.
N o v a binding m a y recruit factors already bound to the adjacent splice sites (as
shown) and stabilize the interaction. Alternatively, N o v a recruitment of protein
factors m a y aid in their association with otherwise weakly recognized splice sites.
Exons are represented by green and blue rectangles.
(B) N o v a recognizes an exonic element in Nova-1 exon H (red bar). I. Binding of
N o v a to this element m a y sterically inhibit binding of other factors necessary for
splicing to this exon. II. Alternatively, N o v a m a y recruit spliceosomal factors as
in (A), but binding m a y be directional, resulting in the recruitment of these
factors to the wrong position relative to the R N A and subsequent inhibition of
exon inclusion.
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